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CHAPTER I: Neurofibromin, a RAS-GAP and more 
Introduction 
Neurofibromatosis type I (NF1, OMIM 162200), formerly known as von 
Recklinghausen Disease, is an autosomal dominant genetic disorder with an incidence of 
1:3000 live births.  The clinical hallmark features of NF1 are cutaneous neurofibromas, 
café-au-lait spots, Lisch nodules, and freckling of axillary and inguinal regions (Huson, et 
al., 1988).  Although most neurofibromas develop in adult patients, NF1 can also occur 
in much younger individuals with manifestations including cognitive deficits, bone 
deformations, plexiform neurofibromas, optic glioma and a variety of neurologic 
syndromes (Czyzyk, et al., 2003; Watson, 1967).  This inherited disorder is due to the 
various mutations of the Nf1 gene at 17q11.2 that encodes neurofibromin (Bader, 1986; 
Riccardi, 1992).  Neurofibromin is known as a tumor suppressor because of its well 
characterized RAS GTPase activating protein related domain (GRD) which negatively 
regulates RAS activity by accelerating the hydrolysis of the active GTP-bound RAS (Xu, 
et al., 1990).  Humans with a genetic mutation in one of the Nf1 alleles show a 
predisposition for many different kinds of tumors.  Patients with plexiform 
neurofibromas have increased lifetime risk for transformation to highly malignant 
peripheral nerve sheath tumors (MPNST) (Evans, et al., 2002b), and glioblastoma 
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multiforme can be another malignant manifestation in NF1 patients (Gutmann, et al., 
2002).  Surgery, the primary treatment, is limited by tumor infiltration and therefore 
patients often experience high relapse rates.  Increased RAS and RAF/MEK/ERK 
pathways activities have been reported (Basu, et al., 1992) in the patients, however, RAS 
and/or MEK1/2 targeted therapeutic strategies have met with limited success 
(Kalamarides, et al., 2012).  
The regulation of RAS pathway by RAS-GRD (330 amino acids) in neurofibromin 
is paramount in development and tumorigenesis; however, as a protein with 2818 amino 
acids, the functions of most other domains are not very clear. An Nf1-/- mouse model with 
complete loss-of-function of neurofibromin shows embryonic lethality resulting from 
cardiac abnormalities (Jacks, et al., 1994), but an inducible neurofibromin GRD alone 
could not rescue the lethality of Nf1-/- in mouse embryos (Ismat, et al., 2006).  Another 
intriguing fact is that many different types of single nonsense mutations in the Nf1 gene 
encoding region outside the GRD sequence can also lead to the Nf1 manifestation in 
patients (L.M.Messiaen, 2008). These findings indicate that neurofibromin may 
participate in different mechanisms in addition to acting as a RAS GTPase activating 
protein in development and tumorigenesis.  A new strategy is required to explore the 
function of neurofibromin in various cellular processes and mechanisms.  
 In this study, we hypothesize that the NF1-related aberrant gene regulations can be 
3 
 
 
identified by the systematic gene expression profile comparisons using MPNST cell lines 
with different Nf1 status.  By revealing and characterizing those gene expression 
changes, the signaling cascades associated with NF1 malignancy may be specified and 
served as druggable targets for the rational treatment of NF1-related tumors.     
Nf1 gene structure and neurofibromin functions 
The Nf1 gene is located at 17q11.2 and spans 280 kb of genomic DNA.  It has 57 
constitutive exons and 4 alternative splices, encoding a 12 kb mRNA transcript, with a ~9 
kb open reading frame (Upadhyaya M, 1998).  The Nf1 gene is conserved in many 
organisms.  Bernards et al. reported more than 98% homology between human and 
mouse amino acid sequences (Bernards, et al., 1993) and approximately 60% homology 
between Drosophila and human (The, et al., 1997).  A much conserved 
CpG-island-containing promoter has been found in the Nf1 gene however 
hypermethylation of this region does not appear to be a common mechanism to silence 
Nf1 expression in any NF1-related tumors (Horan, et al., 2000; Horan, et al., 2004).  The 
Nf1 gene has a myriad of pseudogene sequences on several other human chromosomes 
revealed by fluorescence in situ hybridization (FISH) using labeled Nf1 cDNA, but none 
of these pseudogenes encodes a functional protein (Gasparini, et al., 1993).  From the 
study of Luijten et al., these pseudogene sequences are the result of multiple independent 
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partial duplications of the Nf1 gene at chromosome 17 followed by sequential 
inter-chromosomal transposition events (Luijten, et al., 2001). 
   Neurofibromin is ubiquitously expressed with highest expression level in neural 
tissues, bone, kidney and spleen (Theos and Korf, 2006).  Nf1 knockout in mice causes 
embryonic lethality because of abnormal heart development (Brannan, et al., 1994).  
The protein, neurofibromin, has ~280 kDa molecule weight with several domains such as 
RAS-GRD, cysteine and serine rich domain (CSRD), tubulin binding domain (TUB), 
Sec-14 domain, PH-like domain (PH), and Syndecan binding region (SYN) (Fig.1) (S. 
Welti, 2008).  Using a yeast two hybrid system, several proteins have been reported to 
interact with neurofibromin, including Syndecan (Hsueh, et al., 2001), Caveolin 
(Boyanapalli, et al., 2006), tubulin (Bollag, et al., 1993), protein kinase A (PKA) (Izawa, 
et al., 1996) and C (PKC) (Mangoura, et al., 2006), kinesin-1 (Hakimi, et al., 2002), and 
the amyloid precursor protein (De Schepper, et al., 2006).  However, the biological 
implications of those interactions are still not clear.  
The most intensively studied domain in neurofibromin is RAS-GRD encoded by 
exon 21 to 27a and works as a GTPase activating protein (GAP) to accelerate the 
hydrolysis of RAS-GTP and inactivate RAS activity.  Increased RAS activity has been 
demonstrated in the cells derived from both NF1 patients and transgenic mice.  
Phenotypic features of overactive RAS, such as increased proliferation and survival, have 
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been identified in Nf1+/- and Nf1-/- neural stem cells of mice (Dasgupta, et al., 2005).  
Hiatt et al. reported that the expression of the neurofibromin GRD domain, not p120GAP 
GRD can restore normal growth and cytokine signaling in primary murine embryonic 
(Nf1-/-) fibroblasts and hematopoietic cell cultures (Hiatt, et al., 2001).  Klose et al. 
demonstrated that a missense mutation in Nf1 RAS GRD (R1276P) leading to an 
8000-fold loss of catalytic activity compared to the wild type counterpart is sufficient to 
cause most NF1 phenotypes (Klose, et al., 1998). 
 However, some studies also indicated GRD independent tumor suppressor 
activities in neurofibromin.  Johnson et al. reported the malignant transformation 
efficiency by v-HRAS in the neurofibromin overexpressed NIH3T3 cell line was much 
lower than the control cells (Johnson, et al., 1994).  Another study by Ismat et al. 
showed that inducible ubiquitous expression of neurofibromin GRD rescued the 
mid-gestation lethality of Nf1 null embryos, but the mouse died shortly after birth 
resulting from aberrant proliferation of neural crest-derived tissues (Ismat, et al., 2006).  
Shapira et al. showed that neurofibromin conferred sensitivity to apoptosis by both 
RAS-dependent and RAS-independent pathways (Shapira, et al., 2007).  These studies 
suggest that RAS activity deregulation may not completely explain all the phenotypes in 
the patients and mice models, and neurofibromin GRD independent function may 
contribute to the biological development and tumor initiation.  
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Fig. 1 Domain scheme of neurofibromin with reported protein-ligand interactions.  
Colored domains and interaction partners are confirmed by structural analysis, and grey 
domains are indicated by biochemical experiments.  Red circles mark the positions of 
missense mutations found in patients (including amino acid deletions and tandem 
duplication).  Additional features are potential phosphorylation sites for PKA (blue 
circles) and PKC-alpha (yellow circles, only serine phosphorylation) a bipartite nuclear 
localization sequence (NLS) and several caveolin binding motifs (CBDs).  The GRD 
indicated in the dark blue is the minimal GAP domain, in midblue the crystallized 
fragment and in light blue whole fragment with sequence homology to the p120-GAP 
protein, overlapping with the Tub and Sec domain.  CSRD: Cysteine and serine rich 
domain; Tub: tubulin binding region; Sec: Sec14-like domain; Ph: PH-like domain 
(D.Kaufmann, 2008).  Figure is adapted from Neurofibromatoses (S. Welti, 2008) with 
modification. 
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For other domains in neurofibromin, Sec14 domain is a lipid-binding domain first 
identified in S. cerevisiae phosphatidylinositol transfer protein (Sec14p) and also reported 
in RhoGAPs.  Sec14p-like proteins show a great amount of diversification in terms of 
physiological function and ligand specificity.  In neurofibromin, Sec14 domain folds 
into a globular Sec14p-like lipid binding cage (D'Angelo, et al., 2006) closed by an 
amphipathic helical segment (Sha, et al., 1998).  This structure enables Sec14 domain to 
hypothetically shuttle lipids between membrane compartments through the aqueous 
medium (D.Kaufmann, 2008).  The PH domain of neurofibromin is identified by 
comparison with protein data bank, which is believed to interact closely with Sec14 
domain in neurofibromin.  Generally, PH-like domains show various functions in their 
host proteins which include structural scaffolds for ligand binding and coupling to signal 
transduction pathways (Di Paolo and De Camilli, 2006; Duncan, et al., 2005).  However, 
it is hard to predict the precise function of the PH-like domain in neurofibromin 
considering limited similarity in sequence and structure with other members of the PH 
superfamily. 
Malignant peripheral nerve sheath tumor   
Malignant peripheral nerve sheath tumor (MPNST) is a type of soft tissue sarcoma 
that develops from the peripheral nerves, preexisting benign neurofibromas, or Schwann 
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cells.  Approximately 50% of MPNST occur in the setting of NF1 genetic disease 
(OMIM ID #162200) with the remainder occurring from NF2 patients or sporadically 
(Matsui, et al., 1993; Sorensen, et al., 1986).  The lifetime risk for NF1 patients to 
develop an MPNST is 8~13% (Evans, et al., 2002b), and the five-year survival rate is 
34-43% (Wanebo, et al., 1993).  NF1 patients are most frequently diagnosed with 
MPNST in the third and fourth decades of life whereas the sporadic form of MPNST is 
most frequently diagnosed in the sixth and seventh decades of life (Evans, et al., 2002a).  
MPNST is thought to arise from the accumulation of additional genetic events in 
precursor Schwann cells.  Neurofibromas are benign tumors and may or may not be 
associated with the Nf1 gene.  Plexiform neurofibromas are almost exclusively 
Nf1-associated and easily progress to MPNST.  Mouse model studies have indicated a 
heterozygous Nf1 status was required for the Schwann cells derived plexiform 
neurofibroma formation and tumor microenvironment (Zhu, et al., 2002).  Localized 
cutaneous neurofibromas and diffuse cutaneous neurofibromas are 90% sporadic and 
have lower malignant potential (Carroll and Ratner, 2008).  However, whether the status 
of the Nf1 gene is the only dominator to the malignancy is still questionable.   
Currently, several MPNST cell lines are being used as in vitro study models, 
including ST88-14(Nf1-/-), T265(Nf1-/-), sNF96.2(Nf1-/-), sNF02.2(Nf1-/-) and 
STS26T(Nf1+/+).  The first four cell lines are Nf1-deficient MPNST, whereas 
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STS26T(Nf1+/+), with the wild type Nf1 gene, is from a sporadic MPNST. A cytogenetic 
study of ST88-14(Nf1-/-) showed that the Nf1 locus has been deleted from one allele while 
the transcriptional activity on the other allele is greatly decreased (Reynolds, et al., 1992).  
In addition, a heterozygous nonsense mutation in Nf1 (C910T) in codon 304 (R304X) of 
exon 7 was identified in this line (Barkan, et al., 2006).  For the T265(Nf1-/-) cell line, 
there is no Nf1 mutation reported, however the neurofibromin was hardly detectable in it.  
The sNF96.2(Nf1-/-) cell line was derived from an NF1 patient with a recurrent mass 
associated with nerve tissue diagnosed as MPNST.  It has an abnormal karyotype and 
complete loss of heterozygosity with no detectable wild type Nf1 allele (Fieber, et al., 
2003).  The sNF02.2(Nf1-/-) was derived from a lung metastasis MPNST in an NF1 
patient.  The STS26T(Nf1+/+) cell line, with the wild type Nf1 gene, was established 
from a sporadic malignant Schwannoma, however, Tp53 expression was completely 
absent (Dahlberg, et al., 1993; Miller, et al., 2006a).  
Targeting signaling pathways in the neurofibromatosis type I  
Neurofibromin-NRAS axis 
Given the function of neurofibromin as a GAP, the increased RAS activity in 
neurofibromas and NF1-related MPNSTs is the strong rationale emphasizing the focus on 
neurofibromin-regulated RAS pathway as a potential treatment target in MPNST (Bottillo, 
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et al., 2009; Perry, et al., 2001).  There are three types of related Ras genes, which 
encode highly homologous NRAS, HRAS and KRAS (isoforms 4A and 4B).   
Localization of RAS is critical for its activation.  A post-translational modification 
called prenylation is required to facilitate attachment of RAS to inner cell membrane 
where the guanine nucleotide exchange factor (GEF) catalyzes the GTP to replace the 
GDP-bound RAS.  During this process, a 15-carbon farnesyl group is transferred from a 
farnesyl pyrophosphate and linked to the cysteine from the C-terminus of the RAS, and 
thereafter, the last three residues of the C-terminus are cleaved and the prenylated 
cysteine is methylated, which enables the membrane localization.  This modification 
that facilitates the inner membrane localization of RAS is a rate-limiting step for the 
activity of RAS (Basso, et al., 2006; Roy, et al., 2005).  The GTP-bound RAS is 
activated and initiates a myriad of signalling cascades to control cell processes. 
Two classes of drugs have been used to inhibit the activation of RAS.  Lovastatin, 
from the statin family, can inhibit HMG-CoA reductase and has been clinically used for 
lowering cholesterol.  As an intermediate of cholesterol biosynthesis, farnesyl 
pyrophosphate synthesis is impaired by HMG-CoA reductase inhibition (Morgan, et al., 
2003), which subsequently impairs the prenylation of RAS.  Phase I clinical trials to 
evaluate lovastatin on improvement of neurocognitive and learning deficits are currently 
ongoing (NCT00853580, NCT00352599).  The second class of drugs belongs to the 
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farnesyl protein transferase inhibitor (FTI) family that can catalyze the transfer of a 
farnesyl group to RAS. Growth inhibition of ST88-14(Nf1-/-) has been observed after the 
treatment with FTI BMS-186511, and the patients demonstrates good tolerance profiles 
(Widemann, et al., 2006; Yan, et al., 1995).  Clinical trials using FTI such as tipifarnib to 
treat young NF1 patients and progressive plexiform neurofibromas (NCT00021541) 
passed a phase I trial but was suspended at the phase II trial.  Some in vitro studies 
combining lovastatin with FTI suggested promising effects such as arresting cell cycle at 
the G1 phase and leading to apoptosis by increasing caspase activity in NF90-8(Nf1-/-) 
and ST88-14(Nf1-/-) with no toxic effects in normal rat Schwann cells (Wojtkowiak, et al., 
2008).  However, it was determined that FTI did not effectively block the NRAS and 
KRAS prenylation, membrane association and transforming activity, since another type 
of prenylation of NRAS and KRAS by geranylgeranyl transferase has been reported 
when farnesyl transferase is inhibited (Lerner, et al., 1997; Whyte, et al., 1997).  It can 
be helpful to combine the inhibitors for the both geranylgeranyl and farnesyl transferases 
to suppress RAS activation in vivo (Sun, et al., 1998).  Previous research from our group 
identified that HRAS is undetectable, KRAS is weakly detectable, and NRAS is the 
predominant form of RAS from the other two in MPNST cell lines (Mattingly, et al., 
2006).        
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The RAF-MEK1/2-ERK1/2 axis 
RAF is one immediate downstream mediator of RAS and is activated by RAS-GTP 
(Katz and McCormick, 1997).  The significance of the RAF-MEK1/2-ERK1/2 axis in 
controlling the proliferation and survival of NF1-associated MPNSTs has been 
characterized in both animal models and human patient cell lines (Johannessen, et al., 
2005; Mattingly, et al., 2006).  This axis promotes cellular proliferation through 
upregulation of cyclin D1 expression, and increases the phosphorylation of cyclin 
dependent kinase 4 (CDK4) and retinoblastoma protein pRB (Chang, et al., 2003).  
Phosphorylated MEK1/2 has been reported to be present in 91% of 140 MPNST tissues 
(72 NF1 patients and 68 not), compared with 21% of benign neurofibromas (Zou, et al., 
2009a). 
Several studies have provided disappointing results for RAF-MEK1/2-ERK1/2 
targeted strategies.  Sorafenib is a tyrosine kinase inhibitor with multiple effects 
including inhibition of RAF-dependent phosphorylation of MEK1/2, vascular endothelial 
growth factor receptor (VEGFR) I, II and III, platelet derived growth factor receptor beta 
(PDGFRB) and c-Kit (Rini, 2007).  However, the results from its clinical Phase II trial 
were disappointing because of its very limited effects on patients with advanced soft 
tissue sarcomas (von Mehren, et al., 2012).  As the downstream effectors of RAS, 
MEK1/2-targeted strategies are promising (Diwakar, et al., 2008). The effects of 
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MEK1/2-blocking agents, such as U0126, CI-1040 and PD98059 were evaluated in the 
MPNST cell lines (Mattingly, et al., 2006).  Although all three drugs showed 
concentration-dependent proliferation suppression in tested cell lines, PD98059 has 
primary cytostatic effects, and U0126 and PD184352 (CI-1040) were cytotoxic, which 
limited their clinical application (Mattingly, et al., 2006).  
The PI3K-AKT-mTOR axis 
Based on similar clinical features and molecular phenotypes with other disorders 
known as phakomatoses, Johannessen et al. found that neurofibromin regulated the 
PI3K-AKT-mTOR (mammalian target of rapamycin, mTOR) axis in NF1-associated 
MPNST (Johannessen, et al., 2005).  Using a cell-based high-throughput chemical 
library screening approach, Banerjee et al. found that the growth of MPNST can be 
inhibited by cucurbitacin-I, an inhibitor of the signal transducer and activator of 
transcription-3 (STAT3), and demonstrated that neurofibromin can regulate cell growth 
through PI3K-mTOR-STAT3 signaling (Banerjee, et al., 2010).
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Fig. 2 The signaling pathways downstream of RAS  
Loss of neurofibromin leads to the increased activity of RAS, and further elevates the 
RAF-MEK1/2-ERK1/2 axis and PI3K-AKT-mTOR axis, which promote cell 
proliferation and survival, respectively.  Abbreviations: RAF, Raf proto-oncogene 
serine/threonine-protein kinase; ERK1/2, extracellular signal-regulated kinase; mTOR, 
mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; TSC: tuberous 
sclerosis complex; Rheb: RAS homolog enriched in brain; 4EBP1: eukaryotic translation 
initiation factors 4E binding protein 1; eIF4E: eukaryotic translation initiation factors 4E; 
S6K1, S6 kinase/ribosomal; IRS1, insulin receptor substrate 1; GF, growth factor.
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The hyperactive RAS in the situation of Nf1 deficiency can activate PI3K which 
catalyzes the two phospholipid second messengers, phosphatidylinositol 
3,4,5-trisphosphate [PI(3,4,5)P3] and phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2]. 
These two phospholipids promote the translocation of 3-phosphoinositide-dependent 
protein kinase 1 (PDK1), and PDK1 phosphorylates AKT at Ser473 and Thr308, which 
activates AKT and enables the phosphorylation of AKT downstream effectors including 
mTOR.  The activated mTOR forms two complexes, mTORC1 and mTORC2 by 
binding to RAPTOR (regulatory associated protein of mTOR, complex 1) or RICTOR 
(rapamycin-insensitive companion of mTOR, complex 2), respectively.  mTORC1 can 
activate the downstream S6 kinase (S6K1/ribosomal) and the eIF4E (eukaryotic 
translation initiation factor 4E) to regulate protein translation process (Guertin and 
Sabatini, 2005).  mTORC2 can phosphorylate AKT leading to a positive feedback to 
further increase the activity of mTORC1.  However, the S6K1, downstream of mTORC1, 
has a negative effect on AKT activity by phosphorylating insulin receptor substrate (IRS1) 
protein, the inactive form of IRS1 which cannot stimulate PI3K (LoPiccolo, et al., 2008).  
Both AKT and mTOR have been demonstrated to have increased activities in MPNST 
cell lines, sNF02.2(Nf1-/-), sNF96.2(Nf1-/-), T265(Nf1-/-), ST88-14(Nf1-/-) and the sporadic 
MPNST STS26T(Nf1+/+) and patient tissues (Zou, et al., 2009b). These studies focused 
interest on the mTOR pathway as a potential drug target. 
Rapamycin and its several other analogues have been evaluated in the MPNST cell 
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lines.  Rapamycin is an antifungal agent isolated from Easter Island.  It has been 
approved by US Food and Drug Administration (FDA) for use after renal transplantation 
as an immunosuppressant.  These compounds function as the inhibitor of mTORC1, 
which suppresses the downstream protein synthesis initiation (Wan and Helman, 2007).  
Rapamycin and its derivative RAD001 have been demonstrated to inhibit the 
proliferation of NF1-related and sporadic MPNST cell lines (Johannessen, et al., 2005) 
and the xenograft growth of STS26T(Nf1+/+) (Johansson, et al., 2008).  However, the 
inhibitory effect of rapamycin and RAD001 on MPNST proliferation is reversible after 
stopping the drug treatment.  Despite these limitations, several clinical trials 
(NCT00652990, NCT00634270, NCT01412892, NCT01365468, NCT01031901) are 
currently testing the rapamycin or RAD001 on plexiform neurofibromas, alleviation of 
tuberous sclerosis complex, and low-grade gliomas in children. 
Gene expression studies in NF1-related MPNSTs 
Gene expression microarray studies have been widely used to identify the gene 
signatures of the MPNST.  Lee et al. first applied the cDNA microarray to the 
comparison of T265(Nf1-/-) cell line and normal human Schwann cells, and they 
identified about 900 differentially expressed genes in T265(Nf1-/-) out of 4608 cDNA 
probes (Lee, et al., 2004).  Watson et al. tested the primary human NF1-associated and 
sporadic MPNST samples by using oligonucleotide microarrays representing 8100 
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unique human genes, but they failed to define a reliable molecular signature to 
distinguish sporadic and NF1-associated MPNST tissue samples (Watson, et al., 2004).  
Miller et al. compared eight MPNST cell lines with normal human Schwann cells and 
identified a molecular signature consisting of 159 genes that could separate them (Miller, 
et al., 2006b).  Research from this group compared the primary human samples from 
different subtypes of neurofibromas and MPNSTs, and the results indicated that the 
overexpressed gene Sox9 may provide a biomarker of survival gene in NF1-related 
MPNSTs (Miller, et al., 2009).   
The above studies have provided enormous data on gene expression changes in 
MPNSTs, however, a direct analysis of aberrantly expressed gene regulation by 
neurofibromin deficiency or their relationship to RAS-MEK signaling were not 
demonstrated.  
NF1 tumorigenesis and microenvironment 
NF1 is an autosomal dominant disease, and haploinsufficiency of Nf1 has been 
proven to induce some clinical traits in the NF1 patients.  In particular, the study of 
Cichowski et al. suggested that loss of heterozygosity in the Nf1 locus is required to form 
the neurofibromas (Cichowski, et al., 1999).  To form the malignant neurofibromas, 
additional genetic defects in Tp53, Pten, and Cdkn2a have been reported (Castle, et al., 
2003; Zhu, et al., 2002).  Heterozygous mouse models with both Nf1 and Tp53 
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developed MPNST with complete penetrance (Vogel, et al., 1999).  In addition, 
overexpression of PDGFR (platelet-derived growth factor receptor) and EGFR 
(epidermal growth factor receptor) have been reported by gene expression profiling 
studies as well as by quantitative RT-PCR in MPNST tumor samples (Levy, et al., 2004).  
The connection between Nf1-related malignancy and microenvironment has been 
well-established by the knockout mice studies.  Although the combined Nf1 and Tp53 
heterozygous mice showed 100% penetrance for MPNST occurrence, Nf1 heterozygous 
mice failed to develop neurofibromas (Jacks, et al., 1994).  However, when the Nf1 was 
selectively knocked out in Schwann cells by Cre/LoxP methodology but with 
heterozygous Nf1 status in other somatic tissues, the mice developed classic plexiform 
neurofibromas with mast cell infiltration, resembling human neurofibromas (Zhu, et al., 
2002).  This study confirmed the Schwann cell origin of plexiform neurofibromas and 
indicated that Nf1 haploinsufficiency in the tumor surroundings and nullizygosity at Nf1 
locus in Schwann cell were both required for the neurofibroma formation.  A recent 
study revealed that there are different susceptible windows for Schwann cells to develop 
plexiform neurofibromas (Le, et al., 2011).  When Nf1 was knocked out from Schwann 
cell precursors at E12.5 or immature stage in the neonates with the Nf1 heterozygous 
background, all the mice exhibited plexiform neurofibromas along the spinal cord after 5 
to 6 months, however, Nf1 ablation in adult mice seldom leads to the tumor formation 
according to this study.  
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 The microenvironment was demonstrated to contribute to Nf1-associated dermal 
neurofibromas. Le et al. identified Nf1-deficient skin-derived precursors (SKPs) that can 
give rise to plexiform or dermal neurofibromas with support from their local 
microenvironment after ex vivo ablation of Nf1 in SKPs and subsequent implanting into 
the vicinity of the sciatic nerve in mice (Le, et al., 2009).  This study highlighted that the 
surrounding neurons and adjacent cell types may form the specific microenvironment to 
facilitate the differentiation of SKPs to the Schwann cell lineage, which created an 
opportunity to form neurofibromas.  A mouse embryonic stem cell (ESC) model has 
proved that neuregulin-1, normally secreted by neurons, could induce the ESC to 
differentiate into Schwann cells in vitro (Roth, et al., 2007).  These facts emphasize the 
role of microenvironment in Nf1-related tumorigenesis.  
  In addition to the communication between Schwann cells and neurons during 
tumor formation, mast cells were identified as another effector in microenvironment to 
contribute to the process.  When EGFP; Nf1+/- bone marrow was transferred to lethally 
irradiated mice (Krox20; NF1flox/flox), multiple discrete tumors formed from the dorsal 
root ganglia of recipients and extensive EGFP labeled mast cells infiltration around the 
peripheral nerve were observed after 6 months (Yang, et al., 2008).  Furthermore, Yang 
et al. demonstrated that bone marrow transplant with mutant c-kit receptor and Nf1+/- to 
the same recipients as above decreased the evidence of tumors, which indicated the 
inhibition of c-kit receptor could be an effective method to treat the neurofibromas (Yang, 
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et al., 2008).  Currently, imatinib mesylate, an inhibitor of c-kit dependent tyrosine 
receptor kinase, is at the phase II clinical trial for neurofibroma treatment (Kalamarides, 
et al., 2012).   
In summary, the knowledge of molecular mechanisms in NF1-related tumorigenesis 
has been greatly accumulated by recent studies, and many details indicate that the 
functions of neurofibromin are not limited to the GTPase activating protein to regulate 
RAS signaling.  Since there are so few therapeutic strategies targeting NF1-related 
tumors in clinics, a systematic study to reveal the signaling cascades downstream of 
neurofibromin is required to identify the pathological mechanisms and pathways so as to 
suggest new therapeutic targets.  
 In the following chapters, we establish a high-throughput method to classify the 
aberrant gene expression changes according to the NRAS, MEK1/2 signaling in MPNST 
cell lines and reveal novel neurofibromin related but NRAS-MEK1/2 independent 
pathways. 
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CHAPTER II: Identification of downstream gene 
expression regulation of neurofibromin 
Summary 
The hypothesis in the dissertation is that the NF1-related aberrant gene regulations 
can be identified by systematic gene expression profile comparisons using MPNST cell 
lines with different Nf1 status. We expected to use microarray analysis in MPNST cell 
lines to develop a detailed scheme of gene expression and identify novel regulation of 
downstream targets of neurofibromin thus leading to a better of understanding of 
molecular mechanisms of this disease and new concepts for drug discovery.  Although 
the elevated NRAS and mitogen-activated protein kinase (MAPK) have been 
characterized in NF1 patients and animal models (Kraniak, et al., 2010; Martin, et al., 
1990), the gene expression changes specific to these pathological pathways have not been 
elucidated.  To answer these questions, we developed gene expression data by Agilent 
whole human genome microarray under designed scenarios where the NRAS and 
MEK1/2 activities were manipulated. ST88-14(Nf1-/-) was employed to identify 
neurofibromin related differentially expressed genes accumulated during the MPNST 
tumorigenesis and Nf1 interference in STS26T(Nf1+/+) was used to identify acute Nf1 
deficiency responses.  By integrating Nf1-dependent gene expression with that of altered 
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NRAS and MEK1/2 interference, we could discriminate neurofibromin-related from 
NRAS and MEK1/2 dependent gene expression changes, and these genes may reveal new 
mechanisms in neurofibromin-related tumorigenesis. 
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Materials and Methods 
Cell culture and chemical treatment 
Human MPNST ST88-14(Nf1-/-) cells (a generous gift from T. Glover, University of 
Michigan, Ann Arbor, MI, USA) and STS26T(Nf1+/+) cells (a generous gift from D. 
Scoles, Cedars-Sinai Medical Center, Los Angeles, CA, USA) were maintained in RPMI 
1640 medium (Invitrogen) supplemented with 5% fetal bovine serum (Hyclone 
Laboratories).  T265(Nf1-/-) cell line (a generous gift from G. De Vries, Hines VA 
Hospital, Hines, Illinois, USA) was cultured in DMEM (Invitrogen) supplemented with 
5% fetal bovine serum.  sNF96.2(Nf1-/-) and sNF02.2(Nf1-/-) cell lines were purchased 
from American Type Culture Collection and cultured in DMEM supplemented with 10% 
fetal bovine serum.  Normal human Schwann cell lines HSC291, HSC361, and HSC338 
(generous gifts from Patrick M. Wood, University of Miami Miller School of Medicine, 
Miami, FL, USA) were cultured in DMEM supplemented with 10% FBS, 2 μM forskolin, 
and 10 nM heregulin.  Cell lines were checked periodically for mycoplasma with Venor 
GeM Mycoplasma Detection Kit (Sigma-Aldrich).  Cultures were propagated for no 
more than 3 months, 10 μM U0126 (CalBiochem) was applied to the ST88-14(Nf1-/-) 
pre-seeded in 10 cm plate for 18h before harvest for mRNA.  
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siRNA gene knockdown  
Human Nf1 siRNA, NRas siRNA, control siRNA and siRNA Transfection Reagent 
(Santa Cruz Biotechnology) were used according to the manufacturer’s instructions.  
STS26T(Nf1+/+) cells were plated at 1.5X105 cells per 10 cm plate 24 h prior to 
transfection.  4 μl of siRNA (~30nM) and 4 μl of siRNA transfection reagent, each 
diluted in 400 μl of OptiMem (Invitrogen), were combined and after a 30 minute 
incubation added to the 3.2 ml of OptiMem in each plate.  The same amount of 
scrambled control siRNA was used as control.  Following a 6 h incubation of cells with 
transfection solution, medium was replaced by growth medium.  Cells were harvested 
48 to 72 h later.  For ST88-14(Nf1-/-), similar protocols were used for NRas knockdown 
and detection. 
Western blotting  
Cells grown from 30% to 80% confluence were washed with ice cold PBS, scraped 
and then were lysed with RIPA buffer (150 mM NaCl; 1% Triton X-100; 0.5% 
deoxycholic acid, 0.1% SDS; 50 mM Tris-Cl; pH 8.0) supplemented with 2% protease 
inhibitor cocktail, 1% PMSF (from stock at 10 mg/ml in methanol), 1 mM Na3VO4, 1 
mM Na4P2O7.10H2O, and 1 mM NaF.  Secondary antibodies were conjugated to IRdye 
infrared dyes (Rockland).  Signal was detected and the bands were quantified using the 
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Odyssey infrared imaging system and software (Licor Biosciences). 
Antibodies used in these experiments were rabbit polyclonal anti-neurofibromin 
(#sc-67, Santa Cruze Biotechnology), goat polyclonal anti-NRAS (#ab77392, Abcam), 
mouse monoclonal anti-phospho-ERK1/2 (#9106, Cell Signaling), rabbit polyclonal 
anti-ERK1/2 (#9106, Cell Signaling), and mouse monoclonal anti-α-tubulin (#T5168, 
Sigma-Aldrich).  Neurofibromin, phosphorylated ERK1/2 and NRAS in cell lysates 
were run on 8%, 10% and 15% SDS polyacrylamide gel electrophoresis (SDS-PAGE), 
respectively.  Around 80 μg protein lysate was loaded in each well, and nitrocellulose 
transfer membrane (Protran, Whatmann GmbH) was used for protein transfer. 
RNA isolation and microarray analysis  
Total RNA was extracted from the cells using RNeasy mini Kit (#74106, Qiagen) 
with genomic DNA removal by RNase-Free DNase Set (#79254, Qiagen).  RNA 
integrity was determined by an Agilent Bioanalyzer 2100.  Labeled targets were 
synthesized from the purified RNA using linear amplification and indirect labeling by 
incorporation of aminoallyl-labeled nucleotide with the TargetAmp 1-round 
aminoallyl-aRNA amplification kit 101 (Epicentre Technologies), which was 
subsequently modified by the covalent addition of Alexa dye (Epicentre Technologies).  
Gene expression microarray experiments were performed using the 60-mer 
oligonucleotide arrays (Agilent Whole Human Genome Oligo Microarray chip 44K).  
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Two color hybridizations were performed by using a standardized common reference 
sample (Universal Human Reference RNA, Agilent) and the standard hybridization 
methods described by the manufacturer (Agilent). 
Gene expression data was analyzed with the open source R Statistical Environment 
(www.r-project.org) using libraries from the Bioconductor Project 
(www.bioconductor.org).  Microarray data was normalized within arrays using Lowess 
normalization followed by normalizing between arrays using quantile normalization as 
implemented in the Bioconductor library limma (Smyth, et al., 2005).  Gene expression 
changes among samples were determined using a moderated t-test implemented in 
‘limma’. 
Gene ontology and pathway analysis 
Ingenuity Pathway Analysis (IPA) software (Ingenuity System, 
http://www.ingenuity.com) and Genomatix software suite (http://www.genomatix.de/) 
were used in the gene function enrichment and pathway analysis.  Generally, gene 
official names with fold change from different data sets were used as input, and the 
software generates the biologically significant terms or pathways based on the classic 
knowledge and latest literature reports.  All the analyses were conducted following the 
manufacturer’s instruction and default settings. 
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 Quantitative Real time PCR using SYBR green I 
Three batches of independent total RNA from the same preparations for microarray 
were reverse transcribed by SuperScript® First-Strand Synthesis System (Invitrogene).  
The qRT-PCR SYBR green master mix was purchased from Invitrogene.  ABI 7500 
Sequence Detection System was used to determine the relative quantity of a specific gene 
from the cDNA template.  Default running parameters were used.  Primer sequences 
for validation are show in supplementary table 1.  
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Results 
OncoCarta oncogene survey in the MPNST cell lines 
Hyperactive RAS and MAPK activities are hallmarks of the abnormal signal 
transduction at the molecular level in NF1 patients. Whereas in most situations cells 
exhibit oncogene-induced senescence after activation of RAS, loss-of-function of Nf1 in 
neurofibromas only results in a transitory growth arrest, and finally give rise to MPNSTs 
by escaping the growth limitation (Courtois-Cox, et al., 2006).  A second hit could be 
one theory to explain this escape from oncogene-induced senescence; however, the 
mechanism is not completely clear.    
Because MPNST cell lines are the malignant cell type developed from 
neurofibromas, these cell lines could hold the keys to the phenomenon.  We assembled 
five MPNST cell lines, and sequenced 238 known mutations in 19 oncogenes, 
ABL-1,AKT-1, AKT-2, BRAF, CDK-4, EGFR, ERBB2, FGFR-1, FGFR-3, FLT-3, 
JAK-2, KIT, MET, PDGFRa, PIK3CA, H-RAS, K-RAS, N-RAS, and RET (Table 1) 
based on OncoCarta Panel V1.0 (Sequenom, San Diego, CA, USA) (Sun, et al., 2012).  
ST88-14(Nf1-/-), T265(Nf1-/-), sNF96.2(Nf1-/-) and sNF02.2(Nf1-/-) were derived from NF1 
patients with either undetectable or extremely low neurofibromin protein expression as 
demonstrated by western blotting analysis (Fig. 3).  STS26T(Nf1+/+) cells were derived 
from a sporadic MPNST and have functional neurofibromin (Kraniak, et al., 2010).  We 
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first determined the neurofibromin level in all available MPNST cell lines and a normal 
human Schwann cell (HSC361), with the wild type of neurofibromin, was used as a 
positive control.   
From the OncoCarta sequencing result, none of the candidate mutations was 
identified in the five different MPNST cell lines.  This result suggested that oncogene 
mutation related effects were not necessary in the formation of MPNSTs, especially in the 
context of hyperactive NRAS due to neurofibromin loss.  At the same time, this 
suggested that hyperactive NRAS, resulting from Nf1 deficiency, in an Nf1 
haplo-insufficient microenvironment can initiate the neoplasia and the necessary changes 
in the surrounding tissues that promote the pro-survival signaling to the Nf1 null Schwann 
cells leading to malignancy and bypassing the anti-cancer mechanisms. 
Pathway intervention and intersection analysis scheme in MPNST cell 
lines 
To determine and classify neurofibromin-dependent gene expression, we applied 
pathway-specific interventions.  Using chemical and genetic pathway interference in the 
ST88-14(Nf1-/-), we identified gene expression profiles specific to MEK1/2 and NRAS, 
the predominant RAS isoform in NF1-associated MPNST cell lines (Mattingly, et al., 
2006).  The comparison between ST88-14(Nf1-/-) and normal human Schwann cells 
(HSC) was used to capture the genes deregulated during tumorigenesis after loss of the 
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Nf1 gene in ST88-14(Nf1-/-).   Gene expression changes specific to an Nf1 deficiency 
can be further revealed by siRNA interference to Nf1 in STS26T(Nf1+/+),  a sporadic 
MPNST cell line with wild type Nf1 expression (Dahlberg, et al., 1993; Miller, et al., 
2006b).  Using Agilent whole human genome 4X44K two color microarrays, we 
investigated neurofibromin, NRAS and MEK1/2 related gene expression profiles. 
The gene expression changes were defined as the following data sets (DS): 
DS-1) siRNA targeted knockdown of human Nf1 gene (versus a scrambled control 
siRNA) in STS26T(Nf1+/+), a sporadic MPNST, was performed to distinguish the gene 
changes specific to an Nf1 knockdown. 
DS-2) siRNA targeted knockdown of human NRas (versus a scrambled control siRNA) 
in ST88-14(Nf1-/-) was performed to identify NRas knockdown associated gene changes. 
DS-3) Administration of the MEK1/2 inhibitor, U0126 (versus DMSO control) to 
ST88-14(Nf1-/-) to identify MEK1/2 pathway influenced genes. 
DS-4) Comparison of gene expression of ST88-14(Nf1-/-), a Nf1 associated MPNST cell 
line, versus gene expression of normal human Schwann cells (HSC) to identify gene 
expression changes associated with an Nf1 deficiency. 
In ST88-14(Nf1-/-), the NRas siRNA decreased the expression of NRAS on the 
protein level by 60% and decreased phosphorylated ERK1/2 by 50%, confirming that 
hyperactive NRAS in ST88-14(Nf1-/-) was a strong upstream signal activating the 
MEK-ERK pathway (Fig. 5a).  U0126, an inhibitor of MEK1/2 in NF1 associated 
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MPNST cells (Kraniak, et al., 2010), reduced the level of phosphorylated ERK1/2 by 
90% after 18 h treatment at 10 μM (Fig. 5b).  In the sporadic MPNST cell line 
STS26T(Nf1+/+), Nf1 siRNA (siNf1) knockdown efficiency after 48 h of neurofibromin 
was evaluated by western blotting and neurofibromin was found to decrease by 
approximately 90% at the protein level compared to scrambled control siRNA treated 
(Fig. 5c).  Phosphorylated ERK1/2 increased by about 1.6-fold in siNf1 treated 
STS26T(Nf1+/+) cells, indicating that the neurofibromin-NRAS-MEK1/2 axis was 
functional in the sporadic MPNST (Fig. 5c).   
The differentially expressed gene lists from each comparison provided the basis for 
the intersection analysis of the gene expression profiles.  The overlapped genes were 
then classified into cell signaling axes based on their trend of changes defined in Table 2.  
For example, given that MEK1/2 is downstream of RAS, if a gene is upregulated when 
NRAS is inhibited, and is also upregulated when MEK1/2 is inhibited, the regulation of 
this gene is hypothetically under control of RAS-MEK1/2 axis meaning that the 
suppressed RAS may upregulate that gene through the decreased activity of MEK1/2.  
With similar reasoning, we associated the overlapped genes to the specific signaling axis, 
and defined the genes that belong to neurofibromin related but NRAS and MEK1/2 
independent.  
Around 60 differentially expressed genes were randomly chosen to verify the 
microarray results by quantitative polymerase chain reaction (qRT-PCR) and ~97% of 
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Fig. 3 Neurofibromin and Phos-ERK1/2 in MPNST cell lines 
Neurofibromin is undetectable in ST88-14(Nf1-/-) and T265(Nf1-/-), and there is a very 
weak band in sNF96.2(Nf1-/-) and sNF02.2(Nf1-/-).  Neurofibromin is wild type in 
STS26T(Nf1-/-) and HSC361.  The phosphorylation of ERK1/2 increases in 
ST88-14(Nf1-/-), T265(Nf1-/-), sNF96.2(Nf1-/-) and sNF02.2(Nf1-/-) compared to the 
HSC361.  The figure represents one of the three independent expmeriment replicates. 
 
Fig. 4 Scheme of intersection analysis of gene profiles 
The intersection analysis scheme of gene expression profiles is indicated by Venn 
diagram.  The comparison scheme to identify expression changes associated to 
neurofibromin, but independent from NRAS and MEK1/2 pathways, is indicated. 
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Fig. 5 Verification of interference conditions in MPNST cell lines 
(a) Western blotting indicated the NRAS and phosphorylated ERK1/2 protein were 
greatly decreased comparing to scrambled control siRNA after 48h treatment of siNRas in 
ST88-14(Nf1-/-) cells.  (b) Western blotting indicated the levels of phosphorylated 
ERK1/2 were significantly decreased after U0126 treatment of 18 h compared to DMSO 
control in ST88-14(Nf1-/-) cells.  (c) Neurofibromin decreased after 48h treatment of 
siNf1 whereas phosphorylated ERK1/2 increased compared to scrambled control siRNA 
in STS26T(Nf1+/+) cell line. 
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the trends were confirmed.  The verified list for genes and primers are provided in 
supplementary table 1. 
Intersection analysis revealed the pathway related gene expression 
changes in ST88-14(Nf1-/-) 
As we expected, in ST88-14(Nf1-/-) cell line, when comparing the lists of genes from 
any two of the three experiments (ST88-14 vs. HSC, siNRas vs. control, and U0126 vs. 
DMSO), we found a substantial number of differentially expressed genes shared by the 
lists (Table 2).  This demonstrated that our methods of inhibition, siNRas and U0126, 
were functionally consistent.  The genes differentially expressed when comparing 
ST88-14(Nf1-/-) and HSC included gene changes due to the tumorigenesis process in 
addition to the genes regulated by a wild type neurofibromin.  We employed Nf1 
interference in STS26T(Nf1+/+) to delineate the genes due to the neurofibromin 
deficiency from the genes associated with tumorigenesis. 
The loss-of-function of neurofibromin and hyperactive NRAS have been 
characterized in ST88-14(Nf1-/-) (Kraniak, et al., 2010).  To identify specific targets of 
neurofibromin-NRAS axis (DS-5), we defined two patterns of gene expression changes in 
the comparisons of ST88-14(Nf1-/-) versus HSC (DS-4) and siNRas versus scrambled 
control (DS-2): 1) gene expression upregulated in DS-4, but downregulated in DS-2, or 2) 
downregulated in DS-4 but upregulated in DS-2 (Table 2, DS-5 in supplementary table 
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2).   
Gene set enrichment analysis (GSEA) by Genomatix Pathway System (GePS) 
revealed that the gene ontology (GO) term in biological process such as “positive 
regulation of heart contraction” (GO: 0045823), including genes Adm and Tpm1, and 
“cellular component morphogenesis” (GO: 0032989), including genes Adm, Met, Ptprz1, 
Tpm1 and Smad3 were significantly enriched.  Another interesting gene consistent with 
these patterns was Rgs16, which can activate the GTPase of G protein alpha unit so as to 
inhibit the signal transduction from the outside of the cell.  Rgs16 expression in 
ST88-14(Nf1-/-) decreased by 5.6-fold and increased by about 2-fold in the siNRas treated 
compared to the scramble control siRNA.  This pattern suggested Rgs16 expression was 
regulated by neurofibromin-NRAS negatively associated with the increased RAS activity.  
Considering the complex signaling downstream G-protein subunits including ERK1/2, 
PI3K and adenylate cyclases, the downregulation of Rgs16 by increased NRAS could 
serve another strong enhancer of the MPNST tumorigenesis.  The loss of Rgs16 has 
been reported in some breast cancers, associated with PI3K signaling (Liang, et al., 
2009). 
Gene expression that increased in ST88-14(Nf1-/-) compared to HSC in DS-4 and 
decreased in the U0126 treated cells in DS-3, or alternately decreased expression of genes 
in DS-4 but increased expression in DS-3, could be the regulatory targets of 
neurofibromin-MEK1/2 axis (Table 2, DS-6 in supplementary table 3).  GSEA indicated 
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that ontology terms like “cell cycle” (GO:0007049, p-value=7.65e-8), “cell cycle arrest” 
(GO:0007050, p-value=3.49e-7) and “regulation of serine/threonine kinase activity” 
(GO:0071900, p-value=3.48e-4) were among the most significant terms.  These 
biological process terms were consistent with the ERK1/2 suppression related cell cycle 
arrest (Meloche and Pouyssegur, 2007) and inhibition effects of U0126 to MEK1/2 
(Mattingly, et al., 2006), suggesting deregulation of these processes after defects of 
neurofibromin-MEK1/2 axis in MPNSTs.  Sox9, which is listed in DS-6, has been 
reported as a biomarker in MPNSTs because of its overexpression in NF1-related 
malignancies and its role in the tumor survival (Miller, et al., 2009).  DS-6 confirmed 
that the Sox9 expression was higher in ST88-14(Nf1-/-) compared to HSC and indicated 
that Sox9 expression can be downregulated by U0126.  Additionally, Sox9 expression 
did not change in the siNRas treated sample, which indicated a new mechanism in which 
Sox9 expression is regulated by neurofibromin-MEK1/2 but not by NRAS in 
ST88-14(Nf1-/-) cells.   
Also in DS-6, we observed Edn1 (Endothelin 1) to be strongly inhibited by U0126 
(Fig. 6), indicating that the MEK1/2 cascade signaling was prominent in its mRNA 
expression regulation.  Results from Integrated Pathway Analysis (IPA) identified that 
among the genes that have been reported to be regulated by EDN1, mRNA expression of 
8 genes were positively associated with mRNA level of Edn1 in DS-6, consistent with 
literature supported trend of change.  These genes were Apln, Cdc25a, Egfr, Errfi1, Fst, 
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Il8, Mmp9, and Ptger4 (Table 3) (Fig. 7).  EDN1 is a secreted protein with multiple 
physiological effects on cellular development, differentiation, vasoconstriction and 
mitogenesis (Stow, et al., 2011).  Actually, we have observed Edn1 RNA to be highly 
expressed in several MPNST cell lines (Fig. 8).  It may be an important effector under 
the regulation of neurofibromin-MEK1/2 axis during development and tumorigenesis.   
Comparing DS-2 (siNRas vs. control) and DS-3 (U0126 vs. DMSO), genes both 
up-regulated or both down-regulated in the two different data sets, were identified as 
NRAS-MEK1/2 axis (Table 2, DS-7 in supplementary table 4).  Ecto-5’-nucleotidase 
(NT5E) that converts AMP to adenosine was down-regulated in both data sets, and 
Sunaga et al. reported that NT5E was down-regulated in non-small cell lung cancer 
(NSCLC) lines with KRAS knockdown (Sunaga, et al., 2011).  NT5E has also been 
associated with cell cycle and apoptosis in breast cancer, arterial calcifications and 
immunodeficiency diseases (Edwards, et al., 1978; St Hilaire, et al., 2011; Zhi, et al., 
2010).  Our study indicated its expression was positively controlled by NRAS-MEK1/2 
axis in ST88-14(Nf1-/-) cells.   
Identification of neurofibromin-related gene expression changes 
independent from NRAS and MEK1/2 pathways in MPNST cells 
For the three comparative scenarios involving ST88-14(Nf1-/-) cells (Fig. 4), removal 
from DS-4 of the genes that overlapped with DS-2 and with DS-3 enabled us to identify 
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Fig. 6 Quantitative RT-PCfR verification of Edn1 expression in microarrays  
 Edn1 gene expression changes in microarrays is verified by qRT-PCR indicating the 
gene Edn1 was overexpressed in the ST88-14(Nf1-/-) cells compared to the HSC. Data is 
presented as the means of three independent experiments ± SD. 
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Fig. 7 EDN1 related molecules network built by the IPA  
The network was built by the IPA pathway tool based on the literature.  Each molecule 
was colored according to the ratios in the comparison between ST88-14(Nf1-/-) and HSC, 
DS-4.  Red indicates increased mRNA expression in ST88-14(Nf1-/-) vs. HSC and green 
indicates decreased mRNA expression in ST88-14(Nf1-/-) vs. HSC. 
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Fig. 8 Quantitative RT-PCR analysis of Edn1 mRNA expression in MPNST cell lines 
The relative Edn1 mRNA expression of different MPNST cell lines and normal human 
Schwann cell (HSC361) are presented.  Edn1 mRNA expression was significantly 
higher in MPNST cell lines compared to the HSC.  Paired t-test, n=3, **p<0.01.  Data 
is presented as the means of three independent experiments ± SD. 
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those genes that were independent of the NRAS and MEK1/2 pathways, namely DS-9 
(Fig. 4, Table 2, and DS-9 in supplementary table 6).  The genes in this data set were 
NRAS and MEK1/2 independent but neurofibromin related in ST88-14(Nf1-/-) cells.  
There were 1474 down-regulated and 1223 up-regulated genes in DS-9.  We performed 
pathway analysis using the GePS from the Genomatrix program, which can map the 
genes to the canonical and literature supported pathways (Werner, 2007).  GePS 
provides the significance evaluation by fisher exact test to compare the expected number 
of genes in one pathway/term in the genome to the number of the genes mapped to the 
same pathway/term in the list.  For the downregulated genes, the canonical pathway 
analysis and the literature pathway analysis are shown Table 4 and Table 5, p < 0.01.  
For the upregulated genes, the canonical pathways and literature supported pathways are 
shown as Table 6 and Table 7, p < 0.01.  
We then created a dataset of Nf1 directly regulated genes in Schwann cell derived 
MPNST cell lines, by knocking down Nf1 with siRNA in STS26T(Nf1+/+) cells 
comparing to scrambled control siRNA (DS-1).  By overlapping DS-9 with DS-1, we 
identified 142 unique genes that were downregulated and 73 unique genes that were 
upregulated in both DS-1 and DS-9, namely DS-10 (Table 2, Fig. 4 supplementary table 
7).  Genes in this overlap suggested that their expression was under the regulation of 
neurofibromin, but independent from the NRAS and MEK1/2 pathway.  Among the 
downregulated changes, the canonical pathway analysis by GePS identified “NOTCH” 
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pathway genes, including Adam10, Ncstn and Adam17, and “Toll-like receptor signaling”, 
including Tollip and Mapk14 (Table 8).  The literature supported pathways are shown in 
Table 9.  For the upregulated changes, “signaling by BMP2” was reported by GePS to 
be significant (Table 10).  The GO term SMAD signal transduction (GO:0060395, 
p-value=1.16e-3) including Hipk2 and Bmp2 was significant in the functional enrichment 
analysis by GePS.  These results drew our attention to the aberrant expression of Bmp2 
in NF1-related MPNST cell.  It was notable that GO term RAS GTPase binding 
(GO:0017016, p-value=4.70e-4) including Dock4, Myo5b, Srgap1 and Als2 was also 
significant in up-regulated changes indicating possible multiple regulatory mechanisms 
of activated NRAS activity after loss of function of neurofibromin.    
Bmp2 overexpression was independent from the status of NRAS and 
MEK1/2 in MPNSTs but related to neurofibromin function 
As members of transforming growth factor-beta (TGF-beta) superfamily, bone 
morphogenetic proteins (BMPs) play various roles in morphogenesis and homeostasis in 
many tissues.  Recent studies have pinpointed the role of BMPs in molecular processes 
associated with different human cancers (Singh and Morris, 2010).  Interestingly, we 
also found BMP2 as one of 2827 differentially expressed transcripts in Miller’s 
microarray data on NF1 associated tissue samples, and based on that data, we found the 
there was a positive association between Bmp2 expression and malignancy of 
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NF1-associated tumor (Miller, et al., 2009) (Fig. 9). 
We verified differential Bmp2 gene expression by quantitative RT-PCR under the 
experimental conditions analyzed by microarray (Fig. 10).  Briefly, Bmp2 mRNA was 
overexpressed in ST88-14(Nf1-/-) compared to the normal human Schwann cells.  
Consistent with the microarray data, there was no significant difference in ST88-14(Nf1-/-) 
treated with U0126 or siNRas compared to controls.  In STS26T(Nf1+/+), three different 
siNf1 oligos were used to verify the association between neurofibromin and Bmp2 
expression.  All three of the oligos significantly inhibited the neurofibromin and 
increased the Bmp2 mRNA expression (Fig. 11).  We next used an inducible oncogenic 
RAS expression system in STS26T(Nf1+/+) cells which mimic the loss of function of 
GTPase-activating domain of neurofibromin (Kraniak, et al., 2010) to study the NRas 
dependence of Bmp2 expression in MPNST cells.  After removal of doxycycline from 
the cultural media, the oncogenic RAS was induced and ERK1/2 phosphorylation was 
increased (Fig. 12).  However, Bmp2 expression did not change significantly with 
increased RAS activity in this cell model (Fig. 13), indicating that the increased 
expression of Bmp2 mRNA was dependent on neurofibromin but independent of the 
NRAS activity. 
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Fig. 9 Bmp2 mRNA expression in NF1-associated tissue samples 
The data plotted is from the gene expression study in NF1 patient tissues by Miller et al. 
2009.  The normalized probe intensities of Bmp2 in normal human cells (NHSC) and 
different neurofibromas are shown.  In normal human Schwann cells and cells from 
benign dermal neurofibromas, the expressions of Bmp2 are relatively low.  In high risk 
plexiform neurofibromas and malignant peripheral nerve sheath tumors, Bmp2 expression 
is dramatically increased. 
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Fig. 10 Quantitative RT-PCR verification of Bmp2 mRNA change in different 
comparisons 
In ST88-14(Nf1-/-), the expression of Bmp2 was significantly higher than normal human 
Schwann cells (HSC).  However, siNRas and U0126 failed to significantly affect Bmp2 
expression compared to the controls, respectively.  Paired t-test, n=3, **p<0.01.  Data 
is presented as the means of three independent experiments ± SD 
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Fig. 11 Neurofibromin status influences the Bmp2 mRNA expression in STS26T 
(Nf1+/+) 
Three different siNf1 oligos inhibited neurofibromin expression in STS26T(Nf1+/+) 
as shown in western blotting.  Bmp2 mRNA increased in STS26T(Nf1+/+) after 48 h 
treatment with three different siNf1 oligos compared to the scrambled control, 
respectively.  Paired t-test, *p<0.05, **p<0.01, n=3.  Data is presented as the means of 
three independent experiments ± SD. 
 
 
Fig. 12 Inducible RAS expression system in STS26T(Nf1+/+) 
HA-tagged oncogenic RAS was induced in STS26T(Nf1+/+) with the removal of 
doxcycline (Dox) from the culture media.  48 h after Dox removal, the phosphorylated 
ERK1/2 and HA-tagged RAS increased. 
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Fig. 13 Inducible oncogenic RAS failed to change the expression of Bmp2 mRNA 
In STS26T(Nf1+/+),  oncogenic RAS was induced by removing doxycycline (Dox).  
The Bmp2 mRNA accumulation did not change significantly compared with the 
non-induced cells (NoDox).  The data shown is the means of three independent 
experiments ± SD.  No significant difference identified by paired t-test, n=3, p<0.05.
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Discussion 
The RAS-GAP domain of neurofibromin is the best described functional domain in 
this 250 kDa protein.  However, the malignant phenotypes of neurofibromin deficient 
MPNST cells cannot be totally rescued by the GAP domain reconstitution alone (Ho, et 
al., 2007; Ismat, et al., 2006).  Furthermore, RAS-targeted therapeutic approaches, such 
as S-trans, trans-farnesylthiosalicylic acid, provide limited efficacy in clinical studies of 
NF1 (Kalamarides, et al., 2012; Widemann, et al., 2006).  The understanding of complex 
neurofibromin function in development and tumorigenesis requires insight into Nf1 
related biological processes not only associated RAS-MEK1/2-ERK1/2 axis but also 
independent of it.  
To answer these questions, we used Schwann cell derived MPNST cell lines with 
different Nf1 status and the gene expression profiles at multiple different means of 
interference to reveal the possible function of neurofibromin in MPNST.  Because the 
Nf1-related neurofibromas seldom have oncogene induced senescence, we doubted 
whether there could be an oncogene mutation as an additional hit to Nf1 heterozygous 
Schwann cells to promote tumorigenesis.  We sequenced the known 238 mutations from 
19 oncogenes in ST88-14(Nf1-/-), T265(Nf1-/-), sNF96.2(Nf1-/-), sNF02.2(Nf1-/-) and 
STS26T(Nf1+/+), however, none of these relatively common mutations in oncogenes were 
identified in the above five cell lines.  Based on these results, we can say that oncogene 
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mutation related effects may not be necessary in the formation of MPNSTs, especially in 
the context of hyperactive RAS due to Nf1 loss.  The constitutively active RAS pathway 
provides strong pro-survival signals through its downstream RAF-MEK1/2-ERK1/2 and 
PI3K-AKT-mTOR signaling pathways.  These activated pathways may abrogate the 
selective pressures against mutations in oncogenes such as Akt1, Akt2, Braf, and Pi3kca 
during tumorigenesis, and explain why the common oncogene mutations in cancer were 
not observed in this study.  It is worth noting that among the five MPNST cell lines, 
only STS26T(Nf1-/-) has the null Tp53, and all of the others have the wild type Tp53 (Li, 
et al., 2004; Lopez, et al., 2011; Miller, et al., 2006b).  
 In this study, we performed pathway-specific interventions to the MPNST cell 
lines using genetic and chemical methods.  The intersection analysis of the gene 
expression changes across these treatments enabled us to classify those changes specific 
to the NRAS and MEK1/2 pathways, and further to discover novel changes in MPNST 
cell lines independent from those pathways. This is the first study that associates gene 
expression changes to specific pathways activated in MPNST cell lines so as to identify 
novel neurofibromin related gene expression changes independent of NRAS and MEK1/2 
pathway.  In ST88-14(Nf1-/-), the intersection analysis helps to classify DS-9, and DS-9 
was further refined by neurofibromin association in STS26T(Nf1+/+) to create DS-10 
which specified genes that were neurofibromin-related but NRAS and MEK1/2 
independent changes in gene expression.   
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  By using pathway analysis tools, such as Integrated Pathway Analysis (IPA), 
which has the ability to integrate literature mining with biological information, novel 
hypotheses can be generated.  For example, EDN1 has been reported to play an 
important role in heart development (Chen, et al., 2010) and is associated with cardiac 
hypertrophy in patient cohort studies (Castro, et al., 2007).  These facts may explain the 
embryonic lethality due to failure of heart development in the Nf1 knockout mouse model 
and likewise increased risk for a variety of cardiovascular disorders in NF1 patients 
(Friedman, et al., 2002).  We identified 8 potential downstream effectors of EDN1, those 
genes may contribute to the malignancy of MPNSTs cooperated with EDN1.  Another 
example is the overexpressed gene Adm in DS-5.  Adm encodes the protein 
adrenomedullin which functions as systemic vasodilator and natriuretic peptide, and high 
Adm mRNA level has been correlated to hypertension (Jiang, et al., 2004) and myocyte 
hypertrophy (Romppanen, et al., 1997; Tsuruda, et al., 2003).  NF1 patients with 
hypertension have been reported (Demarchi, et al., 2011; Montani, et al., 2011), but the 
mechanism is still not clear.  In the Nf1 knockout mouse model, Xu et al. reported that 
cardiomyocyte-specific knockdown of Nf1 contributed to cardiac hypertrophy (Xu, et al., 
2009).  These clues and the gene expression changes identified could serve as the 
mechanistic basis for an NF1-related cardiovascular disease study. 
The expression pattern of Bmp2 in the MPNST tissues and DS-10 drew our attention 
to the possible function of BMP2 in MPNSTs.  Bmp2 expression deregulation has been 
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associated to many types of cancers including ovarian (Kiyozuka, et al., 2001; Le Page, et 
al., 2006), glioma (Liu, et al., 2009), salivary adenocarcinoma (Hatakeyama, et al., 1993), 
pancreatic cancer (Kleeff, et al., 1999).  The in vitro studies on the cell lines indicate 
that Bmp2 transcripts increase about 17-fold in non-small cell lung carcinoma (NSCLC) 
(Langenfeld, et al., 2003) and about 25-fold in small cell lung carcinoma (SCLC) 
(Bieniasz, et al., 2009) compared to the normal tissue.  The Bmp2 copy number increase 
has been reported as well in early prostate cancer (Doak, et al., 2007).  However, studies 
also show that exogenous BMP2 may lead to the cell cycle arrest in G1-phase in some 
gastric cancer (Wen, et al., 2004), and suppress estradiol-induced proliferation of MCF-7 
mediated through upregulation of p21CIP1/WAF1 protein and hypophosphorylation of pRB 
(Arnold, et al., 1999; Ghosh-Choudhury, et al., 2000).  The growth stimulatory and 
inhibitory effects of BMP2 may vary according to the cell type, differentiation stage and 
the cancer microenvironment.  The inhibitory effect of BMP2 is not observed in 
MPNST cell lines, as the levels of phosphorylated RB are generally higher in many 
MPNST cell lines than the normal human Schwann cell line (Miller, et al., 2006b) and 
p21CIP1/WAF1 is even undetectable in T265(Nf1-/-) cell line (Lee, et al., 2004).  These 
observations encouraged us to explore other possible mechanisms to explain the actions 
of BMP2 in MPNSTs.  
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Gene name Mutation sites checked 
  ABL‐1       G250e, Q252h, Y253h, Y253F, e255K, e255V, D276G, F311L, T315I, F317L, M351T, e355G, F359V, h396r 
  AKT‐1       V461L, p388T, L357T, e319G, V167A, Q43X, e17del     
  AKT‐2       S302G, r371h     
  BRAF       G464r, G464V/e, G466r, F468C, G469S, G469e, G469A, G469V, G469r, G469r, D594V/G, F595L, G596r, L597S, L597r, 
L597Q, L597V, T599I, V600e, V600K, V600r, V600L, K601N, K601e       
  CDK‐4       r24C, r24h     
  EGFR     
  r108K, T263p, A289V, G598V, e709K/h, e709A/G/V, G719S/C, G719A, M766_A767insAI, S768I, V769_D770insASV, 
V769_D770insCV, p753S, A750p, T751A, T751p, T751I, S752I/F, S752_I759del, L747_Q ins, e746_T751del, I ins 
(combined), e746_A750del, T751A (combined), L747_e749del, A750p (combined), L747_T750del, p ins (combined), 
L747_S752del, Q ins (combined)    D770_N771.AGG/V769_D770insASV/V769_D770insASV, D770_N771insG, 
N771_p772.SVDNr, p772_h773insV, h773.NpY, h773_V774insNph/ph/h, V774_C775inshV, T790M, L858r, L861Q, 
e746_T751del, e746_A750del, e746_T751del, e746, T751del, S752D, L747_e749del, L747_T750del, L747_S752del, 
L747_T751del, L747_S752del,     
  ERBB2       L755p, G776S/LC, G776VC/VC, A775_G776insYVMA, p780_Y781insGSp, p780_Y781insGSp, S779_p780insVGS     
  FGFR‐1       S125L, p252T     
  FGFR‐3       G370C, Y373C, A391e, K650Q/e, K650T/M     
  FLT‐3       I836del, D835h/Y     
  JAK‐2       V617F     
  KIT     
  D52N, Y503_F504insAY, W557r/r/G, V559D/A/G, V559I, V560D/G, K550_K558del, K558_V560del, K558_e562del, 
V559del, V559_V560del, V560del, Y570_L576del, e561K, L576p, p585p, D579del, K642e, D816V, D816h/Y, V825A, 
e839K, M552L, Y568D, F584S, p551_V555del, Y553_Q556del   
  MET       r970C, T992I, Y1230C, Y1235D, M1250T     
  PDGFRa       V561D, T674I, F808L, D846Y, N870S, D1071N, D842_h845del, I843_D846del, S566_e571.K, I843_S847.T, D842V     
  PIK3CA       r88Q, N345K, C420r, p539r, e542K, e545K, Q546K, h701p, h1047r/L, h1047Y, r38h, C901F, M1043I     
  H‐RAS       G12V/D, G13C/r/S, Q61h/h, Q61L/r/p, Q61K     
  K‐RAS       G12C, G12r, G12S, G12V, G12D, G12A, G12F, G13V/D, A59T, Q61e/K, Q61L/r/p, Q61h/h     
  N‐RAS       G12V/A/D, G12C/r/S, G13V/A/D, G13C/r/S, A18T, Q61L/r/p, Q61h, Q61e/K     
  RET       C634r, C634W, C634Y, e632_L633del, M918T, A664D     
Table 1: Mutations assayed for each of the 19 oncogenes in the OncoCarta v1.0 
Mutation Panel.   
A total of 238 mutations in 19 oncogenes were assayed in ST88-14(Nf1-/-), T265(Nf1-/-), 
sNF96.2(Nf1-/-) sNF02.2(Nf1-/-) and STS26T(Nf1+/+).  There was no mutation mentioned 
in this table identified in all five cell lines. 
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Table 2: Definition of data set and pathway association 
The patterns of gene change in data set comparison were defined to associate the genes to 
the specific signal axis.    : gene increase,    : gene decrease. ∩: Intersection 
operation, U: Union operation, \ : Relative Complement operation,  AND, OR, NOT IN: 
Logic operation. 
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Table 3: EDN1 related gene expression changes in DS-6 with literature supports. 
Based on the IPA analysis, the mRNA of 8 genes in DS-6, neurofibromin-MEK1/2 axis 
related data set, changed positively associated with the mRNA level of Edn1 with 
literature supports.  The Pubmed IDs of the specific support article are indicated. 
 
 
Table 4: Canonical pathways associated to the down-regulated genes in DS-9  
Downregulated genes in the DS-9 were uploaded to the GePS of Genomatix, and then 
mapped to the significant canonical pathways by GePS, p < 0.01. 
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Table 5: Literature based pathways associated to the downregulated genes in DS-9 
In GePS analysis, the downregulated genes in DS-9 were mapped to the significant 
pathways supported by literature, p < 0.01. 
 
 
Table 6: Canonical pathways associated to the upregulated genes in DS-9  
The upregulated genes in DS-9 were mapped to the significant canonical pathway by 
GePS, p < 0.01. 
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Table 7: Literature based pathways associated to the upregulated genes in DS-9  
In GePS analysis, the upregulated genes in DS-9 were mapped to the significant 
pathways supported by literature, p < 0.01. 
 
 
 
 
 
Table 8: Canonical pathways associated to the downregulated genes in DS-10 
In GePS analysis, the downregulated genes in DS-10 were mapped to the significant 
canonical pathway, p < 0.05. 
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Table 9: Literature based pathways associated to the downregulated genes in DS-10 
In GePS analysis, the downregulated genes in DS-10 were mapped to the literature 
supported significant pathways, p < 0.05. 
 
 
 
Table 10: Canonical pathways associated to the upregulated genes in DS-10 
The upregulated genes in DS-10 were mapped to the canonical pathway, p < 0.05. 
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CHAPTER III: The role of BMP2 in MPNST cells 
Summary 
The comparative analysis of gene expression profiles using data sets from 
mechanism-specific interventions enabled us to classify the signaling pathways that are 
regulated by neurofibromin.  Among the neurofibromin-related genes whose expression 
was NRAS and MEK1/2 independent, we focused on the upregulation of Bmp2.  BMP2 
is a secreted protein which is overexpressed in many different tumor types and to be 
involved in various processes, reviewed by Singh et al. (Singh and Morris, 2010).  The 
data from Miller et al. 2009 suggested the positive association of Bmp2 expression with 
the malignancy of different stages of neurofibromas.  To address this observation, we 
first confirmed the status of BMP2-SMAD1/5/8 signaling in MPNST cells.  BMP2 
stimulation promoted the phosphorylation of SMAD1/5/8 in MPNST cells after overnight 
serum starvation.  Then, by targeted knockdown of BMP2 using shRNA and 
LDN-193189, a BMP2 signaling inhibitor, we blocked the BMP2-SMAD1/5/8 signaling 
in the MPNST cells.  LDN-193189 effectively inhibited phosphorylated SMAD1/5/8 in 
a dose dependent manner.  In MPNST cells treated with LDN-193189 and the stable 
BMP2 knockdown cell lines, there was no significant differences in growth rate.  
However, we found that cell migration and invasion of MPNST cell lines were impaired 
under the above conditions that blocked BMP2-SMAD1/5/8 signaling.  
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These findings suggest the overexpressed BMP2 in the MPNSTs contributes to the 
malignant phenotype of MPNST cells and can be used to manipulate the malignant 
phenotype of MPNSTs in patients.
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Materials and Methods 
Lentivirus shRNA mediated stable NRas knockdown and inducible 
oncogenic RAS expression system 
Stable MPNST cell lines with targeted gene knockdown and scrambled sequence 
were constructed by lentivirus based shRNA technology.  The lentivirus vector 
containing shRNAs targeting NRAS and scrambled sequence were packed using the 
Trans-Lentiviral™ Packaging System (TLP4615, Open Biosystem, Thermo) in 293T 
cells.  The virus particles were harvested and titered according to the manufacturer’s 
protocol.  The ST88-14 cells were incubated with viral particles for 4 h and selected by 
0.5 μg/ml puromycin for 5 days.  Selected cells were confirmed by fluorescence 
microscopy for GFP expression.  
Tet-off (BD Biosciences) cell line conditionally expressing the oncogenic form of 
RAS-G12V was established using the parent Schwann cell line STS26T(Nf1+/+).  The 
procedure is described in a previous study from our lab (Kraniak, et al., 2010).  
 
Scratch recovery assay  
Cells were seeded at 1x106 cells/well in 6-well plates and pre-incubated with 
LDN-193189 at the same concentrations used in the scratch experiment overnight. The 
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scratch was made on 100% cell monolayer by a plastic tip.  To better quantify the cell 
migration images, T265(Nf1-/-) and ST88-14(Nf1-/-) were infected by the GFP expressed 
lentivirus to create T265NonKD and ST88NonKD cell lines. T265NonKD cells were 
cultured at 0.1% or 5% FBS with 0 μM, 0.001 μM, 0.01 μM and 0.1 μM LDN-193189. 
Because ST88NonKD survived poorly with 0.1% FBS, 1% FBS were used in the 
experiment.  ST88NonKD were cultured at 1% and 5% FBS with same LDN-193189 
concentration series.  Cell migration was monitored after 24 h of cell culture by 
Olympus IX71 fluorescent microscope, and the area of the scratched region in pixels was 
quantified by slidebook 4.2.  This assay was repeated independently at least three times. 
 
Matrigel invasion assay 
BD BioCoatTM Growth Factor Reduced MATRIGELTM invasion Chamber was used 
to access the invasion ability of the ST88-14(Nf1-/-) and T265(Nf1-/-).  Briefly, 2.5X104 
cells were added to the upper chamber coated by Matrigel without serum but with the 
BMP2 and/or LDN-193189.  Cells were stimulated by 200 ng/ml BMP2 for 24 h in the 
chamber before evaluation.  Cells with LDN-193189 were pretreated with 0.1 μM/ml 
LDN-193189 overnight before seeding to the chambers, and the media was changed to 
fresh 0.1 μM/ml LDN-193189 with/without BMP2 200 ng/ml for 24 h for evaluation.  
5% FBS was used as attractant in the lower chamber.  After 24 h, the cells remaining in 
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the chamber were removed by the cotton swab and invaded cells present on the other side 
of the bottom of chamber were fixed and stained by Diff-Quick Stain (Biochemical 
Science, Inc., Swedesboro, NJ).  The invaded cells were counted under the microscope 
and all experiments were repeated three times following the manufacturer’s instructions.  
 
Statistical analysis 
Experiments were subject to at least three independent replicates.  For qRT-PCR 
and scratch assay results, paired t-test was used to determine the significant differences at 
95% or 99% confident interval.  For the western blotting results, one sample-test was 
used on the ratios between the treated and controls from different replicates, 95% or 99% 
confident intervals were indicated on the figures. 
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Results 
BMP2 regulation of Smad1/5/8 activity is independent of NRAS in 
MPNST cells 
In the canonical signaling, BMP2 exerts its function by binding to specific type I 
and II receptors to form a complex with a serine-threonine kinase activity resulting in the 
phosphorylation of SMAD1/5/8 proteins.  Phosphorylated SMAD1/5/8 bind to SMAD4 
and translocate to the nucleus to regulate gene expression (Massague, et al., 2005).  
However, the roles of BMP2 in tumorigenesis are diverse including the epithelial to 
mesenchymal transition, metastasis, and angiogenesis (Singh and Morris, 2010).  We 
found that SMAD1/5/8 phosphorylation was increased in 3 MPNST cell lines, 
ST88-14(Nf1-/-), T265(Nf1-/-) and sNF96.2(Nf1-/-), compared to normal human Schwann 
cells (Fig. 14a).  The BMP2-SMAD1/5/8 pathway activity in ST88-14(Nf1-/-) was 
further evaluated by BMP2 stimulation after overnight serum starvation.  Treating with 
100 ng/ml BMP2 stimulated the phosphorylation of SMAD1/5/8 in 15 min after 
overnight serum starvation, but with limited additional phosphorylation after BMP2 
treatment at 200 ng/ml (Fig. 14b).  Because BMP2 was overexpressed in MPNST cells, 
we suspected that the overexpressed BMP2 could promote SMAD1/5/8 activity.  After 
siBmp2 treatment of ST88-14(Nf1-/-) cells, Bmp2 expression decreased by ~60%, as 
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determined by qRT-PCR (Fig. 15a) and the phosphorylation of SMAD1/5/8 was inhibited 
as demonstrated by western blotting (Fig. 15b).   
A recent report indicated that suppression of RAS activity by salirasib, a S-trans, 
trans-farnesylthiosalicylic acid (FTS), inhibited the expression of Bmp4, and thereafter 
perturbed BMP4 related SMAD signaling in MPNST cell lines (Barkan, et al., 2011).  
To verify that NRAS suppression resulted in negative regulation of SMAD1/5/8 signaling, 
we transfected ST88-14(Nf1-/-) cells with siNRas and found that SMAD1/5/8 
phosphorylation decreased by ~40% compared to control.  However, when siBmp2 was 
transfected into ST88-14(Nf1-/-) cells, the phosphorylation of SMAD1/5/8 was inhibited 
by ~80%, greater than that from the NRAS knockdown alone (Fig. 15b).  A combination 
of siNRas and siBmp2 failed to inhibit phosphorylation of SMAD1/5/8 beyond that of 
siBmp2 alone.  We observed similar results in the comparison between NRAS stable 
knockdown cell line (ST88-NRasKD) and non-silencing control cell line (ST88-NonKD) 
(Fig. 16).  Together, these data indicated that although both NRAS and BMPs can 
control downstream SMADs, BMP2 exerted a greater influence on the phosphorylation 
of SMAD1/5/8 than NRAS. 
LDN-193189 inhibits BMP2-SMAD1/5/8 in time and concentration 
dependent manner 
To study the BMP2-SMAD1/5/8 pathway in the MPNST cell lines, we utilized 
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Fig. 14 Status of phosphorylated SMAD1/5/8 in MPNST cell lines 
Western blotting indicated higher phosphorylation of SMAD1/5/8 in the MPNST cell 
lines compared to the normal human Schwann cells.  BMP2 stimulation for 15 min was 
applied to ST88-14(Nf1-/-) after overnight serum starvation. 100 ng/ml increased the 
phosphorylated SMAD1/5/8 about 2-fold.  200 ng/ml had limited effects to further 
increase the phosphorylation compared to 100 ng/ml suggesting the signaling pathway 
saturation in short time. 
 
 
 
 
 
 
 
67 
 
 
 
Fig. 15 siBmp2 inhibited Bmp2 mRNA accumulation and the phosphorylation of 
SMAD1/5/8 
(a) siBmp2 significantly decreased the Bmp2 mRNA expression in ST88-14(Nf1-/-) cell 
line by quantitative RT-PCR. Paired t-test, n=3, *p<0.05.  Data is presented as means of 
three independent experiments ± SD.  (b) Western blotting indicated both siNRas and 
siBmp2 can decrease the phosphorylated SMAD1/5/8, however, siBmp2 has stronger 
inhibition effects on SMAD1/5/8 phosphorylation than siNRas alone. 
 
Fig. 16 NRAS and BMP2 influence the activity of SMAD1/5/8 independently 
Western blotting indicated the decreased phosphorylation of SMAD1/5/8 in stable NRAS 
knockdown cell line ST88-NRasKD compared to the non-silencing control cell line 
ST88-NonKD.  In ST88-NRasKD, 48 h after siBmp2 treatment, the phosphorylated 
SMAD1/5/8 decreased further compared to that in scrambled siRNA control sample.
a b
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LDN-193189 which has strong potency to bind BMP2 preferred type I receptors (known 
as Activin-receptor-Like-Kinase, ALK), ALK2, ALK3 and ALK6 (Cuny, et al., 2008) and 
subsequently suppress BMP2-SMAD1/5/8 signaling.  We evaluated the inhibition 
efficacy of LDN-193189 at different concentrations and time interrvals in MPNST cells 
to optimize the drug application.  We found that treatment of T265(Nf1-/-) cells with 0.01 
μM LDN-193189 for 15 min can inhibit phosphorylation of SMAD1/5/8 nearly 
completely (Fig. 17).  We further evaluated the time dependency of the drug.  
T265(Nf1-/-) were treated with 0.01 μM LDN-193189 and proteins were harvested at 
different time points.  The inhibitory effects were rapid but decreased with time, and 
~50% inhibition was retained at 24 h post treatment (Fig. 18).  
LDN-193189 inhibits the migration and invasion of MPNSTs in vitro  
Late stage MPNSTs have been reported to frequently metastasize to the lungs, 
lymph nodes, and liver (Wong, et al., 1998).  Because Bmp2 expression increased in 
NF1-related malignant tumors (Miller, et al., 2009) (see Fig. 9), BMP2 may affect 
malignancy via enhancement of cell migration and invasion (Clement, et al., 2005; 
Gordon, et al., 2009).  Therefore, we assessed BMP2 effects on these malignant 
properties of MPNST cell lines.  We tested the MPNST cell line migration with various 
concentrations of LDN-193189, and quantified the ability of cells to migrate to the 
scratched gap.  We quantified the cell migration images of two MPNST cell lines, 
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Fig. 17 Efficacy of LDN-193189 concentration series to inhibit SMAD1/5/8 in 
T265(Nf1-/-) 
LDN-193189 concentration series indicated the effective inhibition of the 
phosphorylation of SMAD1/5/8 after 1.5 h incubation in T265(Nf1-/-) cell line with 5% 
FBS culture medium.  
 
 
Fig. 18 LDN-193189 time dependent inhibition of phosphorylation of SMAD1/5/8 in 
T265(Nf-/-).  
0.01 μM LDN was applied to the T265(Nf1-/-) and the proteins were harvested at the 
indicated time points.  The phosphorylated SMAD1/5/8 decreased with time after the 
LDN-193189 treatment.
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T265NonKD and ST88NonKD, which were previously infected by lentivirus with 
non-silencing shRNA expressing a green fluorescence protein (GFP).  Using 0.1% and 
5% fetal bovine serum (FBS) in T265NonKD, the area of the gap at different 
LDN-193189 concentrations was measured by determining the number of pixels in the 
gap (Fig. 19a).   There were significant differences of the gap area starting from 0.01 
μM with respect to the 0 μM at 24 h after the scratch.  In order to determine whether the 
observed effects of LDN-193189 in the migration assay reflected effects on growth 
retardation, the growth rate of the cell line T265NonKD with 0.01 μM LDN-193189 at 
0.01% FBS and with 0.1 μM LDN-193189 at 5% FBS were evaluated compared to the 
control, respective (Fig. 20).  No significant effect on growth rate was observed at each 
condition, which suggested the cell growth did not influence the change in the area of the 
gap at 24 h in the scratch assay.  Similar results were observed in ST88NonKD (Fig. 19b) 
with 1% and 5% FBS, respectively.  To further confirm the specificity of BMP2 
stimulated migration, we constructed the stable BMP2 knockdown line (ST88Bmp2KD) 
and non-silencing control (ST88NonKD) cell lines (Fig. 21a), and used them in the 
scratch assay (Fig. 21b).  There were significant differences between the areas of gap 
from these two cell lines at 1% or 5% FBS concentrations at 24 h after the scratch (Fig. 
21c), but no significant differences in the growth rate (Fig. 21d) of these two cell lines 
were observed.  This indicated that the differences in scratch assay were resulting from 
cell migration and not proliferation rates within the scratch. 
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The effect of BMP2 on the invasion properties of MPNST cells was measured by 
low growth factor Matrigel invasion assay.  Matrigel was placed on the bottom 
membrane in the upper chamber, and the cells that digested the Matrigel and invaded 
through the 8 μm pores were counted on the other side of membrane.  Medium with 5% 
FBS in the well of each 24-well plate was used as the attractant and BMP2 and/or 
LDN-193189 were added into the serum free media in the upper chamber with same 
amount of cells.  After 24 h, cells on the other side of membrane were stained by 
Quick-Diff and counted using microscopy.  The ability of invasion of MPNST cells was 
significantly increased by 200 ng/ml BMP2 stimulation, and the addition of LDN-193189 
completely blocked the effect induced by BMP2 on MPNST cell invasion (Fig. 22).  
Bmp2 stable knockdown cells, ST88BMP2KD and T265BMP2KD, also had reduced 
invasive properties compared to ST88NonKD and T265NonKD, respectively (Fig. 23).  
Therefore, abrogation of BMP2 signaling in MPNST cells impaired the motility and 
invasive abilities of those cells and also suggested BMP2 signaling could promote the 
malignant phenotypes of MPNSTs.  Collectively, these data indicate that the motility 
and invasiveness of MPNST, as malignant properties, could be reduced by using BMP2 
as a therapeutic target. 
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Discussion 
In chapter II, the differentially expressed genes were classified according to the 
expression patterns.  Based on the intersection analysis, neurofibromin-related but 
NRAS and MEK1/2 independent gene expression was identified in DS-10.  From the 
DS-10, Bmp2 was chosen for further study because of 1) the significance of BMP2 
signaling in pathway analysis and 2) its expression profile in the data of Miller et al. 2009 
that showed the positive association between Bmp2 expressions with increasing 
malignancy of NF1-related tissues (Fig. 9).  Interestingly, a case report suggested a 
connection between acute deterioration of plexiform neurofibroma and exogenous BMP2 
treatment to facilitate bone fusion after surgery (Steib, et al., 2010).   
Bmp2 overexpression resulting from Nf1 deficiency but independent of NRAS and 
MEK1/2 activities was verified in a variety of MPNST cell models.  Although the 
convergence of NRAS and SMAD signaling was observed in this study, the regulation of 
SMAD 1/5/8 signaling by BMP2 was far stronger than that by NRAS alone, which 
indicated that BMP2-SMAD1/5/8 may contribute independently to MPNST formation or 
malignant phenotypes, via mechanisms to control cell motility, invasiveness and tumor 
growth, as it does in other tumor types (Singh and Morris, 2010).  Although BMP2 and 
BMP4 have certain overlapping pathway and functional redundancy, these two factors are 
regulated by different mechanisms (Fritz, et al., 2004).  Barkan et al. 2011 reported that 
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application of FTS in ST88-14 cell leads to significant alteration in transcriptome 
including decrease of expression of Bmp4.  We did not find decreased Bmp4 expression 
after inhibition of NRas by siRNA in our data set, but we identified the expression of 
Gdf6, also known as Bmp13, to be greatly increased in ST88-14(Nf1-/-) (DS-4) and 
decreased in siNRas treated sample (DS-2).  GDF6 is believed to bind the same type I 
and II receptors as BMP2, which results in phosphorylation/activation of SMAD1/5/8 
(Williams, et al., 2008).  This mechanism may explain the phosphorylation/activation of 
SMAD1/5/8 that we observed in the regulation of SMAD1/5/8 by the NRAS pathway.   
To evaluate BMP2-SMAD1/5/8 signaling in MPNST cell lines, LDN-193189, a 
selective inhibitor to BMP2-activated type I receptor kinase (ALK1, ALK2, ALK3, and 
ALK6), was employed in this study.  LDN-193189 has been applied as the 
BMP-activated type I receptor inhibitor (Yu, et al., 2008), and a recent study indicated it 
can inhibit the ability of ALK2 and ALK3 to phosphorylate GST-SMAD1 in vitro at an 
IC50 of 45 nM and 100 nM, respectively.  However, its inhibition to ALK4 and ALK5 is 
with higher IC50 at 0.3 μM and 0.5 μM, respectively, indicating a lesser effect on TGFβ 
signaling (Vogt, et al., 2011).  From the specificity test in the same study, LDN-193189 
inhibited 24 out of 121 protein kinases by >50% at 1 μM, which suggested us that a lower 
concentration was needed to minimize possible side effects.  We studied the 
concentration dependency and time dependency of LDN-193189 in MPNST cell lines 
and chose 0.01 μM of LDN-193189 for the most of experiments in this study, which is 
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lower than the concentration that could have significant side effects based on study of 
Vogt et al 2011.  
Inhibition of BMP2-SMAD1/5/8 signaling by LDN-193189 impaired the motility 
and invasiveness of MPNST cell lines in vitro, and these effects were confirmed by 
BMP2 shRNA interference by lentivirus infection.  Gordon et al. reported BMP2 could 
increase MMP2 (type IV collagenase) expression in pancreatic cancer cell line through 
the SMAD1-dependent mechanism (Gordon, et al., 2009).  This mechanism may have 
been present in the MPNST cells that we tested. 
LDN-193189 can rapidly inhibit the BMP2-SMAD1/5/8 signaling at low 
concentrations, however, the inhibitory effect decreased with the time.  There is no 
significant growth arrest effect on the MPNST cells, indicating the inhibitory effects of 
LDN-193189 on the malignant phenotypes could be reversible.  This may limit its 
application for only BMP2 targeted treatment, but this strategy could still cooperate with 
other treatments to control the malignant phenotype of MPNSTs.
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Fig. 19 Migration of MPNST cell lines with LDN-193189 at 24 h in scratch assay 
with different FBS concentration  
Scratch assay indicated the LDN-193189 treatment inhibition to migration under different 
FBS concentrations.  Figures were captured under the fluorescent microscope at 24 h 
after scratches and then the pixels in the gap (the dark area) were quantified by 
Slidesbook software and shown as a bar graph.  Paired t-test, * p<0.05, ** p<0.01.  
Data is expressed as means of three independent experiments ± SD.  (a) T265Non(Nf1-/-) 
migration at 0.1% FBS and 5% FBS  (b) ST88Non(Nf1-/-) migration at 1% and 5% FBS. 
 
 
 
 
Fig. 20 The growth curve of T265NonKD  
No significant differences were shown in the growth rate of T265NonKD cell lines at 
0.1% FBS with 0.01 μM LDN-193189 or at 5% FBS with 0.1μM LDN-193189 compared 
with DMSO treated control at different time points, respectively.  Data is expressed as 
mean ± SD, and this figure represents one of three independent experiments.  Each time 
point was replicated 4 times within each experiment.  
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Fig. 21 Bmp2 knockdown by lentivirus in ST88-14(Nf1-/-) impaires cell migration  
(a) Quantitative RT-PCR indicated the endogenous Bmp2 expression were significantly 
inhibited by the shRNA lentivirus in ST88-14(Nf1-/-).  Data is presented as mean of 
experiments ± SD, representing one of three independent replicates.  (b) Scratch assay 
images compared the migration ability of ST88Bmp2KD and ST88NonKD at 24 h after 
scratch with 1% FBS and 5% FBS at 24 h.  (c)The number of pixels in the gap (black 
area) from the images were quantified and shown as the bar graph.  Data is represented 
as mean ± SD of three independent experiments, paired t-test, n=3, * p<0.05.  (d) Cell 
growth curve of ST88Bmp2KD and ST88NonKD within 48 h.  No significant growth 
a 
b 
c 
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rate differences were observed between these two cell lines at 1% FBS and 5% FBS.  
This figure represents one of three independent experiments.  Each time point was 
replicated 4 times within each experiment. 
 
 
 
 
Fig. 22 BMP2 and LDN-193189 influenced the invasion ability of ST88-14(Nf1-/-) 
and T265(Nf1-/-) 
The number of cells invaded to the matrigel and presented on the other side of the insert 
chamber under different conditions was quantified by microscopy after the Quick-Diff 
stain.  With the 0.1 μM LDN-193189 in the upper chamber for 24 h, the invasion ability 
was significantly inhibited in both ST88-14(Nf1-/-) and T265(Nf1-/-) compared to the 
controls without treatments.  200 ng/ml BMP2 in the upper chambers for 24 h promoted 
the invasion of two cell lines significantly compared to the controls, and the 
BMP2-related invasion effects were blocked by LDN-193189.  Data is expressed as 
means ± SD of three independent experiments, paired t-test, ** p<0.01, n=3. 
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Fig. 23 Bmp2 stable knockdown lines indicated decreased invasion properties 
compared to the control lines. 
Cells were seeded at 2.5x104 with no serum medium in the insert chambers and 5% FBS 
was used as attractant.  The numbers of invaded BMP2 knockdown cell lines and 
control cell lines were counted.   Data is presented as the mean ± SD of three 
independent experiments, paired t-test, ** p<0.01.  
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CHAPTER IV: Conclusions and significance 
In this dissertation work, I focused on a systematic screen of the downstream gene 
regulation resulting from neurofibromin deficiency in the MPNST cells.  By associating 
the differentially expressed genes to biological pathways, I identified novel mechanisms 
to explain the malignancy of the MPNST cell lines and potential therapeutic targets for 
MPNST treatment. 
Loss-of-function of Nf1 predisposes the formation of multiple different tumors. 
Although many of these tumors are benign such as dermal, plexiform neurofibromas, and 
optical pathway gliomas (Lee and Stephenson, 2007), the patients can develop malignant 
tumors with high mortality such as MPNSTs and glioblastoma multiforme (Blatt, et al., 
1986).  NF1 patients with benign neurofibromas have 8~13% life risk to develop into 
MPNST (Evans, et al., 2002b) and up to 50% of MPNSTs are associated with Nf1 
deficiency (Matsui, et al., 1993; Sorensen, et al., 1986).   
The clinical management of MPNST is quite challenging because of its inherently 
aggressive nature and limited diagnostic and therapeutic options.  MPNST cells 
frequently undergo genetic alterations that cause them to be refractory to traditional 
treatments such as chemotherapy (Casanova, et al., 1999).  Surgical resection as a 
treatment provides a limited outcome to both local recurrence and distant metastases.  
Many preclinical studies and clinical trials are currently testing strategies to target the 
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activated downstream pathways of neurofibromin in MPNSTs, including RAS, MEK1/2, 
and mTOR.  A better understanding of the signaling transduction of neurofibromin in 
MPNST may provide novel therapeutic targets to control or reduce the malignancy of the 
tumor.  
Gene expression profile screening is generally used to identify the disease signatures 
on the molecular level.  Previous NF1-related large scale microarray studies mainly 
focused on differentiating the benign and malignant tumor types, or characterizing gene 
signatures of MPNSTs.  Although the differentially expressed genes improved the 
understanding of NF1 disease, diverse information did not provide an integrated signaling 
network or reveal the aberrant gene regulation mechanisms in NF1-related tumors.  
Currently, the RAS and MEK1/2 targeted strategies are not very successful; however the 
interference to the alternative downstream target such as mTOR is promising.  Novel 
targets for the tumor treatment can be offered by systematically screening to stratify the 
pathway related gene expression changes.  
In this study, MPNST cell lines with different neurofibromin status provided good 
models to classify the signaling pathway related gene expression changes.  The 
hyperactive NRAS and MEK1/2 have been characterized in ST88-14(Nf1-/-) (Mattingly, 
et al., 2006) and functions of wild type neurofibromin in STS26T(Nf1+/+) to regulate 
RAS and ERK1/2 activities have been confirmed as well (Kraniak, et al., 2010).  By 
gene profile comparisons based on pathway interference in these two cell lines, I 
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associated the gene expression changes to the specific pathways in MPNSTs, which is the 
first time to provide the pathway-oriented gene regulations in MPNSTs.  Furthermore, 
according to the biological causality among the interfered pathways, the set theory 
operation allowed us to identify the neurofibromin-associated but NRAS and MEK1/2 
independent changes, enabling the possibility to study the neurofibromin deficiency 
related novel signaling associated or not with NRAS and MEK1/2. 
In chapter II, I described the experiment design and set theory operations to 
associate the differentially expressed genes to the signaling axis.  The results revealed 
the potential regulatory mechanisms for these genes, and a good example was Sox9.  
SOX9 was reported to function as a pro-survival biomarker in MPNSTs from Miller’s 
large scale microarray analysis about NF1-related cells and tissues (Miller, et al., 2009).  
However, the mechanism of regulation of Sox9 expression is unclear.  According to our 
results, the increased expression of Sox9 is probably dependent on the activated MEK1/2 
in MPNSTs.  Similar candidates, such like Edn1, Nt5e and Rgs16, that may influence 
the tumor formation and malignant phenotypes in each category are also discussed in 
chapter II.   
Gene set enrichment analysis by GePS software identified significant gene ontology 
terms and pathway terms from the gene lists in each category, and the significant terms 
provide sources for hypothesis generation.  From the canonical pathway analysis of the 
upregulated gene in DS-10, we found the term “signaling of BMP2”.  This term drew 
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our attention to the aberrant expression of BMP2 in the NF1-related cell lines and human 
samples.  Actually, a positive association of Bmp2 expression with the increasing 
malignancy of NF1 tumors has been indicated as one of 2827 differentially expressed 
transcripts in NF1-related tumors compared to the normal human Schwann cell in 
Miller’s data.  This suggested us a strong connection between the Bmp2 overexpression 
and MPNST malignancy.  I validated the Bmp2 expression changes in microarray 
analysis by qRT-PCR.  By using the inducible oncogenic RAS system in STS26T(Nf1+/+) 
cells, I concluded that the increased RAS and MAPK activity do not significantly 
influence the Bmp2 expression in STS26T(Nf1+/+) cells. 
Next, I evaluated the possible causality between BMP2 overexpression and 
malignant phenotypes in MPNST cell lines in chapter III.  BMP2 overexpression has 
been reported in multiple tumors, such as prostatic adenocarcinoma, bladder cancer, 
breast cancer and prostate cancer (Hatakeyama, et al., 1993; Hung, et al., 2008; Miyazaki, 
et al., 2003), and involves many cancer processes, including metastasis, motility, and 
invasiveness (Langenfeld, et al., 2003; Park, et al., 2008).  We found that the 
phosphorylation of SMAD1/5/8, the downstream effector of BMP2 signaling, is 
relatively higher in the MPNSTs than in the normal human Schwann cells.  Then, by 
employing Bmp2 shRNA or receptor inhibition by LDN-193189, we inhibited the 
BMP2-SMAD1/5/8 signaling in ST88-14(Nf1-/-) and T265(Nf1-/-) cells, and quantified 
their inhibitory effects on the cell migration and invasion.  The results confirmed that 
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BMP2-SMAD1/5/8 inhibition impaired the migration and invasion properties of 
ST88-14(Nf1-/-) and T265(Nf1-/-) cells, indicating that the BMP2 controls these malignant 
properties of MPNST cells.  Although NRAS regulation to the SMAD1/5/8 activity in 
our cell models was confirmed by NRAS specific siRNA and shRNA, we did not 
observed the Bmp4 expression decrease as observed by Barkan et al. in their study of FTS 
treatment (Barkan, et al., 2011).  Actually, our study suggests the expression decrease of 
Gdf6 (Bmp13) could explain the inhibitory effects of NRAS knockdown on the 
SMAD1/5/8 activity, while the FTS related Bmp4 decrease identified by Barkan et al. 
could be the FTS specific effects on the MPNST cells. 
In summary, we systematically described the downstream gene expression changes 
in MPNSTs under the scenarios of Nf1 knockdown, NRas knockdown and MEK1/2 
inhibition.  By comparing different data sets, the overlapped gene expression changes 
were associated to the pathways activated in the cell models.  This is the first study to 
reveal the pathway-orientated gene expression changes in a MPNST cell line.  I not only 
characterized the NRAS and MEK1/2 specific gene changes, but also identified ones that 
neurofibromin-related and independent of NRAS and MEK1/2, which provided novel 
molecular mechanisms to support the further drug target studies.  We identified the 
overexpression of Bmp2 and verified its roles in the malignant phenotypes in the 
MPNSTs.  All these studies significantly expend our knowledge of gene regulations of 
MPNST, and offer novel insights in the future therapeutic strategy in NF1-related tumor 
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types. 
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APPENDIX: SUPPLEMENTARY TABLES 
Suppl. Table 1: Primers for qRT-PCR 
Gene Forward Primer Reverse Primer 
ACTG2 CTGGAGAAGAGCTATGAGCTG ATCTCCTTCTGCATCCTGTC 
ANXA4 CCGGTCTCGTGGGCAGAGGAA ACTCAGGGCCAGACAGCGGG 
APC TGTCCCTCCGTTCTTATGGAA TCTTGGAAATGAACCCATAGGAA 
ATF3 GGCGGAGGTGGGGTTAGCTT TGGGGCAAGGTGCTGAAAATCCT 
Bcl2 GATGTCGCCCCTGGTGGACAAC GGGCCGTACAGTTCCACAAAGGC 
BMP2 GACACTGAGACGCTGTTCC CCATGGTCGACCTTTAGG 
BMP4 TCCATGCTGTACCTGGATGA TGAGTGGATGGGAACGTGT 
CCND1 TATTGCGCTGCTACCGTTGA CCAATAGCAGCAAACAATGTGAAA 
CCND2 TGGAGCTGCTGTGCCACG GTGGCCACCATTCTGCGC 
CDH1 CAGCCACAGACGCGGACGAT CTCTCGGTCCAGCCCAGTGGT 
CDH2 CCTGCGCGTGAAGGTTTGCC CCAAGCCCCGCACCCACAAT 
CDKN2A  CATAGATGCCGCGGAAGGT CCCGAGGTTTCTCAGAGCCT 
CHEK1 TCTCGGCTCCAGCACCACGA GGCCGCTCTGGGCCTGAAAG 
CSNK1E TGAGGGGTCCTCTCTGTGCCC CCGATCTTCCGTCCCAGGCG 
CTNNB1 CCCACTGGCCTCTGATAAAGG ACGCAAAGGTGCATGATTTG 
CTNND1 TGCTGTGGTGGCTGGGATGC AGGAGGGAGAGAGACCCCCTCA 
DKK1 TTCCAAGAGATCCTTGCGTT ACCCCATTGATTGTTATCTTGA 
DOCK4 CAAGTTCTGCTCCATCGAGT CTTTTTCAGGTGCAGAGAGATTTGG 
EDN1 GAGAAACCCACTCCCAGTCC GATGTCCAGGTGGCAGAAGT 
ETV4 GAGGCCGAGCGAAGGAAATGCA TTTTCGGGCGCAGCAGACAGTT 
FMN1 TTTGCCTGCCTCGGTTGGGG TGGGAGGGGGCATCCCAGAT 
FZD2 TCTCCGGCTGCTCAGTCCGAC AACTTTACTCGCGGCCGCAG 
GATA6 CCTTCGGCGAGCGCTGTTTGTT CTCTGCCGGAAAACTGCAGCCT 
GSK3Beta CTCCTCATGCTCGGATTCA TGCAGAAGCAGCATTATTGG 
IGF2 GTGCTGCATCGCTGCTTACG GGAAGTACGGCCTGAGAGGT 
IGF2R  GTTGTCTGCCCTCCAAAGAA CCTTTGGAGTACGTGACAAG 
LEF1 CGACGCCAAAGGAACACTGACATC GCACGCAGATATGGGGGGAGAAA 
MAPK14  GCCGAGCTGTTGACTGGAAG  GGAGGTCCCTGCTTTCAAAGG 
MMP1 AAGACAAAGGCAAGTTGAAAAGCGG TGGTTTCCCAGTCACTTTCAGCCC 
MMP2 TGATCTTGACCAGAATACCATCGA GGCTTGCGAGGGAAGAAGTT 
MMP9 CCTGGAGACCTGAGAACCAATC CCACCCGAGTGTAACCATAGC 
MSX2 GGAGCGGCGTGGATGCAGGAA AAGCACAGGTCTATGGAACGG 
MYC CGTCTCCACACATCAGCACAA CACTGTCCAACTTGACCCTCTTG 
87 
 
Gene Forward Primer Reverse Primer 
MYLK GGCACCCCCGTGAGGAGACA GGCCTTGGGCGTTGGAAGCA 
NPPB TGGGAAGCAAACCCGGACGC GCCCGGGAAGGTGCTGTCTG 
NRP1 CAGAGCGCTCCCGCCTGAAC AAATGGCGCCCTGTGTCCCG 
PAX3 GAGTGAGCGCGAGCCTCTGCAC AGGTGGTTCTGCTCCTGCG 
PIK3R3  GAGAGGGGAATGAAAAGGAGA ATCATGAATCTCACCCAGACG 
PTEN CCGAAAGGTTTTGCTACCATTCT AAAATTATTTCCTTTCTGAGCATTCC 
RUNX2 CCAACCCACGAATGCACTATC TAGTGAGTGGTGGCGGACATAC 
SMAD3 TCCTGGCTACCTGAGTGAAGA GTTGGGAGACTGGACGAAAA 
SNAI1 CAGTGCCTCGACCACTATGCCG CGGTGGGGTTGAGGATCTCCG 
SOX9 AGACCTTTGGGCTGCCTTAT TAGCCTCCCTCACTCCAAGA 
SPARC CTGCCTGCCACTGAGGGTTCC TCCAGGCAGAACAACAAACCATCC 
SPIN4 GCGAGCCCGCCATCTCTACG CGTGAGCACTGGGACAGCGT 
TGFß1 AAGGACCTCGGCTGGAAGTGC CCGGGTTATGCTGGTTGTA 
Twist1 CACTGAAAGGAAAGGCATCA GGCCAGTTTGATCCCAGTAT 
VEGFA  TTTACTGCTGTACCTCCACCA  ATCTCTCCTATGTGCTGGCTTT 
VEGFC GGGAAGAAGTTCCACCATCA ATGTGGCCTTTTCCAATACG 
WNT10B GCACTGTATTGCTCCTCCCACTT  ATAGGGACTCCCCAGCCAAA 
WNT5A AGAAGAAACTGTGCCACTTGTATCAG CCTTCGATGTCGGAATTGATACT 
Zeb1 GGCAGAGAATGAGGGAGAAG CTTCAGACACTTGCTCACTACTC 
Zeb2 GTGACAAGACATTCCAGAAAAGCAG GAGTGAAGCCTTGAGTGCTC 
ZNF185 GCGGATCTGAGCAACTTGTC TTCTGGGGTACTGGGATCTG 
PXN ATGGCTTCGCTGTCGGATTT ATGAACCCTCCCTCGTCCTG 
KIT GCACAATGGCACGGTTGAAT TGGGGATGGATTTGCTCTTTGT 
GATA4 GGAGGAAGGAGCCAGCCTA CCTATTGGGGGCAGAAGACG 
NKX2-5 AGAGCCGAAAAGAAAGCCTG CACCGACACGTCTCACTCAG 
LAT2 AGTGGTGTTGGCATCAGCTT GCCTCTTGTGATGCTGAGAGT 
FOXA1 TGAAACCAGCGACTGGAACA ATGTTGCCGCTCGTAGTCAT 
 
Suppl. Table 2: DS-5  
DS-5, the intersection of DS-4 (ST88-14 vs. HSC) and DS-2 (siNRas vs. Scrambled 
control siRNA), is hypothetically under the control of Neurofibromin-NRAS axis in 
ST88-14(Nf1-/-) cells, and  matching the pattern: 1) increase in ST88-14 vs. HSC but 
decrease in siNRas vs. scrambled control siRNA treated ST88-14, or 2) decrease in 
ST88-14 versus HSC but increase in siNRas versus scrambled control treated ST88-14. 
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Gene 
In DS-5 
ST88 vs HSC 
.logFC 
ST88 vs HSC 
.adjPVal 
siNRas vs SC88 
.logFC 
siNRas vs SC88 
.adjPVal 
Discriptoins 
ADM 5.06 0.0000 -0.68 0.0025 adrenomedullin 
ANXA4 -1.21 0.0000 0.60 0.0020 annexin A4 
ATCAY 2.89 0.0000 -0.63 0.0035 ataxia, cerebellar, Cayman type 
ATF3 -1.42 0.0000 1.04 0.0002 activating transcription factor 3 
C9orf150 -1.92 0.0000 0.69 0.0036 chromosome 9 open reading frame 150 
CLINT1 1.28 0.0000 -1.18 0.0010 clathrin interactor 1 
EPB41L4B 2.81 0.0000 -1.12 0.0003 erythrocyte membrane protein band 4.1 like 4B
FLI1 5.38 0.0000 -0.67 0.0077 Friend leukemia virus integration 1 
GDF6 4.10 0.0000 -0.76 0.0044 growth differentiation factor 6 
LMO7 2.14 0.0000 -0.70 0.0020 LIM domain 7 
MET 1.00 0.0000 -0.93 0.0000 met proto-oncogene (hepatocyte growth factor 
receptor) 
PBLD -1.13 0.0000 0.66 0.0058 phenazine biosynthesis-like protein domain 
containing 
PTPRZ1 -4.50 0.0000 0.96 0.0017 protein tyrosine phosphatase, receptor-type, Z 
polypeptide 1 
RGS16 -2.48 0.0000 1.02 0.0054 regulator of G-protein signaling 16 
SERBP1 0.79 0.0000 -0.60 0.0024 SERPINE1 mRNA binding protein 1 
SH3D19 -1.60 0.0000 0.65 0.0037 SH3 domain containing 19 
SMAD3 3.07 0.0000 -0.76 0.0092 SMAD family member 3 
SNCAIP 3.15 0.0000 -0.68 0.0086 synuclein, alpha interacting protein 
SPIN4 1.43 0.0000 -0.66 0.0041 spindlin family, member 4 
SRD5A1 -1.03 0.0000 0.71 0.0035 steroid-5-alpha-reductase, alpha polypeptide 1 
(3-oxo-5 alpha-steroid delta 4-dehydrogenase 
alpha 1) 
THSD7A -3.26 0.0000 0.77 0.0094 thrombospondin, type I, domain containing 7A
TPM1 2.45 0.0000 -0.79 0.0019 tropomyosin 1 (alpha) 
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Suppl. Table 3: DS-6 
DS-6, intersection of DS-4 (ST88-14 vs. HSC) and DS-3 (U0126 vs. DMSO), is 
hyperthetically under the control the Neurofibromin-MEK1/2 axis in ST88-14(Nf1-/-) 
cells with matching the pattern: 1) increase in ST88-14 versus HSC but decrease in 
U0126VsDMSO, or 2) decrease in ST88-14 versus HSC but increase in U0126 versus 
DMSO. 
Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
AFMID 1.48  0.0000  -0.66  0.0025  arylformamidase 
AHCYL2 -0.92  0.0000  0.59  0.0010  adenosylhomocysteinase-like 2 
ANXA4 -1.21  0.0000  1.24  0.0000  annexin A4 
APLN 2.12  0.0000  -0.95  0.0064  apelin 
ARG2 -2.16  0.0000  1.19  0.0008  arginase, type II 
ARHGAP1
1A 
1.63  0.0000  -1.05  0.0005  Rho GTPase activating protein 11B; Rho GTPase 
activating protein 11A 
ARL2BP -0.87  0.0000  0.60  0.0005  ADP-ribosylation factor-like 2 binding protein 
ARL6IP5 -1.45  0.0000  0.85  0.0001  ADP-ribosylation-like factor 6 interacting protein 5 
ARMCX1 -1.57  0.0000  0.80  0.0014  armadillo repeat containing, X-linked 1 
ARMCX3 -2.60  0.0000  0.69  0.0019  armadillo repeat containing, X-linked 3 
ATF3 -1.42  0.0000  1.01  0.0026  activating transcription factor 3 
ATP2B4 -3.43  0.0000  1.04  0.0003  ATPase, Ca++ transporting, plasma membrane 4 
BRCA1 1.74  0.0000  -0.85  0.0042  breast cancer 1, early onset 
BTN3A1 -1.83  0.0000  0.66  0.0008  butyrophilin, subfamily 3, member A1 
BTN3A2 -2.37  0.0000  0.87  0.0072  butyrophilin, subfamily 3, member A2 
BTN3A3 -1.90  0.0000  0.92  0.0038  butyrophilin, subfamily 3, member A3 
C11orf82 2.32  0.0000  -0.85  0.0061  chromosome 11 open reading frame 82 
C12orf24 2.20  0.0000  -0.71  0.0097  chromosome 12 open reading frame 24 
C15orf42 1.43  0.0000  -0.96  0.0006  chromosome 15 open reading frame 42 
C15orf52 -5.65  0.0000  0.78  0.0021  chromosome 15 open reading frame 52 
C1orf198 -2.61  0.0000  1.09  0.0005  chromosome 1 open reading frame 198 
C3orf23 -2.53  0.0000  0.99  0.0000  chromosome 3 open reading frame 23 
C3orf26 1.16  0.0000  -0.81  0.0001  chromosome 3 open reading frame 26 
C4orf3 -1.16  0.0000  0.71  0.0003  chromosome 4 open reading frame 3 
C5orf41 -1.62  0.0000  1.11  0.0010  chromosome 5 open reading frame 41 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
C6orf35 -1.66  0.0000  0.76  0.0001  chromosome 6 open reading frame 35; 
hCG1820764; tetratricopeptide repeat domain 28 
C6orf89 -1.50  0.0000  0.68  0.0005  chromosome 6 open reading frame 89 
C9orf140 1.45  0.0000  -0.98  0.0005  chromosome 9 open reading frame 140 
C9orf150 -1.92  0.0000  1.05  0.0001  chromosome 9 open reading frame 150 
CCNDBP1 -1.49  0.0000  0.63  0.0043  cyclin D-type binding-protein 1 
CD55 4.89  0.0000  -1.66  0.0000  CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
CD99L2 -1.37  0.0000  0.68  0.0071  CD99 molecule-like 2 
CDC25A 2.10  0.0000  -1.27  0.0001  cell division cycle 25 homolog A (S. pombe) 
CDC6 1.26  0.0000  -0.74  0.0024  cell division cycle 6 homolog (S. cerevisiae) 
CDCA5 1.87  0.0000  -0.85  0.0010  cell division cycle associated 5 
CEP72 2.42  0.0000  -0.82  0.0007  centrosomal protein 72kDa 
CHAF1B 1.73  0.0000  -0.64  0.0062  chromatin assembly factor 1, subunit B (p60) 
CHEK1 1.91  0.0000  -0.66  0.0047  CHK1 checkpoint homolog (S. pombe) 
CKS1B 0.99  0.0000  -0.91  0.0001  CDC28 protein kinase regulatory subunit 1B 
CLEC2B 1.88  0.0000  -0.95  0.0058  C-type lectin domain family 2, member B 
CNKSR3 -2.05  0.0000  1.09  0.0005  membrane associated guanylate kinase, WW and 
PDZ domain containing 1; CNKSR family member 3
COL13A1 3.41  0.0000  -2.38  0.0003  collagen, type XIII, alpha 1 
COL16A1 -2.83  0.0000  0.96  0.0016  collagen, type XVI, alpha 1 
COL1A2 -2.98  0.0000  1.53  0.0078  collagen, type I, alpha 2 
CRISPLD2 -2.15  0.0000  1.50  0.0008  cysteine-rich secretory protein LCCL domain 
containing 2 
CRYL1 -3.61  0.0000  0.95  0.0003  crystallin, lambda 1 
CTPS 1.34  0.0000  -0.72  0.0009  CTP synthase 
DAAM1 -1.31  0.0000  0.91  0.0066  dishevelled associated activator of morphogenesis 1
DDIT4 -1.69  0.0000  0.74  0.0062  DNA-damage-inducible transcript 4 
DECR1 -1.53  0.0000  0.59  0.0077  2,4-dienoyl CoA reductase 1, mitochondrial 
DLC1 -1.68  0.0000  1.00  0.0013  deleted in liver cancer 1 
DNAJC15 -0.87  0.0000  0.59  0.0002  DnaJ (Hsp40) homolog, subfamily C, member 15 
DNMBP 1.84  0.0000  -1.02  0.0000  dynamin binding protein 
DSCC1 1.56  0.0000  -1.10  0.0022  defective in sister chromatid cohesion 1 homolog (S. 
cerevisiae) 
DTL 1.21  0.0000  -0.72  0.0044  denticleless homolog (Drosophila) 
DUSP16 -2.27  0.0000  0.78  0.0015  dual specificity phosphatase 16 
E2F1 1.19  0.0000  -0.76  0.0018  E2F transcription factor 1 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
EDN1 3.83  0.0000  -1.52  0.0000  endothelin 1 
EGFR 3.50  0.0000  -0.79  0.0029  epidermal growth factor receptor (erythroblastic 
leukemia viral (v-erb-b) oncogene homolog, avian) 
EIF2C2 1.31  0.0000  -1.00  0.0000  eukaryotic translation initiation factor 2C, 2 
EPC1 -1.88  0.0000  0.68  0.0079  enhancer of polycomb homolog 1 (Drosophila) 
ERRFI1 1.86  0.0000  -1.16  0.0013  ERBB receptor feedback inhibitor 1 
ESM1 4.30  0.0000  -3.91  0.0000  endothelial cell-specific molecule 1 
ESX1 2.82  0.0000  -1.53  0.0002  ESX homeobox 1 
ETV1 1.29  0.0000  -0.79  0.0010  ets variant 1 
ETV4 2.52  0.0000  -2.09  0.0000  ets variant 4 
EXO1 1.37  0.0000  -0.65  0.0065  exonuclease 1 
FAM105A 3.18  0.0000  -0.61  0.0012  family with sequence similarity 105, member A 
FAM63A -2.85  0.0000  0.60  0.0099  family with sequence similarity 63, member A 
FANCI 1.02  0.0000  -0.72  0.0016  Fanconi anemia, complementation group I 
FGFR3 2.10  0.0000  -1.21  0.0024  fibroblast growth factor receptor 3 
FOXA2 4.61  0.0000  -2.34  0.0000  forkhead box A2 
FOXD1 3.89  0.0000  -0.92  0.0050  forkhead box D1 
FOXF2 1.83  0.0000  -0.59  0.0031  forkhead box F2 
FST 2.72  0.0000  -1.25  0.0021  follistatin 
FTL -2.10  0.0000  0.93  0.0035  similar to ferritin, light polypeptide; ferritin, light 
polypeptide 
GABPB1 1.13  0.0000  -0.99  0.0000  GA binding protein transcription factor, beta subunit 
1 
GBP1 -3.53  0.0000  0.84  0.0016  guanylate binding protein 1, interferon-inducible, 
67kDa 
GLB1 -1.99  0.0000  0.60  0.0022  galactosidase, beta 1 
GLS -2.38  0.0000  0.83  0.0049  glutaminase 
GPR56 -4.61  0.0000  1.04  0.0055  G protein-coupled receptor 56 
GRN -1.66  0.0000  0.76  0.0016  granulin 
H6PD -1.65  0.0000  0.87  0.0013  hexose-6-phosphate dehydrogenase (glucose 
1-dehydrogenase) 
HAS2 5.15  0.0000  -2.97  0.0000  hyaluronan synthase 2 
HBP1 -1.47  0.0000  0.84  0.0056  HMG-box transcription factor 1 
HEATR5A -3.07  0.0000  0.80  0.0009  HEAT repeat containing 5A 
HGF 2.61  0.0000  -0.61  0.0063  hepatocyte growth factor (hepapoietin A; scatter 
factor) 
HHIP 3.86  0.0000  -1.69  0.0000  hedgehog interacting protein 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
HMGA2 7.96  0.0000  -1.10  0.0030  high mobility group AT-hook 2 
HSPE1 1.11  0.0000  -0.85  0.0002  heat shock 10kDa protein 1 (chaperonin 10) 
IFIH1 -1.99  0.0000  1.17  0.0002  interferon induced with helicase C domain 1 
IGBP1 -1.49  0.0000  0.73  0.0001  chromosome 14 open reading frame 19; 
immunoglobulin (CD79A) binding protein 1 
IGF2BP3 4.64  0.0000  -0.90  0.0093  insulin-like growth factor 2 mRNA binding protein 3 
IL8 3.68  0.0000  -4.89  0.0000  interleukin 8 
INHBB 4.43  0.0000  -1.70  0.0006  inhibin, beta B 
ITGAV -2.13  0.0000  0.76  0.0085  integrin, alpha V (vitronectin receptor, alpha 
polypeptide, antigen CD51) 
KCTD1 -1.48  0.0000  0.69  0.0055  potassium channel tetramerisation domain 
containing 1 
KIAA0020 1.45  0.0000  -0.62  0.0013  KIAA0020 
KLHL24 -1.40  0.0000  0.81  0.0000  kelch-like 24 (Drosophila) 
LHPP -3.11  0.0000  1.43  0.0000  phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase 
LIG1 1.39  0.0000  -0.73  0.0022  ligase I, DNA, ATP-dependent 
LIMD2 2.24  0.0000  -0.60  0.0034  LIM domain containing 2 
LMO4 -2.74  0.0000  0.72  0.0033  LIM domain only 4 
LRRC8C 1.51  0.0000  -1.11  0.0000  leucine rich repeat containing 8 family, member C 
LRRN1 -4.21  0.0000  1.76  0.0001  leucine rich repeat neuronal 1 
LXN -5.62  0.0000  1.78  0.0031  latexin 
LYAR 1.25  0.0000  -0.89  0.0000  Ly1 antibody reactive homolog (mouse) 
LYST -3.86  0.0000  1.03  0.0082  lysosomal trafficking regulator 
MAGED1 -0.87  0.0000  0.68  0.0001  melanoma antigen family D, 1 
MAP3K5 2.81  0.0000  -0.86  0.0089  mitogen-activated protein kinase kinase kinase 5 
MATN2 -2.69  0.0000  1.51  0.0041  matrilin 2 
MCM10 1.43  0.0000  -0.96  0.0011  minichromosome maintenance complex component 
10 
MMP9 2.76  0.0000  -0.76  0.0012  matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
MOXD1 -5.46  0.0000  1.21  0.0018  monooxygenase, DBH-like 1 
MTAP 1.31  0.0000  -0.70  0.0018  methylthioadenosine phosphorylase 
MXD4 -1.06  0.0000  0.73  0.0027  MAX dimerization protein 4 
MXRA8 -4.41  0.0000  1.58  0.0091  matrix-remodelling associated 8 
MYO19 1.54  0.0000  -0.64  0.0043  myosin XIX 
NAV2 -3.02  0.0000  1.33  0.0001  neuron navigator 2 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
NETO2 3.29  0.0000  -0.73  0.0028  neuropilin (NRP) and tolloid (TLL)-like 2 
NHS 1.30  0.0000  -0.82  0.0008  Nance-Horan syndrome (congenital cataracts and 
dental anomalies) 
NIPAL3 -1.20  0.0000  0.76  0.0019  NIPA-like domain containing 3 
NOP16 1.16  0.0000  -0.69  0.0036  NOP16 nucleolar protein homolog (yeast) 
NOP56 1.74  0.0000  -0.64  0.0020  NOP56 ribonucleoprotein homolog (yeast) 
NOP58 1.27  0.0000  -0.61  0.0010  NOP58 ribonucleoprotein homolog (yeast) 
NOTCH2 -1.00  0.0000  0.78  0.0002  Notch homolog 2 (Drosophila) 
NQO1 -1.75  0.0000  1.16  0.0017  NAD(P)H dehydrogenase, quinone 1 
NRP2 -2.88  0.0000  0.91  0.0000  neuropilin 2 
NUDCD1 1.19  0.0000  -0.75  0.0000  NudC domain containing 1 
NUP35 1.22  0.0000  -0.75  0.0002  nucleoporin 35kDa 
ODZ3 -3.38  0.0000  0.76  0.0036  odz, odd Oz/ten-m homolog 3 (Drosophila) 
OPTN -3.02  0.0000  0.82  0.0001  optineurin 
ORC1L 1.38  0.0000  -0.60  0.0034  origin recognition complex, subunit 1-like (yeast) 
PAICS 1.52  0.0000  -0.66  0.0001  phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole succinocarboxamide 
synthetase 
PBXIP1 -1.10  0.0000  0.90  0.0000  pre-B-cell leukemia homeobox interacting protein 1 
PIR -1.62  0.0000  0.64  0.0099  pirin (iron-binding nuclear protein) 
PNRC1 -1.90  0.0000  1.40  0.0000  proline-rich nuclear receptor coactivator 1 
POLR3K 1.58  0.0000  -0.78  0.0001  polymerase (RNA) III (DNA directed) polypeptide K, 
12.3 kDa 
PPAP2A -3.06  0.0000  1.35  0.0000  phosphatidic acid phosphatase type 2A 
PPIL5 1.09  0.0000  -0.78  0.0013  peptidylprolyl isomerase (cyclophilin)-like 5 
PQLC3 -1.60  0.0000  0.68  0.0033  PQ loop repeat containing 3 
PRELID2 0.88  0.0000  -0.66  0.0009  PRELI domain containing 2 
PSMB8 -1.16  0.0000  0.60  0.0086  proteasome (prosome, macropain) subunit, beta 
type, 8 (large multifunctional peptidase 7) 
PSMB9 -1.11  0.0000  0.72  0.0035  proteasome (prosome, macropain) subunit, beta 
type, 9 (large multifunctional peptidase 2) 
PSMC3IP 1.37  0.0000  -0.75  0.0012  PSMC3 interacting protein 
PTGER4 3.72  0.0000  -1.20  0.0004  prostaglandin E receptor 4 (subtype EP4) 
PTX3 2.98  0.0000  -2.03  0.0000  pentraxin-related gene, rapidly induced by IL-1 beta
RAD18 1.14  0.0000  -0.71  0.0022  RAD18 homolog (S. cerevisiae) 
RAD54B 1.10  0.0000  -0.74  0.0092  RAD54 homolog B (S. cerevisiae) 
RASGRF2 2.28  0.0000  -1.00  0.0010  Ras protein-specific guanine nucleotide-releasing 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
factor 2 
RFWD3 1.29  0.0000  -0.97  0.0000  ring finger and WD repeat domain 3 
RGNEF 2.18  0.0000  -1.28  0.0001  Rho-guanine nucleotide exchange factor 
RGS17 2.54  0.0000  -1.37  0.0024  regulator of G-protein signaling 17 
RGS5 3.62  0.0000  -1.14  0.0026  regulator of G-protein signaling 5 
RIPK2 1.44  0.0000  -0.90  0.0000  receptor-interacting serine-threonine kinase 2 
RNASEL -1.54  0.0000  0.73  0.0023  ribonuclease L (2',5'-oligoisoadenylate 
synthetase-dependent) 
RNF144B -2.45  0.0000  0.91  0.0099  ring finger protein 144B 
RPS6KA5 -2.12  0.0000  0.84  0.0008  ribosomal protein S6 kinase, 90kDa, polypeptide 5 
RTP4 -1.83  0.0000  1.28  0.0009  receptor (chemosensory) transporter protein 4 
S100A10 -1.73  0.0000  0.74  0.0091  S100 calcium binding protein A10 
SAT2 -1.34  0.0000  0.70  0.0019  spermidine/spermine N1-acetyltransferase family 
member 2 
SERF2 -1.11  0.0000  0.61  0.0085  chromosome 15 open reading frame 63; small 
EDRK-rich factor 2 
SERPINB1 -3.48  0.0000  0.78  0.0054  serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 
SH3BP5 -3.80  0.0000  0.84  0.0011  SH3-domain binding protein 5 (BTK-associated) 
SHISA3 3.99  0.0000  -1.62  0.0050  shisa homolog 3 (Xenopus laevis) 
SIGLEC15 2.03 0.0000 -1.17 0.0013 sialic acid binding Ig-like lectin 15 
SIN3B 1.20 0.0000 -0.74 0.0030 SIN3 homolog B, transcription regulator (yeast) 
SLC16A4 -3.39 0.0000 1.11 0.0018 solute carrier family 16, member 4 (monocarboxylic 
acid transporter 5) 
SLC17A5 -3.39 0.0000 0.69 0.0078 solute carrier family 17 (anion/sugar transporter), 
member 5 
SLC19A1 1.46 0.0000 -0.72 0.0038 solute carrier family 19 (folate transporter), member 
1 
SLCO4A1 3.66 0.0000 -1.34 0.0000 solute carrier organic anion transporter family, 
member 4A1 
SMURF2 2.51 0.0000 -1.13 0.0013 SMAD specific E3 ubiquitin protein ligase 2 
SOLH 1.08 0.0000 -1.04 0.0013 small optic lobes homolog (Drosophila) 
SOX9 5.24 0.0000 -1.40 0.0003 SRY (sex determining region Y)-box 9 
SPARC -2.68 0.0000 1.05 0.0063 secreted protein, acidic, cysteine-rich (osteonectin) 
SPIN4 1.43 0.0000 -0.78 0.0035 spindlin family, member 4 
SPTLC3 -3.57 0.0000 1.48 0.0041 serine palmitoyltransferase, long chain base subunit 
3 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
STAMBPL1 2.33 0.0000 -0.98 0.0002 STAM binding protein-like 1 
STAT6 -5.88 0.0000 0.71 0.0009 signal transducer and activator of transcription 6, 
interleukin-4 induced 
STEAP1 2.23 0.0000 -0.94 0.0026 six transmembrane epithelial antigen of the prostate 
1 
STX1A 2.12 0.0000 -1.05 0.0035 syntaxin 1A (brain) 
SVEP1 1.64 0.0000 -0.78 0.0060 sushi, von Willebrand factor type A, EGF and 
pentraxin domain containing 1 
TBC1D8B -3.01 0.0000 0.99 0.0017 TBC1 domain family, member 8B (with GRAM 
domain) 
TIPIN 1.36 0.0000 -0.90 0.0004 TIMELESS interacting protein 
TLR4 4.44 0.0000 -1.44 0.0015 toll-like receptor 4 
TMEM48 1.07 0.0000 -0.63 0.0017 transmembrane protein 48 
TMEM59 -2.05 0.0000 0.68 0.0056 transmembrane protein 59 
TNFRSF1
0A 
2.02 0.0000 -0.87 0.0035 tumor necrosis factor receptor superfamily, member 
10a 
TNFRSF1
9 
-1.40 0.0000 1.59 0.0001 
tumor necrosis factor receptor superfamily, member 
19 
TP53INP2 -1.95 0.0000 0.93 0.0041 tumor protein p53 inducible nuclear protein 2 
TRIM16L -1.29 0.0000 1.28 0.0000 tripartite motif-containing 16-like 
TRMT6 2.03 0.0000 -0.73 0.0021 tRNA methyltransferase 6 homolog (S. cerevisiae) 
TRPA1 4.21 0.0000 -2.05 0.0000 transient receptor potential cation channel, 
subfamily A, member 1 
TSPAN11 -2.44 0.0000 1.35 0.0036 tetraspanin 11 
TSPAN31 -1.39 0.0000 0.61 0.0046 tetraspanin 31 
UBE2C 1.60 0.0000 -1.03 0.0000 ubiquitin-conjugating enzyme E2C 
UCK2 1.20 0.0000 -0.75 0.0002 uridine-cytidine kinase 2 
UHRF1 2.05 0.0000 -0.81 0.0013 ubiquitin-like with PHD and ring finger domains 1 
UST -1.56 0.0000 0.65 0.0026 uronyl-2-sulfotransferase 
VAV3 -1.11 0.0000 1.15 0.0000 vav 3 guanine nucleotide exchange factor 
VEGFC 1.52 0.0000 -1.60 0.0000 vascular endothelial growth factor C 
VKORC1L1 1.09 0.0000 -0.61 0.0001 vitamin K epoxide reductase complex, subunit 1-like 
1 
VRK1 0.91 0.0000 -0.87 0.0000 vaccinia related kinase 1 
WDHD1 1.36 0.0000 -0.67 0.0033 WD repeat and HMG-box DNA binding protein 1 
WDR5 1.02 0.0000 -0.91 0.0000 WD repeat domain 5 
ZFYVE26 -1.27 0.0000 0.74 0.0028 zinc finger, FYVE domain containing 26 
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Gene 
In DS-6 
ST88 vs HSC 
.logFC 
ST88 vs HSC. 
adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO 
.adjPVal 
Descriptions 
ZNF587 1.45 0.0000 -1.12 0.0000 zinc finger protein 587 
ZNF695 1.46 0.0000 -0.63 0.0014 zinc finger protein 695 
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Suppl. Table 4: DS-7 
DS-7, intersection of DS-2 (siNRas vs. SC) and DS-3(U0126 vs. DMSO), is 
hypothetically regulated by NRAS-MEK1/2 in ST88-14(Nf1-/-) cells, with matching the 
pattern: 1) increase in siNRas versus scrambled control siRNA treated ST88-14 and in 
U0126 versus DMSO, or 2) decrease in siNRas versus scrambled control treated ST88-14 
and in U0126 versus DMSO. 
Gene 
In DS-7 
siNRas vs SC 
.logFC 
siNRas vs SC88 
.adjPVal 
U0126 vs DMSO 
.logFC 
U0126 vs DMSO
.adjPVal 
Descriptions 
ANXA4 0.60 0.0020 1.24 0.0000 annexin A4 
ARHGAP18 0.90 0.0014 0.67 0.0019 Rho GTPase activating protein 18 
ATF3 1.04 0.0002 1.01 0.0026 activating transcription factor 3 
BICD1 -0.79 0.0052 -0.94 0.0007 bicaudal D homolog 1 (Drosophila) 
C21orf34 0.67 0.0090 1.34 0.0004 chromosome 21 open reading frame 34 
C2orf15 1.01 0.0031 1.12 0.0014 chromosome 2 open reading frame 15 
C9orf150 0.69 0.0036 1.05 0.0001 chromosome 9 open reading frame 150 
CHST11 -1.15 0.0007 -1.00 0.0003 carbohydrate (chondroitin 4) sulfotransferase 11 
KCTD9 -0.60 0.0077 -0.70 0.0004 similar to Potassium channel tetramerisation 
domain containing 9; potassium channel 
tetramerisation domain containing 9;  
LOC100128822 0.74 0.0045 0.71 0.0018 hypothetical LOC100128822 
MGC3771 0.69 0.0059 0.85 0.0001 hypothetical LOC81854 
MORC4 -0.79 0.0043 -0.71 0.0025 MORC family CW-type zinc finger 4 
NT5E -1.55 0.0003 -1.26 0.0000 5'-nucleotidase, ecto (CD73) 
PLAT -0.98 0.0018 -0.73 0.0019 plasminogen activator, tissue 
PTTG2 -0.68 0.0093 -0.66 0.0051 pituitary tumor-transforming 1; pituitary 
tumor-transforming 2 
PVRL3 -0.76 0.0003 -0.99 0.0001 poliovirus receptor-related 3 
SNHG8 0.96 0.0003 0.60 0.0019 small nucleolar RNA host gene 8 (non-protein 
coding) 
SPIN4 -0.66 0.0041 -0.78 0.0035 spindlin family, member 4 
TFB1M -0.92 0.0004 -0.92 0.0005 transcription factor B1, mitochondrial 
TUFT1 0.85 0.0003 1.04 0.0000 tuftelin 1 
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Suppl. Table 5: DS-8 
DS-8, intersection of DS-4 (ST88 vs. HSC), DS-2 (siNRas vs. SC) and DS-3 (U0126 vs. DMSO), is 
hypothetically under the regulation of Neurofibromin-NRAS-MEK1/2 axis, with matching the pattern: 1) 
decrease in ST88-14 vs. HSC, increase in siNRas vs. scrambled control treated ST88-14, but decrease in 
U0126 vs. DMSO, or 2) increase in ST88-14 vs. HSC, decrease in siNRas vs. scrambled control treated 
ST88-14, but increase in U0126 vs. DMSO. 
 
 
 
 
 
Gene 
in DS-8 
ST88 vs HSC 
.logFC 
ST88 vs HSC
.adjPVal 
siNRas vs SC 
.logFC 
siNRas vs 
SC88 
.adjPVal 
U0126 vs 
DMSO 
.logFC 
U0126 vs 
DMSO 
.adjPVal 
Descriptions 
ANXA4 -1.21 0.0000 0.60 0.0019 1.24 0.0000 annexin A4 
C21orf34 -1.19 0.0001 0.67 0.0090 1.34 0.0004 chromosome 21 open reading frame 34 
ATF3 -1.42 0.0000 1.04 0.0001 1.01 0.0026 activating transcription factor 3 
CHEK1 1.91 0.0000 -0.58 0.0051 -0.66 0.0047 CHK1 checkpoint homolog (S. pombe) 
SPIN4 1.43 0.0000 -0.66 0.0040 -0.78 0.0035 spindlin family, member 4 
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Suppl. Table 6: DS-9 
DS-9 is obtained by removal of the overlapped gene with DS-2 (siNRas vs. SC) and with 
DS-3 (U0126 vs. DMSO). These genes are hypothetically Neurofibromin-related but 
NRAS and MEK1/2 independent. 
Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
A2M -6.22 0.0000 alpha-2-macroglobulin 
AARSD1 1.21 0.0000 alanyl-tRNA synthetase domain containing 1 
AASDH -1.51 0.0000 aminoadipate-semialdehyde dehydrogenase 
AASDHPPT 1.25 0.0000 aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl 
transferase 
AASS -1.45 0.0000 aminoadipate-semialdehyde synthase 
AATK -3.28 0.0000 apoptosis-associated tyrosine kinase 
ABCA1 -1.74 0.0000 ATP-binding cassette, sub-family A (ABC1), member 1 
ABCB7 -0.78 0.0000 ATP-binding cassette, sub-family B (MDR/TAP), member 7 
ABHD12 -1.58 0.0000 abhydrolase domain containing 12 
ABHD2 -1.32 0.0000 abhydrolase domain containing 2 
ABHD6 -3.20 0.0000 abhydrolase domain containing 6 
ABL2 -1.14 0.0000 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, 
Abelson-related gene) 
ABLIM3 -3.31 0.0000 actin binding LIM protein family, member 3 
ABR -1.42 0.0000 active BCR-related gene 
ACAA1 -1.58 0.0000 acetyl-Coenzyme A acyltransferase 1 
ACADVL -1.26 0.0000 acyl-Coenzyme A dehydrogenase, very long chain 
ACBD5 -1.60 0.0000 acyl-Coenzyme A binding domain containing 5 
ACCN2 1.72 0.0000 amiloride-sensitive cation channel 2, neuronal 
ACER3 -2.13 0.0000 alkaline ceramidase 3 
ACOT9 -1.17 0.0000 acyl-CoA thioesterase 9 
ACSL1 -1.37 0.0000 acyl-CoA synthetase long-chain family member 1 
ACSS2 1.47 0.0000 acyl-CoA synthetase short-chain family member 2 
ACTC1 -2.95 0.0000 actin, alpha, cardiac muscle 1 
ACTG2 -3.96 0.0000 actin, gamma 2, smooth muscle, enteric 
ACTR10 -0.95 0.0000 actin-related protein 10 homolog (S. cerevisiae) 
ACTR3B 1.23 0.0000 ARP3 actin-related protein 3 homolog B (yeast) 
ACTR5 1.44 0.0000 ARP5 actin-related protein 5 homolog (yeast) 
ACVR1B -1.36 0.0000 activin A receptor, type IB 
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Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
ACVR2A 1.02 0.0000 activin A receptor, type IIA 
ACYP2 -2.11 0.0000 acylphosphatase 2, muscle type 
ADAM10 -2.86 0.0000 ADAM metallopeptidase domain 10 
ADAM17 -1.66 0.0000 ADAM metallopeptidase domain 17 
ADAM23 -2.34 0.0000 ADAM metallopeptidase domain 23 
ADAMTS4 -5.04 0.0000 ADAM metallopeptidase with thrombospondin type 1 motif, 4 
ADAMTS6 3.93 0.0000 ADAM metallopeptidase with thrombospondin type 1 motif, 6 
ADAMTS9 -4.04 0.0000 ADAM metallopeptidase with thrombospondin type 1 motif, 9 
ADAMTSL1 -3.03 0.0000 ADAMTS-like 1 
ADCY1 3.11 0.0000 adenylate cyclase 1 (brain) 
ADD1 -1.09 0.0000 adducin 1 (alpha) 
ADD3 -2.73 0.0000 adducin 3 (gamma) 
ADI1 -1.46 0.0000 acireductone dioxygenase 1 
ADRB2 2.01 0.0000 adrenergic, beta-2-, receptor, surface 
AFAP1L2 -5.13 0.0000 actin filament associated protein 1-like 2 
AGA -1.98 0.0000 aspartylglucosaminidase 
AGFG1 -0.82 0.0000 ArfGAP with FG repeats 1 
AGFG2 1.06 0.0000 ArfGAP with FG repeats 2 
AGPAT9 -3.37 0.0000 1-acylglycerol-3-phosphate O-acyltransferase 9 
AHCY 1.06 0.0000 adenosylhomocysteinase 
AHI1 -0.93 0.0000 Abelson helper integration site 1 
AHSA2 1.81 0.0000 AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) 
AIFM2 -2.78 0.0000 apoptosis-inducing factor, mitochondrion-associated, 2 
AIG1 -1.17 0.0000 androgen-induced 1 
AIMP2 0.65 0.0000 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2; 
stromal antigen 3-like 3 
AK2 2.15 0.0000 adenylate kinase 2 
AK3L1 3.44 0.0000 adenylate kinase 3-like 2; adenylate kinase 3-like 1 
AKAP1 1.48 0.0000 A kinase (PRKA) anchor protein 1 
AKAP11 -1.37 0.0000 A kinase (PRKA) anchor protein 11 
AKAP13 -2.01 0.0000 A kinase (PRKA) anchor protein 13 
AKAP6 -1.76 0.0000 A kinase (PRKA) anchor protein 6 
AKIRIN2 -1.14 0.0000 akirin 2 
AKR1B1 -1.85 0.0000 aldo-keto reductase family 1, member B1 (aldose reductase) 
AKR1B10 -2.78 0.0000 aldo-keto reductase family 1, member B10 (aldose reductase); aldo-keto 
reductase family 1, member B10-like 
AKR1C1 -2.22 0.0000 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 
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Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
20-alpha (3-alpha)-hydroxysteroid dehydrogenase) 
ALDH1A1 -3.18 0.0000 aldehyde dehydrogenase 1 family, member A1 
ALDH1A2 2.46 0.0000 aldehyde dehydrogenase 1 family, member A2 
ALDH3A2 -1.57 0.0000 aldehyde dehydrogenase 3 family, member A2 
ALDH3B1 -1.11 0.0000 aldehyde dehydrogenase 3 family, member B1 
ALDH5A1 2.00 0.0000 aldehyde dehydrogenase 5 family, member A1 
ALDOA 1.17 0.0000 aldolase A, fructose-bisphosphate 
ALG9 -0.70 0.0000 asparagine-linked glycosylation 9, alpha-1,2-mannosyltransferase homolog 
(S. cerevisiae) 
ALS2CR4 2.44 0.0000 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4 
AMIGO2 5.18 0.0000 adhesion molecule with Ig-like domain 2 
AMOTL1 -1.44 0.0000 angiomotin like 1 
AMOTL2 2.42 0.0000 angiomotin like 2 
AMZ2 1.23 0.0000 archaelysin family metallopeptidase 2 
ANAPC1 0.80 0.0000 anaphase promoting complex subunit 1; similar to anaphase promoting 
complex subunit 1 
ANG -2.13 0.0000 angiogenin, ribonuclease, RNase A family, 5 
ANK2 -2.71 0.0000 ankyrin 2, neuronal 
ANK3 -2.19 0.0000 ankyrin 3, node of Ranvier (ankyrin G) 
ANKFY1 -0.97 0.0000 ankyrin repeat and FYVE domain containing 1 
ANKH -1.23 0.0000 ankylosis, progressive homolog (mouse) 
ANKRD10 -1.48 0.0000 ankyrin repeat domain 10 
ANKRD12 -1.74 0.0000 ankyrin repeat domain 12 
ANKRD17 -1.28 0.0000 ankyrin repeat domain 17 
ANKRD18A 3.91 0.0000 ankyrin repeat domain 18A 
ANKRD20A2 2.37 0.0000 hCG2042718; chromosome 21 open reading frame 81; ankyrin repeat 
domain 20 family, member A1; ankyrin repeat domain 20 family, member A3; 
ankyrin repeat domain 20 family, member A2 
ANKRD28 -2.33 0.0000 ankyrin repeat domain 28 
ANKRD35 -2.45 0.0000 ankyrin repeat domain 35 
ANKRD42 -0.82 0.0000 ankyrin repeat domain 42 
ANKRD44 -1.90 0.0000 ankyrin repeat domain 44 
ANKRD50 -1.66 0.0000 ankyrin repeat domain 50 
ANKRD6 -2.45 0.0000 ankyrin repeat domain 6 
ANKRD7 1.82 0.0000 ankyrin repeat domain 7 
ANKS1A -0.86 0.0000 ankyrin repeat and sterile alpha motif domain containing 1A 
ANO6 -2.22 0.0000 anoctamin 6 
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Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
ANXA1 -1.38 0.0000 annexin A1 
ANXA11 -1.43 0.0000 annexin A11 
ANXA5 -1.65 0.0000 annexin A5 
ANXA7 -1.31 0.0000 annexin A7 
AP1G1 -0.77 0.0000 adaptor-related protein complex 1, gamma 1 subunit 
AP3D1 -2.30 0.0000 adaptor-related protein complex 3, delta 1 subunit 
AP4E1 -1.18 0.0000 adaptor-related protein complex 4, epsilon 1 subunit 
APBA2 1.90 0.0000 amyloid beta (A4) precursor protein-binding, family A, member 2 
APC2 2.04 0.0000 adenomatosis polyposis coli 2 
APH1B -1.51 0.0000 anterior pharynx defective 1 homolog B (C. elegans) 
API5 -0.95 0.0000 API5-like 1; apoptosis inhibitor 5 
AQP7 -2.25 0.0000 aquaporin 7 
AQR 1.17 0.0000 aquarius homolog (mouse) 
AR 2.70 0.0000 androgen receptor 
ARF6 -1.10 0.0000 ADP-ribosylation factor 6 
ARFIP1 -1.56 0.0000 ADP-ribosylation factor interacting protein 1 
ARHGAP12 -1.90 0.0000 Rho GTPase activating protein 12 
ARHGAP17 1.09 0.0000 Rho GTPase activating protein 17 
ARHGAP19 -1.41 0.0000 Rho GTPase activating protein 19 
ARHGAP21 -1.93 0.0000 Rho GTPase activating protein 21 
ARHGAP26 -1.74 0.0000 Rho GTPase activating protein 26 
ARHGAP28 3.65 0.0000 Rho GTPase activating protein 28 
ARHGAP29 5.08 0.0000 Rho GTPase activating protein 29 
ARHGAP5 -1.80 0.0000 Rho GTPase activating protein 5 
ARHGDIA -1.92 0.0000 Rho GDP dissociation inhibitor (GDI) alpha 
ARHGDIB 2.43 0.0000 Rho GDP dissociation inhibitor (GDI) beta 
ARHGEF12 -1.26 0.0000 Rho guanine nucleotide exchange factor (GEF) 12 
ARHGEF19 1.26 0.0000 Rho guanine nucleotide exchange factor (GEF) 19 
ARID3B 1.92 0.0000 AT rich interactive domain 3B (BRIGHT-like) 
ARID4A -1.07 0.0000 AT rich interactive domain 4A (RBP1-like) 
ARIH2 -1.09 0.0000 ariadne homolog 2 (Drosophila) 
ARL16 1.39 0.0000 ADP-ribosylation factor-like 16 
ARL3 -1.47 0.0000 ADP-ribosylation factor-like 3 
ARL4D -0.99 0.0000 ADP-ribosylation factor-like 4D 
ARL5A -1.47 0.0000 ADP-ribosylation factor-like 5A 
ARL8B -1.65 0.0000 ADP-ribosylation factor-like 8B 
ARMC8 0.79 0.0000 armadillo repeat containing 8 
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Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
ARMC9 -2.52 0.0000 armadillo repeat containing 9 
ARNTL -1.94 0.0000 aryl hydrocarbon receptor nuclear translocator-like 
ARNTL2 1.73 0.0000 aryl hydrocarbon receptor nuclear translocator-like 2 
ARPC1B -2.26 0.0000 actin related protein 2/3 complex, subunit 1B, 41kDa; similar to Actin-related 
protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41-ARC)
ARSA -1.34 0.0000 arylsulfatase A 
ARSE -1.55 0.0000 arylsulfatase E (chondrodysplasia punctata 1) 
ARSJ 3.09 0.0000 arylsulfatase family, member J 
ASAH1 -3.01 0.0000 N-acylsphingosine amidohydrolase (acid ceramidase) 1 
ASAM 2.18 0.0000 adipocyte-specific adhesion molecule 
ASAP3 2.79 0.0000 ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 
ASB1 1.20 0.0000 ankyrin repeat and SOCS box-containing 1 
ASH2L -0.94 0.0000 ash2 (absent, small, or homeotic)-like (Drosophila) 
ASL -1.53 0.0000 argininosuccinate lyase 
ASRGL1 1.86 0.0000 asparaginase like 1 
ASTN1 2.71 0.0000 astrotactin 1 
ASTN2 1.52 0.0000 astrotactin 2 
ASXL1 0.83 0.0000 additional sex combs like 1 (Drosophila) 
ATAD1 -0.79 0.0000 ATPase family, AAA domain containing 1 
ATAD2 2.24 0.0000 ATPase family, AAA domain containing 2 
ATF6B -1.62 0.0000 activating transcription factor 6 beta 
ATF7IP -1.71 0.0000 activating transcription factor 7 interacting protein 
ATG16L2 -1.94 0.0000 ATG16 autophagy related 16-like 2 (S. cerevisiae) 
ATG3 -0.62 0.0000 ATG3 autophagy related 3 homolog (S. cerevisiae) 
ATG7 -1.23 0.0000 ATG7 autophagy related 7 homolog (S. cerevisiae) 
ATIC 1.53 0.0000 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP 
cyclohydrolase 
ATOX1 -1.37 0.0000 ATX1 antioxidant protein 1 homolog (yeast) 
ATP10A 2.43 0.0000 ATPase, class V, type 10A 
ATP11C 1.56 0.0000 ATPase, class VI, type 11C 
ATP1A1 -1.94 0.0000 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
ATP1A3 -1.81 0.0000 ATPase, Na+/K+ transporting, alpha 3 polypeptide 
ATP1A4 -1.11 0.0000 ATPase, Na+/K+ transporting, alpha 4 polypeptide 
ATP2A2 -1.32 0.0000 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
ATP6AP2 -1.83 0.0000 ATPase, H+ transporting, lysosomal accessory protein 2 
ATP6V0A4 -1.98 0.0000 ATPase, H+ transporting, lysosomal V0 subunit a4 
ATP6V0B -1.58 0.0000 ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 
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Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
ATP6V0C -0.89 0.0000 ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c 
ATP6V0D1 -1.61 0.0000 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
ATP6V0E1 -0.97 0.0000 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 
ATP6V1A -2.07 0.0000 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
ATP6V1B2 -1.97 0.0000 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
ATP6V1C1 -0.98 0.0000 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 
ATP6V1E1 -1.64 0.0000 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
ATP6V1H -1.65 0.0000 ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 
ATP8A1 -1.77 0.0000 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 
ATP8B3 -2.96 0.0000 ATPase, class I, type 8B, member 3 
ATP9A 5.12 0.0000 ATPase, class II, type 9A 
ATR 0.66 0.0000 ataxia telangiectasia and Rad3 related; similar to ataxia telangiectasia and 
Rad3 related protein 
ATXN2L 1.30 0.0000 ataxin 2-like 
AVPI1 -3.00 0.0000 arginine vasopressin-induced 1 
AZGP1 -3.74 0.0000 alpha-2-glycoprotein 1, zinc-binding pseudogene 1; alpha-2-glycoprotein 1, 
zinc-binding 
AZI1 1.39 0.0000 5-azacytidine induced 1 
B2M -3.51 0.0000 beta-2-microglobulin 
B3GALT4 -4.85 0.0000 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4 
B4GALNT4 1.65 0.0000 beta-1,4-N-acetyl-galactosaminyl transferase 4 
BACE1 -2.15 0.0000 beta-site APP-cleaving enzyme 1 
BACE2 -3.41 0.0000 beta-site APP-cleaving enzyme 2 
BACH1 1.33 0.0000 BTB and CNC homology 1, basic leucine zipper transcription factor 1 
BAG2 1.82 0.0000 BCL2-associated athanogene 2 
BAI1 2.83 0.0000 brain-specific angiogenesis inhibitor 1 
BAIAP2L1 2.07 0.0000 BAI1-associated protein 2-like 1 
BAIAP2L2 -1.96 0.0000 BAI1-associated protein 2-like 2 
BASP1 4.16 0.0000 brain abundant, membrane attached signal protein 1 
BATF3 1.91 0.0000 basic leucine zipper transcription factor, ATF-like 3 
BAZ1B 1.15 0.0000 bromodomain adjacent to zinc finger domain, 1B 
BBS2 1.04 0.0000 Bardet-Biedl syndrome 2 
BBS7 -1.13 0.0000 Bardet-Biedl syndrome 7 
BCAT1 4.11 0.0000 branched chain aminotransferase 1, cytosolic 
BCL11B 2.20 0.0000 B-cell CLL/lymphoma 11B (zinc finger protein) 
BCL2 -1.42 0.0000 B-cell CLL/lymphoma 2 
BCL2L13 -1.20 0.0000 BCL2-like 13 (apoptosis facilitator) 
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Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
BCL7C 1.11 0.0000 B-cell CLL/lymphoma 7C 
BEND5 2.38 0.0000 BEN domain containing 5 
BEST1 -2.55 0.0000 bestrophin 1 
BET1 1.05 0.0000 hypothetical protein LOC100128542; blocked early in transport 1 homolog (S. 
cerevisiae) 
BFSP1 3.82 0.0000 beaded filament structural protein 1, filensin 
BHLHB9 -1.14 0.0000 basic helix-loop-helix domain containing, class B, 9 
BHLHE40 -2.20 0.0000 basic helix-loop-helix family, member e40 
BHLHE41 2.00 0.0000 basic helix-loop-helix family, member e41 
BIN3 -1.31 0.0000 bridging integrator 3 
BLMH -0.91 0.0000 bleomycin hydrolase 
BMP2 1.77 0.0000 bone morphogenetic protein 2 
BMP2K -1.70 0.0000 BMP2 inducible kinase 
BMP4 3.53 0.0000 bone morphogenetic protein 4 
BMP6 4.95 0.0000 bone morphogenetic protein 6 
BMP7 4.88 0.0000 bone morphogenetic protein 7 
BNC1 3.66 0.0000 basonuclin 1 
BNC2 1.98 0.0000 basonuclin 2 
BNIP3L -1.50 0.0000 BCL2/adenovirus E1B 19kDa interacting protein 3-like 
BOD1 0.95 0.0000 biorientation of chromosomes in cell division 1 
BOLA2B 1.56 0.0000 bolA homolog 2 (E. coli); bolA homolog 2B (E. coli) 
BOP1 2.31 0.0000 block of proliferation 1 
BPGM -1.45 0.0000 2,3-bisphosphoglycerate mutase 
BRI3 -1.65 0.0000 brain protein I3; brain protein I3 pseudogene 1 
BRIP1 1.90 0.0000 BRCA1 interacting protein C-terminal helicase 1 
BSG -0.94 0.0000 basigin (Ok blood group) 
BST1 -3.39 0.0000 bone marrow stromal cell antigen 1 
BTBD1 -0.81 0.0000 BTB (POZ) domain containing 1 
BTBD3 -1.54 0.0000 BTB (POZ) domain containing 3 
BTD -3.25 0.0000 biotinidase 
BTG1 -2.10 0.0000 B-cell translocation gene 1, anti-proliferative 
BTN2A2 -1.76 0.0000 butyrophilin, subfamily 2, member A2 
BVES -2.29 0.0000 blood vessel epicardial substance 
C10orf10 -2.29 0.0000 chromosome 10 open reading frame 10 
C10orf11 -2.61 0.0000 chromosome 10 open reading frame 11 
C10orf111 1.10 0.0000 chromosome 10 open reading frame 111 
C10orf114 -2.44 0.0000 chromosome 10 open reading frame 114 
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C10orf116 -2.33 0.0000 chromosome 10 open reading frame 116 
C10orf18 -1.87 0.0000 chromosome 10 open reading frame 18 
C10orf2 0.88 0.0000 chromosome 10 open reading frame 2 
C10orf32 -1.47 0.0000 chromosome 10 open reading frame 32 
C10orf35 2.36 0.0000 chromosome 10 open reading frame 35 
C11orf1 1.15 0.0000 chromosome 11 open reading frame 1 
C11orf61 1.86 0.0000 chromosome 11 open reading frame 61 
C11orf75 1.56 0.0000 hypothetical LOC728675; chromosome 11 open reading frame 75 
C11orf9 1.79 0.0000 chromosome 11 open reading frame 9 
C12orf26 -1.66 0.0000 chromosome 12 open reading frame 26 
C12orf45 1.21 0.0000 chromosome 12 open reading frame 45 
C12orf47 1.85 0.0000 chromosome 12 open reading frame 47 
C12orf53 1.81 0.0000 chromosome 12 open reading frame 53 
C12orf66 1.01 0.0000 chromosome 12 open reading frame 66 
C13orf18 -1.80 0.0000 similar to protein phosphatase 1, regulatory subunit 2; protein phosphatase 1, 
regulatory (inhibitor) subunit 2 pseudogene 4; chromosome 13 open reading 
frame 18 
C14orf128 -1.64 0.0000 chromosome 14 open reading frame 128 
C14orf139 -2.15 0.0000 chromosome 14 open reading frame 139 
C14orf147 -2.09 0.0000 chromosome 14 open reading frame 147 
C14orf166 -1.18 0.0000 chromosome 14 open reading frame 166 
C14orf4 -1.31 0.0000 chromosome 14 open reading frame 4 
C14orf43 -1.30 0.0000 chromosome 14 open reading frame 43 
C15orf41 2.07 0.0000 chromosome 15 open reading frame 41 
C15orf48 -4.09 0.0000 chromosome 15 open reading frame 48 
C16orf5 2.41 0.0000 chromosome 16 open reading frame 5 
C16orf53 1.22 0.0000 chromosome 16 open reading frame 53 
C16orf59 1.49 0.0000 chromosome 16 open reading frame 59 
C16orf68 1.82 0.0000 chromosome 16 open reading frame 68 
C16orf74 3.12 0.0000 chromosome 16 open reading frame 74 
C16orf75 3.75 0.0000 chromosome 16 open reading frame 75 
C16orf86 -1.88 0.0000 chromosome 16 open reading frame 86 
C17orf37 -1.67 0.0000 chromosome 17 open reading frame 37 
C17orf39 1.37 0.0000 chromosome 17 open reading frame 39 
C17orf56 0.99 0.0000 chromosome 17 open reading frame 56 
C17orf58 1.91 0.0000 chromosome 17 open reading frame 58 
C17orf59 -1.39 0.0000 chromosome 17 open reading frame 59 
107 
 
Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
C17orf67 1.96 0.0000 chromosome 17 open reading frame 67 
C17orf72 2.47 0.0000 chromosome 17 open reading frame 72 
C17orf75 0.95 0.0000 chromosome 17 open reading frame 75 
C17orf79 -0.70 0.0000 chromosome 17 open reading frame 79 
C17orf80 1.28 0.0000 chromosome 17 open reading frame 80 
C17orf86 1.92 0.0000 chromosome 17 open reading frame 86 
C17orf89 1.39 0.0000 chromosome 17 open reading frame 89 
C18orf32 -1.34 0.0000 chromosome 18 open reading frame 32 
C18orf56 1.65 0.0000 chromosome 18 open reading frame 56 
C18orf8 -0.84 0.0000 chromosome 18 open reading frame 8 
C19orf28 -4.54 0.0000 chromosome 19 open reading frame 28 
C19orf56 -1.07 0.0000 chromosome 19 open reading frame 56 
C19orf63 -2.17 0.0000 chromosome 19 open reading frame 63 
C19orf66 -2.24 0.0000 chromosome 19 open reading frame 66 
C1D 1.52 0.0000 C1D nuclear receptor co-repressor; similar to nuclear DNA-binding protein; 
similar to hCG1791993 
C1GALT1C1 -1.43 0.0000 C1GALT1-specific chaperone 1 
C1orf103 1.97 0.0000 chromosome 1 open reading frame 103 
C1orf106 2.51 0.0000 chromosome 1 open reading frame 106 
C1orf174 0.72 0.0000 chromosome 1 open reading frame 174 
C1orf204 1.29 0.0000 chromosome 1 open reading frame 204; V-set and immunoglobulin domain 
containing 8 
C1orf213 2.00 0.0000 chromosome 1 open reading frame 213 
C1orf53 2.06 0.0000 chromosome 1 open reading frame 53 
C1orf59 3.28 0.0000 chromosome 1 open reading frame 59 
C1orf85 -2.03 0.0000 chromosome 1 open reading frame 85 
C1orf88 -1.49 0.0000 chromosome 1 open reading frame 88 
C1orf9 0.95 0.0000 chromosome 1 open reading frame 9 
C1QBP 0.78 0.0000 complement component 1, q subcomponent binding protein 
C20orf108 -1.09 0.0000 chromosome 20 open reading frame 108 
C20orf11 1.59 0.0000 chromosome 20 open reading frame 11 
C20orf111 1.13 0.0000 chromosome 20 open reading frame 111 
C20orf199 2.04 0.0000 chromosome 20 open reading frame 199 
C20orf20 1.57 0.0000 chromosome 20 open reading frame 20 
C20orf24 0.97 0.0000 chromosome 20 open reading frame 24 
C20orf27 1.24 0.0000 chromosome 20 open reading frame 27 
C20orf3 -0.99 0.0000 chromosome 20 open reading frame 3 
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C21orf45 1.60 0.0000 chromosome 21 open reading frame 45 
C21orf91 1.03 0.0000 chromosome 21 open reading frame 91 
C22orf29 1.22 0.0000 chromosome 22 open reading frame 29 
C22orf32 -1.32 0.0000 chromosome 22 open reading frame 32 
C22orf9 -1.64 0.0000 chromosome 22 open reading frame 9 
C2orf27A -1.08 0.0000 hypothetical LOC642669; chromosome 2 open reading frame 27A; 
hypothetical LOC644525 
C2orf34 -1.06 0.0000 chromosome 2 open reading frame 34 
C2orf44 1.19 0.0000 chromosome 2 open reading frame 44 
C2orf47 0.91 0.0000 chromosome 2 open reading frame 47 
C2orf79 -0.92 0.0000 chromosome 2 open reading frame 79 
C3AR1 -3.72 0.0000 complement component 3a receptor 1 
C3orf10 -0.92 0.0000 chromosome 3 open reading frame 10 
C3orf52 1.65 0.0000 chromosome 3 open reading frame 52 
C3orf59 1.06 0.0000 chromosome 3 open reading frame 59 
C4orf19 1.72 0.0000 chromosome 4 open reading frame 19 
C4orf27 -1.27 0.0000 chromosome 4 open reading frame 27 
C4orf32 1.63 0.0000 chromosome 4 open reading frame 32 
C4orf33 -1.54 0.0000 chromosome 4 open reading frame 33 
C4orf49 2.66 0.0000 chromosome 4 open reading frame 49 
C5orf23 4.23 0.0000 chromosome 5 open reading frame 23 
C5orf30 -1.31 0.0000 chromosome 5 open reading frame 30 
C5orf32 -2.18 0.0000 chromosome 5 open reading frame 32 
C5orf34 1.26 0.0000 chromosome 5 open reading frame 34 
C6orf1 -2.11 0.0000 chromosome 6 open reading frame 1 
C6orf106 -0.96 0.0000 chromosome 6 open reading frame 106 
C6orf129 -1.11 0.0000 chromosome 6 open reading frame 129 
C6orf134 -1.26 0.0000 chromosome 6 open reading frame 134 
C6orf203 -1.14 0.0000 chromosome 6 open reading frame 203 
C6orf204 -1.12 0.0000 chromosome 6 open reading frame 204 
C6orf218 -2.19 0.0000 chromosome 6 open reading frame 218 
C7orf13 1.23 0.0000 chromosome 7 open reading frame 13 
C7orf29 -2.63 0.0000 chromosome 7 open reading frame 29 
C7orf30 1.07 0.0000 chromosome 7 open reading frame 30 
C7orf40 1.74 0.0000 chromosome 7 open reading frame 40 
C7orf58 2.75 0.0000 chromosome 7 open reading frame 58 
C7orf68 1.11 0.0000 chromosome 7 open reading frame 68 
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C8orf33 1.73 0.0000 chromosome 8 open reading frame 33 
C8orf4 -3.77 0.0000 chromosome 8 open reading frame 4 
C8orf46 -1.50 0.0000 chromosome 8 open reading frame 46 
C8orf58 1.08 0.0000 chromosome 8 open reading frame 58 
C8orf76 0.96 0.0000 chromosome 8 open reading frame 76 
C8ORFK29 1.53 0.0000 hypothetical LOC340393 
C9orf109 2.31 0.0000 chromosome 9 open reading frame 109 
C9orf116 1.37 0.0000 chromosome 9 open reading frame 116 
C9orf123 1.04 0.0000 chromosome 9 open reading frame 123 
C9orf80 1.03 0.0000 chromosome 9 open reading frame 80 
C9orf86 2.24 0.0000 chromosome 9 open reading frame 86 
C9orf91 1.36 0.0000 chromosome 9 open reading frame 91 
CA13 -1.16 0.0000 carbonic anhydrase XIII 
CAB39L -4.28 0.0000 calcium binding protein 39-like 
CABLES1 2.58 0.0000 Cdk5 and Abl enzyme substrate 1 
CABLES2 2.31 0.0000 Cdk5 and Abl enzyme substrate 2 
CACNA1H 1.78 0.0000 calcium channel, voltage-dependent, T type, alpha 1H subunit 
CACNA2D4 -2.57 0.0000 calcium channel, voltage-dependent, alpha 2/delta subunit 4 
CACNG6 2.05 0.0000 calcium channel, voltage-dependent, gamma subunit 6 
CADPS2 2.24 0.0000 Ca++-dependent secretion activator 2 
CALB1 2.79 0.0000 calbindin 1, 28kDa 
CALHM2 -3.99 0.0000 calcium homeostasis modulator 2 
CALML4 1.66 0.0000 calmodulin-like 4 
CALU -1.88 0.0000 calumenin 
CAMK1D 2.57 0.0000 calcium/calmodulin-dependent protein kinase ID 
CAMK2D -0.92 0.0000 calcium/calmodulin-dependent protein kinase II delta 
CAMK2G 1.40 0.0000 calcium/calmodulin-dependent protein kinase II gamma 
CAMKV 1.31 0.0000 CaM kinase-like vesicle-associated 
CAMTA1 -1.01 0.0000 calmodulin binding transcription activator 1 
CANX -1.39 0.0000 calnexin 
CAP1 -2.47 0.0000 CAP, adenylate cyclase-associated protein 1 (yeast) 
CAPN3 -2.95 0.0000 calpain 3, (p94) 
CAPN5 -1.11 0.0000 calpain 5 
CAPRIN2 -1.81 0.0000 caprin family member 2 
CAPS -2.29 0.0000 calcyphosine 
CAPSL 0.97 0.0000 calcyphosine-like 
CARD10 -1.81 0.0000 caspase recruitment domain family, member 10 
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CARD6 -1.92 0.0000 caspase recruitment domain family, member 6 
CARD8 -1.08 0.0000 caspase recruitment domain family, member 8 
CARS2 -1.68 0.0000 cysteinyl-tRNA synthetase 2, mitochondrial (putative) 
CASKIN1 1.38 0.0000 CASK interacting protein 1 
CASP2 0.93 0.0000 caspase 2, apoptosis-related cysteine peptidase 
CASP6 -1.27 0.0000 caspase 6, apoptosis-related cysteine peptidase 
CASP9 -0.91 0.0000 caspase 9, apoptosis-related cysteine peptidase 
CAT -1.19 0.0000 catalase 
CAV1 1.56 0.0000 caveolin 1, caveolae protein, 22kDa 
CBLB 2.00 0.0000 Cas-Br-M (murine) ecotropic retroviral transforming sequence b 
CBR1 -1.27 0.0000 carbonyl reductase 1 
CBR4 -0.76 0.0000 carbonyl reductase 4 
CBWD5 2.08 0.0000 COBW domain containing 5; similar to COBW domain containing 1; COBW 
domain containing 7; COBW domain containing 3 
CCDC102A 2.12 0.0000 coiled-coil domain containing 102A 
CCDC113 1.50 0.0000 coiled-coil domain containing 113 
CCDC137 1.65 0.0000 coiled-coil domain containing 137 
CCDC144NL 1.92 0.0000 coiled-coil domain containing 144 family, N-terminal like 
CCDC22 -0.87 0.0000 coiled-coil domain containing 22 
CCDC25 -0.85 0.0000 coiled-coil domain containing 25 
CCDC3 3.72 0.0000 coiled-coil domain containing 3 
CCDC53 -1.07 0.0000 coiled-coil domain containing 53 
CCDC55 -1.19 0.0000 coiled-coil domain containing 55 
CCDC59 -1.14 0.0000 coiled-coil domain containing 59 
CCDC71 -2.64 0.0000 coiled-coil domain containing 71 
CCDC80 -1.47 0.0000 coiled-coil domain containing 80 
CCDC85C 4.43 0.0000 coiled-coil domain containing 85C 
CCDC86 1.42 0.0000 coiled-coil domain containing 86 
CCDC99 2.29 0.0000 coiled-coil domain containing 99 
CCK 3.93 0.0000 cholecystokinin 
CCNE1 1.61 0.0000 cyclin E1 
CCNI -1.24 0.0000 cyclin I 
CCNO 1.98 0.0000 cyclin O 
CCPG1 -2.04 0.0000 cell cycle progression 1 
CCR1 -3.72 0.0000 chemokine (C-C motif) receptor 1 
CCT6A 0.69 0.0000 chaperonin containing TCP1, subunit 6A (zeta 1) 
CCT6P1 0.90 0.0000 chaperonin containing TCP1, subunit 6 (zeta) pseudogene 1 
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CCT8 0.97 0.0000 similar to chaperonin containing TCP1, subunit 8 (theta); chaperonin 
containing TCP1, subunit 8 (theta) 
CD109 -1.32 0.0000 CD109 molecule 
CD14 -0.96 0.0000 CD14 molecule 
CD164 -1.12 0.0000 CD164 molecule, sialomucin 
CD1D 4.11 0.0000 CD1d molecule 
CD24 7.05 0.0000 CD24 molecule; CD24 molecule-like 4 
CD276 -1.88 0.0000 CD276 molecule 
CD2BP2 1.60 0.0000 CD2 (cytoplasmic tail) binding protein 2 
CD34 5.23 0.0000 CD34 molecule 
CD3EAP 1.67 0.0000 CD3e molecule, epsilon associated protein 
CD58 -3.02 0.0000 CD58 molecule 
CD59 -1.82 0.0000 CD59 molecule, complement regulatory protein 
CD63 -2.47 0.0000 CD63 molecule 
CD68 -2.31 0.0000 CD68 molecule 
CD70 3.40 0.0000 CD70 molecule 
CD81 -1.97 0.0000 CD81 molecule 
CD9 -3.05 0.0000 CD9 molecule 
CD97 -3.82 0.0000 CD97 molecule 
CD99 -1.94 0.0000 CD99 molecule 
CDADC1 -2.06 0.0000 cytidine and dCMP deaminase domain containing 1 
CDC14B -1.28 0.0000 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
CDC14C -1.11 0.0000 CDC14 cell division cycle 14 homolog C (S. cerevisiae) 
CDC42EP3 1.32 0.0000 CDC42 effector protein (Rho GTPase binding) 3 
CDC42SE1 -1.28 0.0000 CDC42 small effector 1 
CDCA7 2.85 0.0000 cell division cycle associated 7 
CDCA7L 1.33 0.0000 cell division cycle associated 7-like 
CDH13 3.83 0.0000 cadherin 13, H-cadherin (heart) 
CDH15 -2.72 0.0000 cadherin 15, type 1, M-cadherin (myotubule) 
CDK2AP1 -1.46 0.0000 cyclin-dependent kinase 2 associated protein 1 
CDK7 0.95 0.0000 cyclin-dependent kinase 7 
CDKL2 -2.00 0.0000 cyclin-dependent kinase-like 2 (CDC2-related kinase) 
CDKN1B -1.32 0.0000 cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
CDKN2A -3.86 0.0000 cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 
CDKN2AIPNL 1.06 0.0000 CDKN2A interacting protein N-terminal like 
CDKN2C -2.84 0.0000 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) 
CDS1 1.82 0.0000 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 
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CEACAM1 -5.76 0.0000 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary 
glycoprotein) 
CEBPA 1.65 0.0000 CCAAT/enhancer binding protein (C/EBP), alpha 
CEBPG 1.27 0.0000 CCAAT/enhancer binding protein (C/EBP), gamma 
CELSR2 -2.04 0.0000 cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, 
Drosophila) 
CENPH 1.42 0.0000 centromere protein H 
CENPK 2.10 0.0000 centromere protein K 
CENPV 3.80 0.0000 centromere protein V 
CETN2 1.25 0.0000 centrin, EF-hand protein, 2 
CETN3 1.10 0.0000 centrin, EF-hand protein, 3 (CDC31 homolog, yeast) 
CFDP1 -0.89 0.0000 craniofacial development protein 1 
CGREF1 2.57 0.0000 cell growth regulator with EF-hand domain 1 
CHADL -1.76 0.0000 chondroadherin-like 
CHCHD5 -1.58 0.0000 coiled-coil-helix-coiled-coil-helix domain containing 5 
CHFR -1.49 0.0000 checkpoint with forkhead and ring finger domains 
CHKB -1.54 0.0000 choline kinase beta; carnitine palmitoyltransferase 1B (muscle) 
CHML 1.67 0.0000 choroideremia-like (Rab escort protein 2) 
CHMP1B -1.36 0.0000 chromatin modifying protein 1B 
CHMP2A -2.38 0.0000 chromatin modifying protein 2A 
CHMP4A -0.97 0.0000 chromatin modifying protein 4A 
CHRAC1 1.35 0.0000 chromatin accessibility complex 1 
CHRD 2.45 0.0000 chordin 
CHRNA5 2.28 0.0000 cholinergic receptor, nicotinic, alpha 5 
CHST3 -2.12 0.0000 carbohydrate (chondroitin 6) sulfotransferase 3 
CHURC1 -2.19 0.0000 churchill domain containing 1 
CIB1 -1.22 0.0000 calcium and integrin binding 1 (calmyrin) 
CIITA -2.98 0.0000 class II, major histocompatibility complex, transactivator 
CITED4 2.86 0.0000 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 4 
CKAP4 2.92 0.0000 cytoskeleton-associated protein 4 
CLASP2 -1.67 0.0000 cytoplasmic linker associated protein 2 
CLCF1 -1.80 0.0000 cardiotrophin-like cytokine factor 1 
CLCN3 -2.35 0.0000 chloride channel 3 
CLCN5 -2.08 0.0000 chloride channel 5 
CLDN1 4.87 0.0000 claudin 1 
CLDN11 2.48 0.0000 claudin 11 
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CLDN23 -1.64 0.0000 claudin 23 
CLDND1 -1.04 0.0000 claudin domain containing 1 
CLIC4 -1.82 0.0000 chloride intracellular channel 4 
CLIP1 -1.01 0.0000 CAP-GLY domain containing linker protein 1 
CLIP4 -2.00 0.0000 CAP-GLY domain containing linker protein family, member 4 
CLMN -3.09 0.0000 calmin (calponin-like, transmembrane) 
CLN3 1.61 0.0000 ceroid-lipofuscinosis, neuronal 3 
CLN5 -2.32 0.0000 ceroid-lipofuscinosis, neuronal 5 
CLOCK -1.30 0.0000 clock homolog (mouse) 
CLP1 0.93 0.0000 CLP1, cleavage and polyadenylation factor I subunit, homolog (S. cerevisiae)
CLSTN1 -1.41 0.0000 calsyntenin 1 
CLU 1.95 0.0000 clusterin 
CMBL 2.72 0.0000 carboxymethylenebutenolidase homolog (Pseudomonas) 
CMTM6 -1.03 0.0000 CKLF-like MARVEL transmembrane domain containing 6 
CNN3 -1.89 0.0000 calponin 3, acidic 
CNOT1 1.44 0.0000 CCR4-NOT transcription complex, subunit 1 
CNP -2.68 0.0000 2',3'-cyclic nucleotide 3' phosphodiesterase 
CNPY2 -2.17 0.0000 canopy 2 homolog (zebrafish) 
CNPY3 -1.12 0.0000 canopy 3 homolog (zebrafish) 
CNRIP1 2.44 0.0000 cannabinoid receptor interacting protein 1 
CNTNAP1 1.90 0.0000 contactin associated protein 1 
CNTNAP3 6.08 0.0000 contactin associated protein-like 3; contactin associated protein-like 3B 
COCH 4.21 0.0000 coagulation factor C homolog, cochlin (Limulus polyphemus) 
COL11A2 -4.08 0.0000 collagen, type XI, alpha 2 
COL12A1 1.52 0.0000 collagen, type XII, alpha 1 
COL14A1 -4.56 0.0000 collagen, type XIV, alpha 1 
COL18A1 -2.58 0.0000 collagen, type XVIII, alpha 1 
COL21A1 4.72 0.0000 collagen, type XXI, alpha 1 
COL4A3BP -3.42 0.0000 collagen, type IV, alpha 3 (Goodpasture antigen) binding protein 
COL4A5 1.38 0.0000 collagen, type IV, alpha 5 
COL4A6 1.51 0.0000 collagen, type IV, alpha 6 
COL7A1 -3.26 0.0000 collagen, type VII, alpha 1 
COL9A2 -3.59 0.0000 collagen, type IX, alpha 2 
COL9A3 -2.95 0.0000 collagen, type IX, alpha 3 
COMP 3.07 0.0000 cartilage oligomeric matrix protein 
COPS6 0.93 0.0000 COP9 constitutive photomorphogenic homolog subunit 6 (Arabidopsis) 
COQ9 0.99 0.0000 coenzyme Q9 homolog (S. cerevisiae) 
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COX17 -1.02 0.0000 COX17 cytochrome c oxidase assembly homolog (S. cerevisiae) 
COX4I1 -1.28 0.0000 cytochrome c oxidase subunit IV isoform 1 
COX7A2 -0.84 0.0000 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 
CPA4 5.06 0.0000 carboxypeptidase A4 
CPD -1.54 0.0000 carboxypeptidase D 
CPEB1 -2.35 0.0000 cytoplasmic polyadenylation element binding protein 1 
CPM 1.45 0.0000 carboxypeptidase M 
CPNE3 -1.37 0.0000 copine III 
CPNE5 -1.41 0.0000 copine V 
CPT1C -3.69 0.0000 carnitine palmitoyltransferase 1C 
CPT2 -1.07 0.0000 carnitine palmitoyltransferase 2 
CPVL 4.57 0.0000 carboxypeptidase, vitellogenic-like 
CRABP2 2.62 0.0000 cellular retinoic acid binding protein 2 
CRADD -1.62 0.0000 CASP2 and RIPK1 domain containing adaptor with death domain 
CRBN -1.77 0.0000 cereblon 
CREB3L2 -1.29 0.0000 cAMP responsive element binding protein 3-like 2 
CREB3L4 1.60 0.0000 cAMP responsive element binding protein 3-like 4 
CREBL2 -2.23 0.0000 cAMP responsive element binding protein-like 2 
CREBZF 2.16 0.0000 CREB/ATF bZIP transcription factor 
CRELD1 -1.49 0.0000 cysteine-rich with EGF-like domains 1 
CREM -1.29 0.0000 cAMP responsive element modulator 
CRHBP -1.78 0.0000 corticotropin releasing hormone binding protein 
CRIM1 2.33 0.0000 cysteine rich transmembrane BMP regulator 1 (chordin-like) 
CRIP1 -1.75 0.0000 cysteine-rich protein 1 (intestinal) 
CRLF1 -4.05 0.0000 cytokine receptor-like factor 1 
CRLS1 1.19 0.0000 cardiolipin synthase 1 
CRMP1 3.09 0.0000 collapsin response mediator protein 1 
CRNDE 3.53 0.0000 hCG1815491 
CRNKL1 1.07 0.0000 crooked neck pre-mRNA splicing factor-like 1 (Drosophila) 
CRY1 1.42 0.0000 cryptochrome 1 (photolyase-like) 
CRYAB -5.56 0.0000 crystallin, alpha B 
CRYGS -3.56 0.0000 crystallin, gamma S 
CSDA 1.60 0.0000 cold shock domain protein A; cold shock domain protein A pseudogene 1 
CSDE1 -1.00 0.0000 cold shock domain containing E1, RNA-binding 
CSGALNACT2 -1.75 0.0000 chondroitin sulfate N-acetylgalactosaminyltransferase 2; novel protein similar 
to chondroitin sulfate GalNAcT-2 (GALNACT-2) 
CSH1 -0.89 0.0000 chorionic somatomammotropin hormone 1 (placental lactogen) 
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CSNK1E -1.53 0.0000 casein kinase 1, epsilon 
CSNK2A2 1.08 0.0000 casein kinase 2, alpha prime polypeptide 
CSRNP1 -0.80 0.0000 cysteine-serine-rich nuclear protein 1 
CSRP1 -2.39 0.0000 cysteine and glycine-rich protein 1 
CSRP2 -3.11 0.0000 cysteine and glycine-rich protein 2 
CSTB -1.16 0.0000 cystatin B (stefin B) 
CSTF1 0.99 0.0000 cleavage stimulation factor, 3' pre-RNA, subunit 1, 50kDa 
CSTF2T -2.12 0.0000 cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa, tau variant 
CTDSPL2 1.33 0.0000 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small 
phosphatase like 2 
CTGF 3.10 0.0000 connective tissue growth factor 
CTNNA1 -1.94 0.0000 catenin (cadherin-associated protein), alpha 1, 102kDa 
CTNNAL1 -1.38 0.0000 catenin (cadherin-associated protein), alpha-like 1 
CTNND1 -1.56 0.0000 catenin (cadherin-associated protein), delta 1 
CTNND2 3.16 0.0000 catenin (cadherin-associated protein), delta 2 (neural plakophilin-related 
arm-repeat protein) 
CTNS -1.62 0.0000 cystinosis, nephropathic 
CTPS2 -0.99 0.0000 CTP synthase II 
CTSA -1.19 0.0000 cathepsin A 
CTSB -1.83 0.0000 cathepsin B 
CTSC -2.40 0.0000 cathepsin C 
CTSD -2.70 0.0000 cathepsin D 
CTSH 1.68 0.0000 cathepsin H 
CTSL2 2.03 0.0000 cathepsin L2 
CTSO -2.54 0.0000 cathepsin O 
CTSZ -3.74 0.0000 cathepsin Z 
CTTNBP2NL -0.90 0.0000 CTTNBP2 N-terminal like 
CUTA -1.25 0.0000 cutA divalent cation tolerance homolog (E. coli) 
CXorf23 -1.83 0.0000 chromosome X open reading frame 23 
CXorf26 -1.60 0.0000 chromosome X open reading frame 26 
CXorf38 -1.13 0.0000 chromosome X open reading frame 38 
CYB561D2 -1.49 0.0000 cytochrome b-561 domain containing 2 
CYB5R3 -1.34 0.0000 cytochrome b5 reductase 3 
CYBRD1 -1.17 0.0000 cytochrome b reductase 1 
CYLD -1.83 0.0000 cylindromatosis (turban tumor syndrome) 
CYP24A1 3.22 0.0000 cytochrome P450, family 24, subfamily A, polypeptide 1 
CYP27B1 2.39 0.0000 cytochrome P450, family 27, subfamily B, polypeptide 1 
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CYP4V2 -3.21 0.0000 cytochrome P450, family 4, subfamily V, polypeptide 2 
CYTSB -2.14 0.0000 cytospin B 
D4S234E 2.37 0.0000 DNA segment on chromosome 4 (unique) 234 expressed sequence 
DAAM2 -2.13 0.0000 dishevelled associated activator of morphogenesis 2 
DACH1 3.93 0.0000 dachshund homolog 1 (Drosophila) 
DAD1 -0.96 0.0000 defender against cell death 1 
DAG1 -2.92 0.0000 dystroglycan 1 (dystrophin-associated glycoprotein 1) 
DAPK1 3.12 0.0000 death-associated protein kinase 1 
DBI -1.52 0.0000 diazepam binding inhibitor (GABA receptor modulator, acyl-Coenzyme A 
binding protein) 
DBNDD1 -2.15 0.0000 dysbindin (dystrobrevin binding protein 1) domain containing 1 
DBT -1.24 0.0000 dihydrolipoamide branched chain transacylase E2 
DCAF13 1.34 0.0000 WD repeats and SOF1 domain containing 
DCPS -1.22 0.0000 decapping enzyme, scavenger 
DCTN6 -1.96 0.0000 dynactin 6 
DCTPP1 2.12 0.0000 dCTP pyrophosphatase 1 
DCUN1D1 0.67 0.0000 DCN1, defective in cullin neddylation 1, domain containing 1 (S. cerevisiae) 
DDAH1 2.17 0.0000 dimethylarginine dimethylaminohydrolase 1 
DDB2 1.40 0.0000 damage-specific DNA binding protein 2, 48kDa 
DDR1 -2.96 0.0000 discoidin domain receptor tyrosine kinase 1 
DDX10 1.07 0.0000 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 
DDX17 -1.11 0.0000 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
DDX23 0.93 0.0000 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 
DDX27 1.30 0.0000 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 
DDX46 1.24 0.0000 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 
DEFB109P1 -3.42 0.0000 defensin, beta 109, pseudogene 1; defensin, beta 109, pseudogene 1B 
DEGS1 -1.65 0.0000 degenerative spermatocyte homolog 1, lipid desaturase (Drosophila) 
DENND1A 1.01 0.0000 DENN/MADD domain containing 1A 
DENND2A 3.05 0.0000 DENN/MADD domain containing 2A 
DENND2D 2.22 0.0000 DENN/MADD domain containing 2D 
DENND3 2.29 0.0000 DENN/MADD domain containing 3 
DENND5A -1.72 0.0000 DENN/MADD domain containing 5A 
DEPDC4 1.33 0.0000 DEP domain containing 4 
DERA -1.49 0.0000 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) 
DEXI 1.32 0.0000 dexamethasone-induced transcript 
DFFA 0.96 0.0000 DNA fragmentation factor, 45kDa, alpha polypeptide 
DGAT2 2.09 0.0000 diacylglycerol O-acyltransferase homolog 2 (mouse) 
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DGCR2 -1.20 0.0000 DiGeorge syndrome critical region gene 2 
DGKD 1.51 0.0000 diacylglycerol kinase, delta 130kDa 
DGUOK -0.78 0.0000 deoxyguanosine kinase 
DHODH 1.35 0.0000 dihydroorotate dehydrogenase 
DHRS1 -1.74 0.0000 dehydrogenase/reductase (SDR family) member 1 
DHRS7 -1.27 0.0000 dehydrogenase/reductase (SDR family) member 7 
DHRS7B -0.95 0.0000 dehydrogenase/reductase (SDR family) member 7B 
DHX35 1.33 0.0000 DEAH (Asp-Glu-Ala-His) box polypeptide 35 
DHX58 -2.79 0.0000 DEXH (Asp-Glu-X-His) box polypeptide 58 
DIABLO 0.80 0.0000 diablo homolog (Drosophila) 
DIDO1 1.97 0.0000 death inducer-obliterator 1 
DIP2B -1.91 0.0000 DIP2 disco-interacting protein 2 homolog B (Drosophila) 
DIP2C -2.75 0.0000 DIP2 disco-interacting protein 2 homolog C (Drosophila) 
DIS3 -1.18 0.0000 DIS3 mitotic control homolog (S. cerevisiae) 
DKC1 1.84 0.0000 dyskeratosis congenita 1, dyskerin 
DKK1 5.15 0.0000 dickkopf homolog 1 (Xenopus laevis) 
DKK2 2.93 0.0000 dickkopf homolog 2 (Xenopus laevis) 
DKK3 -3.36 0.0000 dickkopf homolog 3 (Xenopus laevis) 
DLGAP4 -1.54 0.0000 discs, large (Drosophila) homolog-associated protein 4 
DLL1 2.95 0.0000 delta-like 1 (Drosophila) 
DLL3 2.93 0.0000 delta-like 3 (Drosophila) 
DLX1 1.47 0.0000 distal-less homeobox 1 
DLX4 3.16 0.0000 distal-less homeobox 4 
DMKN 2.71 0.0000 dermokine 
DMXL1 -1.86 0.0000 Dmx-like 1 
DNAH14 0.87 0.0000 dynein, axonemal, heavy chain 14 
DNAJA3 1.62 0.0000 DnaJ (Hsp40) homolog, subfamily A, member 3 
DNAJB11 -0.67 0.0000 DnaJ (Hsp40) homolog, subfamily B, member 11 
DNAJB12 -1.23 0.0000 DnaJ (Hsp40) homolog, subfamily B, member 12 
DNAJC1 -1.80 0.0000 DnaJ (Hsp40) homolog, subfamily C, member 1 
DNAJC2 1.43 0.0000 DnaJ (Hsp40) homolog, subfamily C, member 2 
DNAJC21 0.92 0.0000 DnaJ (Hsp40) homolog, subfamily C, member 21 
DNAJC22 1.98 0.0000 DnaJ (Hsp40) homolog, subfamily C, member 22 
DNAJC3 -1.64 0.0000 DnaJ (Hsp40) homolog, subfamily C, member 3 
DNAJC6 -1.92 0.0000 DnaJ (Hsp40) homolog, subfamily C, member 6 
DNALI1 -4.36 0.0000 dynein, axonemal, light intermediate chain 1 
DOCK1 -1.36 0.0000 dedicator of cytokinesis 1 
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DOCK10 1.53 0.0000 dedicator of cytokinesis 10 
DOCK3 1.56 0.0000 dedicator of cytokinesis 3 
DOCK4 1.55 0.0000 dedicator of cytokinesis 4 
DOCK7 -1.07 0.0000 dedicator of cytokinesis 7 
DOCK8 2.07 0.0000 dedicator of cytokinesis 8 
DOK1 -1.15 0.0000 docking protein 1-like protein; docking protein 1, 62kDa (downstream of 
tyrosine kinase 1) 
DPF2 0.88 0.0000 D4, zinc and double PHD fingers family 2 
DPF3 2.15 0.0000 D4, zinc and double PHD fingers, family 3 
DPP8 -1.15 0.0000 dipeptidyl-peptidase 8 
DPYSL2 1.42 0.0000 dihydropyrimidinase-like 2 
DPYSL4 3.01 0.0000 dihydropyrimidinase-like 4 
DRAM2 -1.32 0.0000 DNA-damage regulated autophagy modulator 2 
DSN1 1.64 0.0000 DSN1, MIND kinetochore complex component, homolog (S. cerevisiae) 
DST -1.61 0.0000 dystonin 
DSTN 1.11 0.0000 destrin (actin depolymerizing factor) 
DTWD2 -1.53 0.0000 similar to DTW domain containing 2; DTW domain containing 2 
DUS4L 1.84 0.0000 dihydrouridine synthase 4-like (S. cerevisiae) 
DUSP1 2.55 0.0000 dual specificity phosphatase 1 
DUSP10 -2.05 0.0000 dual specificity phosphatase 10 
DUSP12 -1.21 0.0000 dual specificity phosphatase 12 
DUSP5P 0.96 0.0000 dual specificity phosphatase 5 pseudogene 
DUSP8 -1.74 0.0000 dual specificity phosphatase 8 
DUXAP10 3.18 0.0000 double homeobox A pseudogene 10 
DYNC1I1 -1.80 0.0000 dynein, cytoplasmic 1, intermediate chain 1 
DYNC1I2 -0.85 0.0000 similar to dynein cytoplasmic 1 intermediate chain 2; dynein, cytoplasmic 1, 
intermediate chain 2 
DYNC1LI2 -2.13 0.0000 dynein, cytoplasmic 1, light intermediate chain 2 
E2F2 1.59 0.0000 E2F transcription factor 2 
E2F6 1.15 0.0000 E2F transcription factor 6 
E2F8 2.34 0.0000 E2F transcription factor 8 
EBF4 1.50 0.0000 early B-cell factor 4 
ECHDC1 -1.83 0.0000 enoyl Coenzyme A hydratase domain containing 1 
ECHDC2 -4.02 0.0000 enoyl Coenzyme A hydratase domain containing 2 
ECM1 -2.22 0.0000 extracellular matrix protein 1 
EDEM1 -0.92 0.0000 ER degradation enhancer, mannosidase alpha-like 1 
EDNRB -7.37 0.0000 endothelin receptor type B 
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EEA1 -1.24 0.0000 early endosome antigen 1 
EEF1A2 3.47 0.0000 eukaryotic translation elongation factor 1 alpha 2 
EFEMP1 6.53 0.0000 EGF-containing fibulin-like extracellular matrix protein 1 
EFHA1 -3.82 0.0000 EF-hand domain family, member A1 
EFHD1 2.64 0.0000 EF-hand domain family, member D1 
EFNA4 1.49 0.0000 ephrin-A4 
EFNB2 2.03 0.0000 ephrin-B2 
EGFL8 -3.50 0.0000 EGF-like-domain, multiple 8 
EGLN3 3.28 0.0000 egl nine homolog 3 (C. elegans) 
EGR3 -2.74 0.0000 early growth response 3 
EHBP1 -3.61 0.0000 EH domain binding protein 1 
EID2 1.22 0.0000 EP300 interacting inhibitor of differentiation 2 
EID2B 1.09 0.0000 EP300 interacting inhibitor of differentiation 2B 
EIF1 -1.27 0.0000 similar to eukaryotic translation initiation factor 1; eukaryotic translation 
initiation factor 1 
EIF1AD 0.96 0.0000 eukaryotic translation initiation factor 1A domain containing 
EIF2AK3 -1.67 0.0000 eukaryotic translation initiation factor 2-alpha kinase 3 
EIF3C 1.24 0.0000 eukaryotic translation initiation factor 3, subunit C 
EIF3F -1.25 0.0000 eukaryotic translation initiation factor 3, subunit F; similar to hCG2040283 
EIF4B 0.66 0.0000 similar to eukaryotic translation initiation factor 4H; eukaryotic translation 
initiation factor 4B 
EIF4EBP1 1.33 0.0000 eukaryotic translation initiation factor 4E binding protein 1 
ELF1 -2.09 0.0000 E74-like factor 1 (ets domain transcription factor) 
ELFN2 3.40 0.0000 extracellular leucine-rich repeat and fibronectin type III domain containing 2 
ELK3 1.40 0.0000 ELK3, ETS-domain protein (SRF accessory protein 2) 
ELL2 2.06 0.0000 elongation factor, RNA polymerase II, 2 
ELMO2 0.78 0.0000 engulfment and cell motility 2 
ELMOD1 2.62 0.0000 ELMO/CED-12 domain containing 1 
ELMOD2 -1.27 0.0000 ELMO/CED-12 domain containing 2 
ELOVL7 2.85 0.0000 ELOVL family member 7, elongation of long chain fatty acids (yeast) 
EME1 1.85 0.0000 essential meiotic endonuclease 1 homolog 1 (S. pombe) 
EMG1 1.18 0.0000 EMG1 nucleolar protein homolog (S. cerevisiae) 
EMILIN3 1.10 0.0000 elastin microfibril interfacer 3 
EMP2 -2.50 0.0000 epithelial membrane protein 2 
ENG -0.85 0.0000 endoglin 
ENO1 1.57 0.0000 enolase 1, (alpha) 
ENOSF1 -3.42 0.0000 enolase superfamily member 1 
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ENOX2 -1.18 0.0000 ecto-NOX disulfide-thiol exchanger 2 
EPB41L1 1.89 0.0000 erythrocyte membrane protein band 4.1-like 1 
EPB41L2 -1.28 0.0000 erythrocyte membrane protein band 4.1-like 2 
EPB41L3 -2.11 0.0000 erythrocyte membrane protein band 4.1-like 3 
EPCAM 2.17 0.0000 epithelial cell adhesion molecule 
EPHB2 3.26 0.0000 EPH receptor B2 
EPHB4 1.27 0.0000 EPH receptor B4 
EPHX4 1.95 0.0000 epoxide hydrolase 4 
EPRS -0.87 0.0000 glutamyl-prolyl-tRNA synthetase 
ERBB2 -1.99 0.0000 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
ERBB3 -5.22 0.0000 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
ERC1 -3.07 0.0000 ELKS/RAB6-interacting/CAST family member 1 
ERCC5 -0.99 0.0000 excision repair cross-complementing rodent repair deficiency, 
complementation group 5 
EREG -2.92 0.0000 epiregulin 
ERLIN1 -0.83 0.0000 ER lipid raft associated 1 
ESD -1.28 0.0000 esterase D/formylglutathione hydrolase 
ESPNL 1.39 0.0000 espin-like 
ESYT2 -1.40 0.0000 family with sequence similarity 62 (C2 domain containing), member B 
ETS2 1.79 0.0000 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 
EVC -1.90 0.0000 Ellis van Creveld syndrome 
EVI2A -2.04 0.0000 ecotropic viral integration site 2A 
EVL 2.31 0.0000 Enah/Vasp-like 
EXOC1 -0.74 0.0000 exocyst complex component 1 
EXOSC10 -1.61 0.0000 exosome component 10 
EXOSC5 1.16 0.0000 exosome component 5 
EXT1 2.26 0.0000 exostoses (multiple) 1 
EXT2 -1.38 0.0000 exostoses (multiple) 2 
EYA2 1.51 0.0000 eyes absent homolog 2 (Drosophila) 
EZH2 1.83 0.0000 enhancer of zeste homolog 2 (Drosophila) 
F2R 3.02 0.0000 coagulation factor II (thrombin) receptor 
F2RL1 3.17 0.0000 coagulation factor II (thrombin) receptor-like 1 
F2RL2 4.61 0.0000 coagulation factor II (thrombin) receptor-like 2 
FABP7 -5.06 0.0000 fatty acid binding protein 7, brain 
FADS2 -2.65 0.0000 fatty acid desaturase 2 
FAF2 0.70 0.0000 Fas associated factor family member 2 
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FAM102A -3.67 0.0000 family with sequence similarity 102, member A 
FAM105B 0.84 0.0000 family with sequence similarity 105, member B 
FAM108A1 -1.43 0.0000 family with sequence similarity 108, member A4; family with sequence 
similarity 108, member A5; family with sequence similarity 108, member A1 
FAM109B -0.86 0.0000 family with sequence similarity 109, member B 
FAM116A -1.35 0.0000 family with sequence similarity 116, member A 
FAM117B 1.40 0.0000 family with sequence similarity 117, member B 
FAM119B 0.76 0.0000 family with sequence similarity 119, member B 
FAM127B -1.35 0.0000 family with sequence similarity 127, member B 
FAM134A -1.58 0.0000 family with sequence similarity 134, member A 
FAM155A 3.80 0.0000 family with sequence similarity 155, member A 
FAM161A 1.77 0.0000 family with sequence similarity 161, member A 
FAM169A 5.15 0.0000 family with sequence similarity 169, member A 
FAM175A -1.15 0.0000 family with sequence similarity 175, member A 
FAM176A 2.79 0.0000 family with sequence similarity 176, member A 
FAM177A1 -1.35 0.0000 family with sequence similarity 177, member A1 
FAM181B 1.40 0.0000 family with sequence similarity 181, member B 
FAM184A 2.03 0.0000 family with sequence similarity 184, member A 
FAM188A -1.58 0.0000 chromosome 10 open reading frame 97 
FAM189A2 -2.12 0.0000 chromosome 9 open reading frame 61 
FAM190B -1.46 0.0000 KIAA1128 
FAM19A5 -4.40 0.0000 family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 
FAM20C -2.47 0.0000 family with sequence similarity 20, member C 
FAM21A -1.41 0.0000 family with sequence similarity 21, member B; family with sequence similarity 
21, member A 
FAM21C -1.68 0.0000 family with sequence similarity 21, member D; family with sequence similarity 
21, member C 
FAM24B 1.92 0.0000 family with sequence similarity 24, member B 
FAM27E1 1.46 0.0000 hypothetical LOC100287333 
FAM3C -1.67 0.0000 family with sequence similarity 3, member C 
FAM41C -1.15 0.0000 family with sequence similarity 41, member C 
FAM46A -2.84 0.0000 family with sequence similarity 46, member A 
FAM47E -1.92 0.0000 family with sequence similarity 47, member E 
FAM50B -3.20 0.0000 family with sequence similarity 50, member B 
FAM59A -3.20 0.0000 hypothetical protein LOC100130616; family with sequence similarity 59, 
member A 
FAM60A 1.78 0.0000 similar to hCG2020539; family with sequence similarity 60, member A; similar 
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to family with sequence similarity 60, member A 
FAM63B -1.69 0.0000 family with sequence similarity 63, member B 
FAM69B 2.96 0.0000 family with sequence similarity 69, member B 
FAM82B -1.42 0.0000 family with sequence similarity 82, member B 
FAM83D 2.29 0.0000 family with sequence similarity 83, member D 
FAM84A 2.37 0.0000 hypothetical LOC653602; family with sequence similarity 84, member A 
FAM86A 1.52 0.0000 family with sequence similarity 86, member B2; family with sequence 
similarity 86, member A; family with sequence similarity 86, member B1 
FAM8A1 -0.72 0.0000 family with sequence similarity 8, member A1 
FAM96B -1.27 0.0000 family with sequence similarity 96, member B 
FANCG 1.91 0.0000 Fanconi anemia, complementation group G 
FANCL 1.40 0.0000 Fanconi anemia, complementation group L 
FAR2 4.76 0.0000 fatty acyl CoA reductase 2 
FARSB -1.66 0.0000 phenylalanyl-tRNA synthetase, beta subunit 
FAS 1.87 0.0000 Fas (TNF receptor superfamily, member 6) 
FASTKD2 0.92 0.0000 FAST kinase domains 2 
FASTKD3 1.80 0.0000 FAST kinase domains 3 
FASTKD5 0.62 0.0000 FAST kinase domains 5 
FBL 1.71 0.0000 fibrillarin 
FBLN2 -2.41 0.0000 fibulin 2 
FBN2 5.48 0.0000 fibrillin 2 
FBXL15 -1.40 0.0000 F-box and leucine-rich repeat protein 15 
FBXL16 5.56 0.0000 F-box and leucine-rich repeat protein 16 
FBXL17 -1.63 0.0000 F-box and leucine-rich repeat protein 17 
FBXL2 -1.22 0.0000 F-box and leucine-rich repeat protein 2 
FBXL20 -1.05 0.0000 F-box and leucine-rich repeat protein 20 
FBXL21 4.72 0.0000 F-box and leucine-rich repeat protein 21 
FBXL3 -1.36 0.0000 F-box and leucine-rich repeat protein 3 
FBXL4 -1.07 0.0000 F-box and leucine-rich repeat protein 4 
FBXO25 -3.10 0.0000 F-box protein 25 
FBXO30 -1.45 0.0000 F-box protein 30 
FBXO32 -2.85 0.0000 F-box protein 32 
FBXO33 -0.86 0.0000 F-box protein 33 
FBXO38 -3.51 0.0000 F-box protein 38 
FBXO7 -2.21 0.0000 F-box protein 7 
FBXO8 -1.51 0.0000 F-box protein 8 
FCGR2A -3.74 0.0000 Fc fragment of IgG, low affinity IIa, receptor (CD32) 
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FCGRT 3.54 0.0000 Fc fragment of IgG, receptor, transporter, alpha 
FCHSD2 2.40 0.0000 FCH and double SH3 domains 2 
FCRLA -5.77 0.0000 Fc receptor-like A 
FDXR 1.56 0.0000 ferredoxin reductase 
FERMT1 3.58 0.0000 fermitin family homolog 1 (Drosophila) 
FERMT2 -2.64 0.0000 fermitin family homolog 2 (Drosophila) 
FGD6 2.07 0.0000 FYVE, RhoGEF and PH domain containing 6 
FGF13 5.86 0.0000 fibroblast growth factor 13 
FGF2 2.46 0.0000 fibroblast growth factor 2 (basic) 
FGF5 -3.63 0.0000 fibroblast growth factor 5 
FGF9 1.18 0.0000 fibroblast growth factor 9 (glia-activating factor) 
FGFR1 2.46 0.0000 fibroblast growth factor receptor 1 
FGFRL1 2.06 0.0000 fibroblast growth factor receptor-like 1 
FHDC1 -4.79 0.0000 FH2 domain containing 1 
FICD -0.97 0.0000 FIC domain containing 
FIG4 -1.09 0.0000 FIG4 homolog (S. cerevisiae) 
FIGNL1 1.65 0.0000 fidgetin-like 1 
FJX1 2.26 0.0000 four jointed box 1 (Drosophila) 
FKBP1A -2.04 0.0000 FK506 binding protein 1A, 12kDa 
FKBP2 -1.61 0.0000 FK506 binding protein 2, 13kDa 
FKBP4 0.86 0.0000 FK506 binding protein 4, 59kDa 
FLAD1 1.02 0.0000 FAD1 flavin adenine dinucleotide synthetase homolog (S. cerevisiae) 
FLJ22536 -2.91 0.0000 hypothetical locus LOC401237 
FLJ30064 -2.42 0.0000 hypothetical protein LOC644975 
FLJ32255 -1.70 0.0000 hypothetical protein LOC643977 
FLJ35934 3.11 0.0000 FLJ35934 protein 
FLJ39632 3.54 0.0000 hypothetical LOC642477; hypothetical LOC400879 
FLJ40504 5.79 0.0000 hypothetical protein FLJ40504 
FLOT1 -1.44 0.0000 flotillin 1 
FMN1 -3.62 0.0000 formin 1 
FMR1 1.07 0.0000 fragile X mental retardation 1 
FN3KRP 0.97 0.0000 fructosamine 3 kinase related protein 
FNBP1 1.16 0.0000 formin binding protein 1 
FNIP2 -1.34 0.0000 folliculin interacting protein 2 
FNTA -1.11 0.0000 farnesyltransferase, CAAX box, alpha 
FNTB -2.63 0.0000 farnesyltransferase, CAAX box, beta 
FOS -2.59 0.0000 v-fos FBJ murine osteosarcoma viral oncogene homolog 
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FOSL2 -1.45 0.0000 FOS-like antigen 2 
FOXA1 4.68 0.0000 forkhead box A1 
FOXD3 -0.74 0.0000 forkhead box D3 
FOXD4 1.53 0.0000 forkhead box D4 
FOXF1 4.67 0.0000 forkhead box F1 
FOXG1 6.09 0.0000 forkhead box G1 
FOXK2 1.61 0.0000 forkhead box K2 
FOXL2 4.52 0.0000 forkhead box L2 
FOXN2 -1.58 0.0000 forkhead box N2 
FOXP1 2.41 0.0000 forkhead box P1 
FRG1 -0.82 0.0000 FSHD region gene 1 
FRMD5 -2.25 0.0000 FERM domain containing 5 
FRMD6 -1.49 0.0000 FERM domain containing 6 
FSTL1 3.40 0.0000 follistatin-like 1 
FTH1 -1.97 0.0000 ferritin, heavy polypeptide 1; ferritin, heavy polypeptide-like 16; similar to 
ferritin, heavy polypeptide 1; ferritin, heavy polypeptide-like 3 pseudogene 
FTHL17 -1.40 0.0000 ferritin, heavy polypeptide-like 17 
FTSJ3 0.91 0.0000 FtsJ homolog 3 (E. coli) 
FUCA2 -1.55 0.0000 fucosidase, alpha-L- 2, plasma 
FUK -1.50 0.0000 fucokinase 
FUNDC1 -1.10 0.0000 FUN14 domain containing 1 
FUT11 -1.40 0.0000 fucosyltransferase 11 (alpha (1,3) fucosyltransferase) 
FXN 1.39 0.0000 frataxin 
FXYD3 -3.74 0.0000 FXYD domain containing ion transport regulator 3 
FXYD6 2.63 0.0000 FXYD domain containing ion transport regulator 6 
FYCO1 -1.35 0.0000 FYVE and coiled-coil domain containing 1 
FYN -2.26 0.0000 FYN oncogene related to SRC, FGR, YES 
FZD2 2.18 0.0000 frizzled homolog 2 (Drosophila) 
FZD4 -1.88 0.0000 frizzled homolog 4 (Drosophila) 
FZD7 1.66 0.0000 frizzled homolog 7 (Drosophila) 
GAB1 -1.75 0.0000 GRB2-associated binding protein 1 
GABARAP -1.70 0.0000 GABA(A) receptor-associated protein 
GABARAPL2 -1.52 0.0000 GABA(A) receptor-associated protein-like 2 
GABPB2 -2.43 0.0000 GA binding protein transcription factor, beta subunit 2 
GABRA2 -3.22 0.0000 gamma-aminobutyric acid (GABA) A receptor, alpha 2 
GADD45A 2.50 0.0000 growth arrest and DNA-damage-inducible, alpha 
GAL3ST1 -3.89 0.0000 galactose-3-O-sulfotransferase 1 
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GALE 1.40 0.0000 UDP-galactose-4-epimerase 
GALK2 -1.64 0.0000 galactokinase 2 
GALNT10 1.32 0.0000 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 
GALNT14 5.02 0.0000 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 14 (GalNAc-T14) 
GALNTL1 3.31 0.0000 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase-like 1 
GAPVD1 -1.05 0.0000 GTPase activating protein and VPS9 domains 1 
GART 1.68 0.0000 phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide 
synthetase, phosphoribosylaminoimidazole synthetase 
GAS1 3.72 0.0000 growth arrest-specific 1 
GAS2L1 -1.21 0.0000 growth arrest-specific 2 like 1 
GAS2L3 -3.02 0.0000 growth arrest-specific 2 like 3 
GAS5 1.64 0.0000 growth arrest-specific 5 (non-protein coding) 
GAS8 -1.45 0.0000 growth arrest-specific 8 
GATA4 2.15 0.0000 GATA binding protein 4 
GATA6 4.28 0.0000 GATA binding protein 6 
GATM -3.56 0.0000 glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
GBA -1.98 0.0000 glucosidase, beta; acid (includes glucosylceramidase) 
GBE1 -1.74 0.0000 glucan (1,4-alpha-), branching enzyme 1 
GBP2 -2.05 0.0000 guanylate binding protein 2, interferon-inducible 
GCNT1 -2.34 0.0000 glucosaminyl (N-acetyl) transferase 1, core 2 
(beta-1,6-N-acetylglucosaminyltransferase) 
GDE1 -1.85 0.0000 glycerophosphodiester phosphodiesterase 1 
GFPT2 3.00 0.0000 glutamine-fructose-6-phosphate transaminase 2 
GFRA1 -3.74 0.0000 GDNF family receptor alpha 1 
GFRA3 -2.68 0.0000 GDNF family receptor alpha 3 
GFRA4 -1.45 0.0000 GDNF family receptor alpha 4 
GGH -1.53 0.0000 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
GGNBP2 -0.87 0.0000 gametogenetin binding protein 2 
GIYD1 1.26 0.0000 GIY-YIG domain containing 2; GIY-YIG domain containing 1 
GJA3 -2.29 0.0000 gap junction protein, alpha 3, 46kDa 
GJB1 -2.49 0.0000 gap junction protein, beta 1, 32kDa 
GJC3 -2.18 0.0000 gap junction protein, gamma 3, 30.2kDa 
GK -1.83 0.0000 glycerol kinase 3 pseudogene; glycerol kinase 
GKAP1 3.18 0.0000 G kinase anchoring protein 1 
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GLG1 -1.35 0.0000 golgi apparatus protein 1 
GLIPR1 -1.94 0.0000 GLI pathogenesis-related 1 
GLIS1 4.07 0.0000 GLIS family zinc finger 1 
GLRX 1.38 0.0000 glutaredoxin (thioltransferase) 
GLT8D1 -1.22 0.0000 glycosyltransferase 8 domain containing 1 
GLTP -2.24 0.0000 glycolipid transfer protein; glycolipid transfer protein pseudogene 1 
GLYATL1 1.78 0.0000 glycine-N-acyltransferase-like 1 
GM2A -1.34 0.0000 GM2 ganglioside activator 
GMFB -1.94 0.0000 glia maturation factor, beta 
GMPPB -1.26 0.0000 GDP-mannose pyrophosphorylase B 
GMPS 1.07 0.0000 guanine monphosphate synthetase 
GNAL 2.73 0.0000 guanine nucleotide binding protein (G protein), alpha activating activity 
polypeptide, olfactory type 
GNAS 1.11 0.0000 GNAS complex locus 
GNG2 -2.90 0.0000 guanine nucleotide binding protein (G protein), gamma 2 
GNG7 -2.52 0.0000 guanine nucleotide binding protein (G protein), gamma 7 
GNPTAB -1.70 0.0000 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 
GNPTG -2.07 0.0000 N-acetylglucosamine-1-phosphate transferase, gamma subunit 
GOLGA7 -1.11 0.0000 golgi autoantigen, golgin subfamily a, 7 
GOLGA8A 3.05 0.0000 golgi autoantigen, golgin subfamily a, 8B; golgi autoantigen, golgin subfamily 
a, 8A 
GOLGA8E 2.63 0.0000 golgi autoantigen, golgin subfamily a, 8E 
GOLGA8F 2.31 0.0000 golgi autoantigen, golgin subfamily a, 8D; golgi autoantigen, golgin subfamily 
a, 8C; similar to Golgin subfamily A member 8-like protein 1; golgi 
autoantigen, golgin subfamily a, 8F; golgi autoantigen, golgin subfamily a, 8G
GOSR2 1.06 0.0000 golgi SNAP receptor complex member 2 
GOT2 1.39 0.0000 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate 
aminotransferase 2) 
GP9 -1.22 0.0000 glycoprotein IX (platelet) 
GPAT2 3.61 0.0000 hypothetical protein LOC150763; similar to hCG1732629; similar to 
glycerol-3-phosphate acyltransferase, mitochondrial 
GPC1 -2.72 0.0000 glypican 1 
GPC4 4.52 0.0000 glypican 4 
GPER -4.15 0.0000 G protein-coupled estrogen receptor 1 
GPM6B -4.93 0.0000 glycoprotein M6B 
GPN3 1.39 0.0000 GPN-loop GTPase 3 
GPNMB -6.49 0.0000 glycoprotein (transmembrane) nmb 
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GPR126 -2.30 0.0000 G protein-coupled receptor 126 
GPR137B -3.58 0.0000 G protein-coupled receptor 137B 
GPR155 -2.91 0.0000 G protein-coupled receptor 155 
GPR158 -3.56 0.0000 G protein-coupled receptor 158 
GPR19 1.59 0.0000 G protein-coupled receptor 19 
GPRC5A 2.42 0.0000 G protein-coupled receptor, family C, group 5, member A 
GPRC5B 1.58 0.0000 G protein-coupled receptor, family C, group 5, member B 
GPRC5C 2.18 0.0000 G protein-coupled receptor, family C, group 5, member C 
GPSM2 -1.57 0.0000 G-protein signaling modulator 2 (AGS3-like, C. elegans) 
GPX1 -0.98 0.0000 glutathione peroxidase 1 
GRAMD3 -1.62 0.0000 GRAM domain containing 3 
GRASP -2.40 0.0000 GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein
GSC 2.78 0.0000 goosecoid homeobox 
GSN -2.85 0.0000 gelsolin (amyloidosis, Finnish type) 
GSTM4 -1.02 0.0000 glutathione S-transferase mu 4 
GSTO1 -1.02 0.0000 glutathione S-transferase omega 1 
GSTT2 -5.59 0.0000 glutathione S-transferase theta 2B (gene/pseudogene); glutathione 
S-transferase theta 2 
GTDC1 -1.78 0.0000 glycosyltransferase-like domain containing 1 
GTF2B -0.76 0.0000 general transcription factor IIB 
GTF2F2 -0.99 0.0000 general transcription factor IIF, polypeptide 2, 30kDa 
GTPBP10 1.23 0.0000 GTP-binding protein 10 (putative) 
GTPBP2 -0.83 0.0000 GTP binding protein 2 
GTPBP3 1.25 0.0000 GTP binding protein 3 (mitochondrial) 
GTPBP4 0.97 0.0000 GTP binding protein 4 
GTPBP6 -1.03 0.0000 GTP binding protein 6 (putative) 
GUSB -1.19 0.0000 glucuronidase, beta 
GYLTL1B 1.67 0.0000 glycosyltransferase-like 1B 
H2AFJ -1.69 0.0000 H2A histone family, member J 
H2AFY 1.63 0.0000 H2A histone family, member Y 
H2AFY2 3.73 0.0000 H2A histone family, member Y2 
H3F3A -1.14 0.0000 H3 histone, family 3B (H3.3B); H3 histone, family 3A pseudogene; H3 
histone, family 3A; similar to H3 histone, family 3B; similar to histone H3.3B 
HACL1 -1.78 0.0000 2-hydroxyacyl-CoA lyase 1 
HADHB -0.97 0.0000 hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), beta subunit 
HARBI1 -0.59 0.0000 harbinger transposase derived 1 
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HAUS5 1.58 0.0000 HAUS augmin-like complex, subunit 5 
HAUS6 1.49 0.0000 HAUS augmin-like complex, subunit 6 
HAUS7 2.36 0.0000 three prime repair exonuclease 2; HAUS augmin-like complex, subunit 7 
HBEGF -1.29 0.0000 heparin-binding EGF-like growth factor 
HBS1L -1.30 0.0000 HBS1-like (S. cerevisiae) 
HBXIP -1.31 0.0000 hepatitis B virus x interacting protein 
HCP5 -2.42 0.0000 HLA complex P5 
HDGFRP3 1.46 0.0000 hepatoma-derived growth factor, related protein 3 
HDHD2 -1.29 0.0000 haloacid dehalogenase-like hydrolase domain containing 2 
HECTD1 -0.99 0.0000 HECT domain containing 1 
HELQ -1.23 0.0000 helicase, POLQ-like 
HEPH -3.35 0.0000 hephaestin 
HERC5 3.25 0.0000 hect domain and RLD 5 
HEXB -2.04 0.0000 hexosaminidase B (beta polypeptide) 
HFE -1.22 0.0000 hemochromatosis 
HIC1 1.34 0.0000 hypermethylated in cancer 1 
HIF1A 1.29 0.0000 hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription 
factor) 
HIP1R 1.63 0.0000 huntingtin interacting protein 1 related 
HIPK2 1.79 0.0000 homeodomain interacting protein kinase 2; similar to homeodomain 
interacting protein kinase 2 
HK1 -1.10 0.0000 hexokinase 1 
HKDC1 -3.75 0.0000 hexokinase domain containing 1 
HLA-A -2.75 0.0000 major histocompatibility complex, class I, A 
HLA-B -2.50 0.0000 major histocompatibility complex, class I, C; major histocompatibility complex, 
class I, B 
HLA-C -4.21 0.0000 major histocompatibility complex, class I, C; major histocompatibility complex, 
class I, B 
HLA-DMA -5.07 0.0000 major histocompatibility complex, class II, DM alpha 
HLA-DMB -4.75 0.0000 major histocompatibility complex, class II, DM beta 
HLA-DOA -3.93 0.0000 major histocompatibility complex, class II, DO alpha 
HLA-DPA1 -4.20 0.0000 major histocompatibility complex, class II, DP alpha 1 
HLA-DPB1 -2.52 0.0000 major histocompatibility complex, class II, DP beta 1 
HLA-DPB2 -2.77 0.0000 major histocompatibility complex, class II, DP beta 2 (pseudogene) 
HLA-DRA -4.97 0.0000 major histocompatibility complex, class II, DR alpha 
HLA-DRB1 -3.30 0.0000 major histocompatibility complex, class II, DR beta 4; major histocompatibility 
complex, class II, DR beta 1 
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HLA-DRB3 -3.83 0.0000 major histocompatibility complex, class II, DR beta 3 
HLA-DRB4 -3.96 0.0000 major histocompatibility complex, class II, DR beta 4; major histocompatibility 
complex, class II, DR beta 1 
HLA-DRB5 -3.64 0.0000 major histocompatibility complex, class II, DR beta 5 
HLA-E -2.61 0.0000 major histocompatibility complex, class I, E 
HLA-F -2.54 0.0000 major histocompatibility complex, class I, F 
HLA-G -2.85 0.0000 major histocompatibility complex, class I, G 
HLA-H -3.02 0.0000 major histocompatibility complex, class I, H (pseudogene) 
HLA-J -2.57 0.0000 major histocompatibility complex, class I, J (pseudogene) 
HLTF 1.52 0.0000 helicase-like transcription factor 
HMBOX1 -1.76 0.0000 homeobox containing 1 
HMG20B -2.35 0.0000 high-mobility group 20B 
HMGB2 1.33 0.0000 high-mobility group box 2 
HMGN2 0.93 0.0000 hypothetical LOC729505; similar to hCG2040565; high-mobility group 
nucleosomal binding domain 2; similar to high-mobility group nucleosomal 
binding domain 2 
HN1 2.08 0.0000 hematological and neurological expressed 1 
HN1L 1.13 0.0000 hematological and neurological expressed 1-like 
HNRNPA1L2 0.77 0.0000 heterogeneous nuclear ribonucleoprotein A1-like 2 
HNRNPA3 1.56 0.0000 heterogeneous nuclear ribonucleoprotein A3 
HNRNPH1 1.41 0.0000 heterogeneous nuclear ribonucleoprotein H1 (H) 
HNRNPH2 -1.22 0.0000 ribosomal protein L36a pseudogene 51; ribosomal protein L36a pseudogene 
37; ribosomal protein L36a pseudogene 49; heterogeneous nuclear 
ribonucleoprotein H2 (H'); ribosomal protein L36a 
HNRNPUL2 -1.98 0.0000 heterogeneous nuclear ribonucleoprotein U-like 2 
HOOK3 -2.09 0.0000 hook homolog 3 (Drosophila) 
HOPX 4.46 0.0000 HOP homeobox 
HOXA13 3.44 0.0000 homeobox A13 
HOXA3 2.09 0.0000 homeobox A3 
HOXA5 1.57 0.0000 homeobox A5 
HOXA9 2.17 0.0000 homeobox A9 
HOXB13 3.90 0.0000 homeobox B13 
HOXB9 2.85 0.0000 homeobox B9 
HOXC13 3.43 0.0000 homeobox C13 
HOXD3 1.93 0.0000 homeobox D3 
HPCAL1 -1.87 0.0000 hippocalcin-like 1 
HPS1 -2.51 0.0000 Hermansky-Pudlak syndrome 1 
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HPS5 -1.01 0.0000 Hermansky-Pudlak syndrome 5 
HR -1.03 0.0000 hairless homolog (mouse) 
HRASLS 3.06 0.0000 HRAS-like suppressor 
HRASLS2 -1.78 0.0000 HRAS-like suppressor 2 
HRH1 2.20 0.0000 histamine receptor H1 
HS1BP3 -1.69 0.0000 HCLS1 binding protein 3 
HS3ST3A1 3.05 0.0000 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 
HS6ST2 5.95 0.0000 heparan sulfate 6-O-sulfotransferase 2 
HSBP1 -1.76 0.0000 heat shock factor binding protein 1 
HSD17B10 -0.84 0.0000 hydroxysteroid (17-beta) dehydrogenase 10 
HSD17B11 -1.50 0.0000 hydroxysteroid (17-beta) dehydrogenase 11 
HSD17B12 -1.68 0.0000 hydroxysteroid (17-beta) dehydrogenase 12 
HSPA12A -2.95 0.0000 heat shock 70kDa protein 12A 
HSPA1L 1.44 0.0000 heat shock 70kDa protein 1-like 
HSPA4L 1.69 0.0000 heat shock 70kDa protein 4-like 
HSPA5 -1.57 0.0000 hypothetical gene supported by AF216292; NM_005347; heat shock 70kDa 
protein 5 (glucose-regulated protein, 78kDa) 
HSPA6 -2.18 0.0000 heat shock 70kDa protein 7 (HSP70B); heat shock 70kDa protein 6 
(HSP70B') 
HSPA9 0.73 0.0000 heat shock 70kDa protein 9 (mortalin) 
HSPBAP1 0.77 0.0000 HSPB (heat shock 27kDa) associated protein 1 
HSPC157 1.73 0.0000 hypothetical LOC29092 
HSPC159 2.92 0.0000 galectin-related protein 
HSPD1 1.56 0.0000 heat shock 60kDa protein 1 (chaperonin) pseudogene 5; heat shock 60kDa 
protein 1 (chaperonin) pseudogene 6; heat shock 60kDa protein 1 
(chaperonin) pseudogene 1; heat shock 60kDa protein 1 (chaperonin) 
pseudogene 4; heat shock 60kDa protein 1 (chaperonin) 
HSPG2 -1.30 0.0000 heparan sulfate proteoglycan 2 
HTATIP2 -2.29 0.0000 HIV-1 Tat interactive protein 2, 30kDa 
HTR7 3.24 0.0000 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled) 
HTRA3 2.84 0.0000 HtrA serine peptidase 3 
HUWE1 -1.97 0.0000 HECT, UBA and WWE domain containing 1 
HYAL1 -3.11 0.0000 hyaluronoglucosaminidase 1 
IBTK -1.24 0.0000 inhibitor of Bruton agammaglobulinemia tyrosine kinase 
ICAM1 -2.22 0.0000 intercellular adhesion molecule 1 
IER5 1.63 0.0000 immediate early response 5 
IFI27L2 -1.78 0.0000 interferon, alpha-inducible protein 27-like 2 
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IFI30 -1.68 0.0000 interferon, gamma-inducible protein 30 
IFI6 -1.33 0.0000 interferon, alpha-inducible protein 6 
IFIT2 -1.96 0.0000 interferon-induced protein with tetratricopeptide repeats 2 
IFIT3 -3.04 0.0000 interferon-induced protein with tetratricopeptide repeats 3 
IFITM3 -1.37 0.0000 interferon induced transmembrane protein 3 (1-8U) 
IFNE 2.18 0.0000 interferon, epsilon 
IFRD1 1.49 0.0000 interferon-related developmental regulator 1 
IFT88 -1.55 0.0000 intraflagellar transport 88 homolog (Chlamydomonas) 
IGDCC4 4.12 0.0000 immunoglobulin superfamily, DCC subclass, member 4 
IGF2 3.10 0.0000 insulin-like growth factor 2 (somatomedin A); insulin; INS-IGF2 readthrough 
transcript 
IGF2BP1 5.22 0.0000 insulin-like growth factor 2 mRNA binding protein 1 
IGFBP3 4.14 0.0000 insulin-like growth factor binding protein 3 
IGFBP5 -3.53 0.0000 insulin-like growth factor binding protein 5 
IGFBPL1 4.59 0.0000 insulin-like growth factor binding protein-like 1 
IGHD -1.87 0.0000 immunoglobulin heavy constant delta 
IGSF11 -3.13 0.0000 immunoglobulin superfamily, member 11 
IGSF9 2.61 0.0000 immunoglobulin superfamily, member 9 
IKBKB -1.28 0.0000 inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta 
IKZF4 -1.48 0.0000 IKAROS family zinc finger 4 (Eos) 
IL12A 1.47 0.0000 interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte 
maturation factor 1, p35) 
IL13RA1 -2.08 0.0000 interleukin 13 receptor, alpha 1 
IL17RD 2.42 0.0000 interleukin 17 receptor D 
IL1RAP -1.53 0.0000 interleukin 1 receptor accessory protein 
IL28RA 3.76 0.0000 interleukin 28 receptor, alpha (interferon, lambda receptor) 
IL6 -3.63 0.0000 interleukin 6 (interferon, beta 2) 
IL7 2.85 0.0000 interleukin 7 
ILK -1.67 0.0000 integrin-linked kinase 
IMP4 1.19 0.0000 IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) 
IMPAD1 -1.80 0.0000 inositol monophosphatase domain containing 1 
INPP4B -1.61 0.0000 inositol polyphosphate-4-phosphatase, type II, 105kDa 
INPP5F -3.31 0.0000 inositol polyphosphate-5-phosphatase F 
INPP5K -2.11 0.0000 inositol polyphosphate-5-phosphatase K 
INTS2 1.24 0.0000 integrator complex subunit 2 
IP6K2 1.47 0.0000 inositol hexakisphosphate kinase 2 
IQCA1 2.58 0.0000 IQ motif containing with AAA domain 1 
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IQCC 1.23 0.0000 IQ motif containing C 
IQSEC1 -1.18 0.0000 IQ motif and Sec7 domain 1 
IRAK1 1.65 0.0000 interleukin-1 receptor-associated kinase 1 
IRF9 -1.35 0.0000 interferon regulatory factor 9 
IRS1 2.66 0.0000 insulin receptor substrate 1 
IRS2 -1.73 0.0000 insulin receptor substrate 2 
IRX3 4.04 0.0000 iroquois homeobox 3 
IRX4 3.66 0.0000 iroquois homeobox 4 
IRX5 3.39 0.0000 iroquois homeobox 5 
ISG20 -2.09 0.0000 interferon stimulated exonuclease gene 20kDa 
ISOC1 1.46 0.0000 isochorismatase domain containing 1 
ITFG1 -1.62 0.0000 integrin alpha FG-GAP repeat containing 1 
ITGB1 -1.65 0.0000 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes 
MDF2, MSK12) 
ITGB2 1.91 0.0000 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 
ITGB3 -3.39 0.0000 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
ITGB3BP 1.32 0.0000 integrin beta 3 binding protein (beta3-endonexin) 
ITGB8 -5.83 0.0000 integrin, beta 8 
ITIH5 -4.30 0.0000 inter-alpha (globulin) inhibitor H5 
ITPK1 -3.05 0.0000 inositol 1,3,4-triphosphate 5/6 kinase 
ITPKB -1.91 0.0000 inositol 1,4,5-trisphosphate 3-kinase B 
ITPR1 -2.01 0.0000 inositol 1,4,5-triphosphate receptor, type 1 
ITPR3 -3.03 0.0000 inositol 1,4,5-triphosphate receptor, type 3 
JAGN1 -0.91 0.0000 jagunal homolog 1 (Drosophila) 
JAKMIP2 -1.15 0.0000 Janus kinase and microtubule interacting protein 2 
JAM2 3.39 0.0000 junctional adhesion molecule 2 
JARID2 -2.12 0.0000 jumonji, AT rich interactive domain 2 
JMJD7 -1.02 0.0000 JMJD7-PLA2G4B readthrough transcript; phospholipase A2, group IVB 
(cytosolic); jumonji domain containing 7 
JMJD8 -1.62 0.0000 jumonji domain containing 8 
JUN -1.66 0.0000 jun oncogene 
JUNB -1.93 0.0000 jun B proto-oncogene 
KALRN 2.73 0.0000 kalirin, RhoGEF kinase 
KAT2A 1.78 0.0000 K(lysine) acetyltransferase 2A 
KAT2B -4.03 0.0000 K(lysine) acetyltransferase 2B 
KATNAL1 -1.55 0.0000 katanin p60 subunit A-like 1 
KBTBD10 -1.63 0.0000 kelch repeat and BTB (POZ) domain containing 10 
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KBTBD11 3.09 0.0000 kelch repeat and BTB (POZ) domain containing 11 
KCNAB1 -2.99 0.0000 potassium voltage-gated channel, shaker-related subfamily, beta member 1 
KCNG1 2.14 0.0000 potassium voltage-gated channel, subfamily G, member 1 
KCNG3 2.42 0.0000 potassium voltage-gated channel, subfamily G, member 3 
KCNIP3 3.25 0.0000 Kv channel interacting protein 3, calsenilin 
KCNK1 4.40 0.0000 potassium channel, subfamily K, member 1 
KCNMA1 3.05 0.0000 potassium large conductance calcium-activated channel, subfamily M, alpha 
member 1 
KCNN2 3.08 0.0000 potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 2 
KCNN4 -3.91 0.0000 potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 4 
KCNQ2 5.20 0.0000 potassium voltage-gated channel, KQT-like subfamily, member 2 
KCNS3 -3.37 0.0000 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 
KCTD11 -0.69 0.0000 potassium channel tetramerisation domain containing 11 
KCTD12 -3.15 0.0000 potassium channel tetramerisation domain containing 12 
KCTD20 -2.30 0.0000 potassium channel tetramerisation domain containing 20 
KCTD3 -1.20 0.0000 potassium channel tetramerisation domain containing 3 
KDELR3 -1.36 0.0000 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 
KDM4D 2.01 0.0000 lysine (K)-specific demethylase 4D 
KDSR -1.62 0.0000 3-ketodihydrosphingosine reductase 
KHDRBS1 0.79 0.0000 KH domain containing, RNA binding, signal transduction associated 1 
KIAA0101 1.98 0.0000 KIAA0101 
KIAA0174 -0.78 0.0000 similar to CG10103; KIAA0174 
KIAA0232 -1.02 0.0000 KIAA0232 
KIAA0247 -1.11 0.0000 KIAA0247 
KIAA0391 -1.10 0.0000 KIAA0391 
KIAA0494 -1.21 0.0000 KIAA0494 
KIAA0513 -2.16 0.0000 KIAA0513 
KIAA0802 1.87 0.0000 KIAA0802 
KIAA1012 -1.29 0.0000 KIAA1012 
KIAA1033 -2.01 0.0000 KIAA1033 
KIAA1147 1.36 0.0000 KIAA1147 
KIAA1199 3.09 0.0000 KIAA1199 
KIAA1244 -1.15 0.0000 KIAA1244 
KIAA1274 3.02 0.0000 KIAA1274 
KIAA1279 -1.12 0.0000 KIAA1279 
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KIAA1430 -0.93 0.0000 KIAA1430 
KIAA1468 -0.97 0.0000 KIAA1468 
KIAA1539 -0.95 0.0000 KIAA1539 
KIAA1549 2.08 0.0000 KIAA1549 
KIAA1598 -3.53 0.0000 KIAA1598 
KIAA1731 1.07 0.0000 KIAA1731 
KIAA1804 2.76 0.0000 mixed lineage kinase 4 
KIAA1826 1.06 0.0000 KIAA1826 
KIAA1841 -1.22 0.0000 KIAA1841 
KIAA1919 -1.05 0.0000 KIAA1919 
KIF13A -2.11 0.0000 kinesin family member 13A 
KIF13B -4.42 0.0000 kinesin family member 13B 
KIF16B -1.76 0.0000 kinesin family member 16B 
KIF1B -1.05 0.0000 kinesin family member 1B 
KIF26A 2.84 0.0000 kinesin family member 26A 
KIF2A 1.18 0.0000 kinesin heavy chain member 2A 
KIF5B -1.47 0.0000 kinesin family member 5B 
KIF5C 4.32 0.0000 kinesin family member 5C 
KIFAP3 -1.59 0.0000 kinesin-associated protein 3 
KIT 4.20 0.0000 similar to Mast/stem cell growth factor receptor precursor (SCFR) 
(Proto-oncogene tyrosine-protein kinase Kit) (c-kit) (CD117 antigen); v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
KITLG 2.03 0.0000 KIT ligand 
KLC1 1.51 0.0000 kinesin light chain 1 
KLF13 -1.22 0.0000 Kruppel-like factor 13 
KLF5 1.77 0.0000 Kruppel-like factor 5 (intestinal) 
KLF6 -1.74 0.0000 Kruppel-like factor 6 
KLF9 -3.42 0.0000 Kruppel-like factor 9 
KLHL12 0.70 0.0000 kelch-like 12 (Drosophila) 
KLHL22 -0.90 0.0000 kelch-like 22 (Drosophila) 
KLHL23 4.04 0.0000 kelch-like 23 (Drosophila) 
KLHL35 2.12 0.0000 kelch-like 35 (Drosophila) 
KLHL5 1.77 0.0000 kelch-like 5 (Drosophila) 
KNTC1 1.38 0.0000 kinetochore associated 1 
KPNA5 -1.26 0.0000 karyopherin alpha 5 (importin alpha 6) 
KRAS -1.07 0.0000 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
KRCC1 -1.22 0.0000 lysine-rich coiled-coil 1 
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KRT10 -1.04 0.0000 keratin 10 
KRT18 5.60 0.0000 keratin 18; keratin 18 pseudogene 26; keratin 18 pseudogene 19 
KRT8 2.29 0.0000 keratin 8 pseudogene 9; similar to keratin 8; keratin 8 
KRT80 1.53 0.0000 keratin 80 
KRTAP6-3 -3.03 0.0000 keratin associated protein 6-3 
KYNU -1.85 0.0000 kynureninase (L-kynurenine hydrolase) 
LAGE3 1.13 0.0000 L antigen family, member 3 
LAMA1 4.20 0.0000 laminin, alpha 1 
LAMA2 -2.22 0.0000 laminin, alpha 2 
LAMA4 -2.55 0.0000 laminin, alpha 4 
LAMB2 -2.20 0.0000 laminin, beta 2 (laminin S) 
LAMC1 -2.20 0.0000 laminin, gamma 1 (formerly LAMB2) 
LAMC3 2.01 0.0000 laminin, gamma 3 
LAMP1 -2.00 0.0000 lysosomal-associated membrane protein 1 
LAMP2 -4.26 0.0000 lysosomal-associated membrane protein 2 
LAMP3 2.31 0.0000 lysosomal-associated membrane protein 3 
LANCL3 1.28 0.0000 LanC lantibiotic synthetase component C-like 3 (bacterial) 
LAPTM4B 1.05 0.0000 lysosomal protein transmembrane 4 beta 
LARGE -3.08 0.0000 like-glycosyltransferase 
LARP7 -1.23 0.0000 La ribonucleoprotein domain family, member 7 
LARS 0.87 0.0000 leucyl-tRNA synthetase 
LAT 2.47 0.0000 linker for activation of T cells 
LATS2 -1.41 0.0000 LATS, large tumor suppressor, homolog 2 (Drosophila) 
LCP1 -2.04 0.0000 lymphocyte cytosolic protein 1 (L-plastin) 
LDLRAP1 -1.65 0.0000 low density lipoprotein receptor adaptor protein 1 
LEF1 -2.50 0.0000 lymphoid enhancer-binding factor 1 
LEPREL1 3.95 0.0000 leprecan-like 1 
LEPROT -1.20 0.0000 leptin receptor overlapping transcript 
LGALS1 -2.54 0.0000 lectin, galactoside-binding, soluble, 1 
LGALS3 -4.61 0.0000 lectin, galactoside-binding, soluble, 3 
LGALS8 -0.95 0.0000 lectin, galactoside-binding, soluble, 8 
LHX2 5.37 0.0000 LIM homeobox 2 
LIFR 1.92 0.0000 leukemia inhibitory factor receptor alpha 
LIG4 -1.64 0.0000 ligase IV, DNA, ATP-dependent 
LIMK2 -1.69 0.0000 LIM domain kinase 2 
LIN52 1.25 0.0000 lin-52 homolog (C. elegans) 
LIPA -1.67 0.0000 lipase A, lysosomal acid, cholesterol esterase 
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LIPG 2.99 0.0000 lipase, endothelial 
LMAN1 -1.27 0.0000 lectin, mannose-binding, 1 
LMBRD1 -3.30 0.0000 LMBR1 domain containing 1 
LMO2 2.63 0.0000 LIM domain only 2 (rhombotin-like 1) 
LNX1 1.98 0.0000 ligand of numb-protein X 1 
LOC100126784 -2.40 0.0000 hypothetical LOC100126784 
LOC100127980 1.69 0.0000 hypothetical protein LOC100127980 
LOC100128164 2.83 0.0000 four and a half LIM domains 1 pseudogene 
LOC100129113 -1.56 0.0000 hypothetical protein LOC100129113 
LOC100130175 -1.00 0.0000 hypothetical protein LOC100130175 
LOC100130890 -1.23 0.0000 similar to hCG2030844 
LOC100132244 -2.19 0.0000 hypothetical protein LOC100132244 
LOC100190939 -1.41 0.0000 hypothetical LOC100190939 
LOC100271840 4.22 0.0000 hypothetical LOC100271840 
LOC100288144 2.08 0.0000 hypothetical protein LOC100288144 
LOC145783 -0.85 0.0000 hypothetical LOC145783 
LOC149501 2.22 0.0000 keratin 8 pseudogene 9; similar to keratin 8; keratin 8 
LOC151009 1.63 0.0000 hypothetical LOC151009 
LOC254057 2.14 0.0000 hypothetical protein LOC254057 
LOC257396 2.00 0.0000 hypothetical protein LOC257396 
LOC283658 2.32 0.0000 hypothetical protein LOC283658 
LOC284542 -2.10 0.0000 hypothetical protein LOC284542 
LOC375010 2.61 0.0000 ankyrin repeat domain 20 family, member A pseudogene 
LOC388152 0.81 0.0000 hypothetical LOC388152 
LOC388796 1.43 0.0000 hypothetical LOC388796 
LOC389634 -1.36 0.0000 hypothetical LOC389634 
LOC389641 0.89 0.0000 hypothetical gene supported by AK124295 
LOC390414 0.92 0.0000 hypothetical LOC390414 
LOC392288 -1.96 0.0000 similar to microtubule-associated proteins 1A/1B light chain 3 
LOC399959 2.96 0.0000 hypothetical LOC399959 
LOC400236 1.50 0.0000 hypothetical LOC400236 
LOC401022 2.24 0.0000 hypothetical LOC401022 
LOC407835 -1.24 0.0000 mitogen-activated protein kinase kinase 2 pseudogene; mitogen-activated 
protein kinase kinase 2 
LOC439949 3.31 0.0000 hypothetical protein LOC439949 
LOC440104 -1.51 0.0000 hypothetical LOC440104 
LOC442249 6.06 0.0000 similar to keratin 18 
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LOC442421 -0.91 0.0000 hypothetical LOC442421 
LOC550643 -1.01 0.0000 hypothetical LOC550643 
LOC554202 1.58 0.0000 hypothetical LOC554202 
LOC572558 2.60 0.0000 hypothetical locus LOC572558 
LOC644563 -0.86 0.0000 similar to general transcription factor IIIC, polypeptide 6, alpha 35kDa 
LOC645249 3.32 0.0000 hypothetical protein LOC645249 
LOC653071 -1.59 0.0000 similar to CG32820-PA, isoform A 
LOC654433 -3.32 0.0000 hypothetical LOC654433 
LOC728142 -1.81 0.0000 hypothetical LOC728142 
LOC728705 1.19 0.0000 hypothetical protein LOC728705 
LOC729082 -1.66 0.0000 hypothetical protein LOC729082 
LOC729683 2.19 0.0000 hypothetical protein LOC729683 
LOC730091 1.80 0.0000 hypothetical protein LOC730091 
LOC730144 -1.01 0.0000 similar to eukaryotic translation initiation factor 1; eukaryotic translation 
initiation factor 1 
LOC80154 2.26 0.0000 hypothetical LOC80154 
LOH12CR1 -2.05 0.0000 loss of heterozygosity, 12, chromosomal region 1 
LONRF2 3.63 0.0000 LON peptidase N-terminal domain and ring finger 2 
LOXL3 -3.39 0.0000 lysyl oxidase-like 3 
LPCAT4 1.12 0.0000 lysophosphatidylcholine acyltransferase 4 
LPGAT1 -1.72 0.0000 lysophosphatidylglycerol acyltransferase 1 
LPHN3 1.61 0.0000 latrophilin 3 
LPIN1 -1.43 0.0000 lipin 1 
LPL 3.31 0.0000 lipoprotein lipase 
LPP -1.87 0.0000 LIM domain containing preferred translocation partner in lipoma 
LRAT -4.14 0.0000 lecithin retinol acyltransferase (phosphatidylcholine--retinol 
O-acyltransferase) 
LRIG1 -1.83 0.0000 leucine-rich repeats and immunoglobulin-like domains 1 
LRP1 -1.16 0.0000 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 
LRP10 -2.49 0.0000 low density lipoprotein receptor-related protein 10 
LRP4 3.33 0.0000 low density lipoprotein receptor-related protein 4 
LRP5 2.08 0.0000 low density lipoprotein receptor-related protein 5 
LRP6 -1.06 0.0000 low density lipoprotein receptor-related protein 6 
LRP8 -1.38 0.0000 low density lipoprotein receptor-related protein 8, apolipoprotein e receptor 
LRPPRC 1.06 0.0000 leucine-rich PPR-motif containing 
LRRC1 1.93 0.0000 leucine rich repeat containing 1 
LRRC15 -4.36 0.0000 leucine rich repeat containing 15 
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LRRC17 4.59 0.0000 leucine rich repeat containing 17 
LRRC4 -1.71 0.0000 leucine rich repeat containing 4 
LRRC42 0.93 0.0000 leucine rich repeat containing 42 
LRRC47 1.21 0.0000 leucine rich repeat containing 47 
LRRC8D -0.75 0.0000 leucine rich repeat containing 8 family, member D 
LRRFIP1 2.78 0.0000 leucine rich repeat (in FLII) interacting protein 1 
LRRK1 -2.25 0.0000 leucine-rich repeat kinase 1 
LRRN3 2.90 0.0000 leucine rich repeat neuronal 3 
LSM14A 1.27 0.0000 LSM14A, SCD6 homolog A (S. cerevisiae) 
LSM14B 0.96 0.0000 LSM14B, SCD6 homolog B (S. cerevisiae) 
LSM5 0.91 0.0000 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
LTBR -1.66 0.0000 lymphotoxin beta receptor (TNFR superfamily, member 3) 
LUC7L 0.96 0.0000 LUC7-like (S. cerevisiae) 
LUC7L3 1.91 0.0000 cisplatin resistance-associated overexpressed protein 
LY6K 6.39 0.0000 lymphocyte antigen 6 complex, locus K 
LYN 1.34 0.0000 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
LYPD6 2.03 0.0000 LY6/PLAUR domain containing 6 
LYPD6B 3.50 0.0000 LY6/PLAUR domain containing 6B 
LYRM2 -1.56 0.0000 LYR motif containing 2 
LYRM5 -2.03 0.0000 LYR motif containing 5 
LYZ -2.85 0.0000 lysozyme (renal amyloidosis) 
LZTFL1 -1.03 0.0000 leucine zipper transcription factor-like 1 
MAD2L1BP -1.06 0.0000 MAD2L1 binding protein 
MAF -5.89 0.0000 v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) 
MAGEA1 2.09 0.0000 melanoma antigen family A, 1 (directs expression of antigen MZ2-E) 
MAGEA6 1.32 0.0000 melanoma antigen family A, 6 
MAGOHB 1.08 0.0000 mago-nashi homolog B (Drosophila) 
MAGT1 -1.96 0.0000 magnesium transporter 1 
MAL -3.77 0.0000 mal, T-cell differentiation protein 
MALT1 1.65 0.0000 mucosa associated lymphoid tissue lymphoma translocation gene 1 
MAN1A2 -1.08 0.0000 mannosidase, alpha, class 1A, member 2 
MAN2A2 -2.46 0.0000 mannosidase, alpha, class 2A, member 2 
MAN2B1 -1.62 0.0000 mannosidase, alpha, class 2B, member 1 
MANEA -2.17 0.0000 mannosidase, endo-alpha 
MANEAL 3.43 0.0000 mannosidase, endo-alpha-like 
MANF -1.05 0.0000 mesencephalic astrocyte-derived neurotrophic factor 
MAP1LC3B -2.14 0.0000 microtubule-associated protein 1 light chain 3 beta 
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MAP2K2 -1.06 0.0000 mitogen-activated protein kinase kinase 2 pseudogene; mitogen-activated 
protein kinase kinase 2 
MAP3K14 2.23 0.0000 mitogen-activated protein kinase kinase kinase 14 
MAP3K6 -1.69 0.0000 mitogen-activated protein kinase kinase kinase 6 
MAP3K9 1.74 0.0000 mitogen-activated protein kinase kinase kinase 9 
MAP4 -2.44 0.0000 microtubule-associated protein 4 
MAPK1 -1.50 0.0000 mitogen-activated protein kinase 1 
MAPK14 -1.07 0.0000 mitogen-activated protein kinase 14 
MAPKAPK2 -1.04 0.0000 mitogen-activated protein kinase-activated protein kinase 2 
MAPKAPK5 0.80 0.0000 mitogen-activated protein kinase-activated protein kinase 5 
MAPRE2 -1.82 0.0000 microtubule-associated protein, RP/EB family, member 2 
MAPRE3 -0.95 0.0000 microtubule-associated protein, RP/EB family, member 3 
MARCH2 -0.94 0.0000 membrane-associated ring finger (C3HC4) 2 
MAX -1.17 0.0000 MYC associated factor X 
MBD4 0.85 0.0000 methyl-CpG binding domain protein 4 
MBOAT1 -2.17 0.0000 membrane bound O-acyltransferase domain containing 1 
MBP -4.50 0.0000 myelin basic protein 
MC1R -2.89 0.0000 tubulin, beta 3; melanocortin 1 receptor (alpha melanocyte stimulating 
hormone receptor) 
MCAM -2.10 0.0000 melanoma cell adhesion molecule 
MCM2 1.03 0.0000 minichromosome maintenance complex component 2 
MCM6 1.32 0.0000 minichromosome maintenance complex component 6 
MCM9 -1.17 0.0000 minichromosome maintenance complex component 9 
MDC1 0.86 0.0000 mediator of DNA-damage checkpoint 1 
MDFI 0.93 0.0000 MyoD family inhibitor 
MDGA1 -2.26 0.0000 MAM domain containing glycosylphosphatidylinositol anchor 1 
MDK 3.33 0.0000 midkine (neurite growth-promoting factor 2) 
MDM4 -1.42 0.0000 Mdm4 p53 binding protein homolog (mouse) 
ME2 -3.21 0.0000 malic enzyme 2, NAD(+)-dependent, mitochondrial 
MED1 -0.65 0.0000 mediator complex subunit 1 
MED10 0.70 0.0000 mediator complex subunit 10 
MED11 -1.14 0.0000 mediator complex subunit 11 
MED14 -1.01 0.0000 mediator complex subunit 14 
MED28 1.16 0.0000 mediator complex subunit 28 
MEF2C -3.56 0.0000 myocyte enhancer factor 2C 
MEG3 -1.03 0.0000 maternally expressed 3 (non-protein coding) 
MEGF10 3.80 0.0000 multiple EGF-like-domains 10 
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MEGF6 2.20 0.0000 multiple EGF-like-domains 6 
MEIS2 4.49 0.0000 Meis homeobox 2 
MEST 6.80 0.0000 mesoderm specific transcript homolog (mouse) 
METTL2B 0.82 0.0000 methyltransferase like 2B 
MEX3A 2.83 0.0000 mex-3 homolog A (C. elegans) 
MFI2 -0.93 0.0000 antigen p97 (melanoma associated) identified by monoclonal antibodies 
133.2 and 96.5 
MFSD1 -1.60 0.0000 major facilitator superfamily domain containing 1 
MFSD10 -0.88 0.0000 major facilitator superfamily domain containing 10 
MFSD6 -2.45 0.0000 major facilitator superfamily domain containing 6 
MFSD8 -1.42 0.0000 major facilitator superfamily domain containing 8 
MGAT5B 4.42 0.0000 mannosyl (alpha-1,6-)-glycoprotein 
beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B 
MGC16025 -2.05 0.0000 hypothetical LOC85009 
MGC16275 -1.08 0.0000 hypothetical protein MGC16275 
MGC27345 1.53 0.0000 hypothetical protein MGC27345 
MGC42105 -3.86 0.0000 serine/threonine-protein kinase NIM1 
MIA -6.47 0.0000 melanoma inhibitory activity 
MICA -1.16 0.0000 MHC class I polypeptide-related sequence A 
MICAL3 -0.84 0.0000 microtubule associated monoxygenase, calponin and LIM domain containing 
3 
MICALL2 -1.76 0.0000 MICAL-like 2 
MICB 1.53 0.0000 MHC class I polypeptide-related sequence B 
MID1IP1 -0.91 0.0000 MID1 interacting protein 1 (gastrulation specific G12 homolog (zebrafish)) 
MIOS 1.13 0.0000 missing oocyte, meiosis regulator, homolog (Drosophila) 
MIR17HG 2.00 0.0000 microRNA host gene 1 (non-protein coding) 
MKNK2 -1.53 0.0000 MAP kinase interacting serine/threonine kinase 2 
MKRN1 -1.17 0.0000 makorin ring finger protein pseudogene 6; makorin ring finger protein 1 
MKS1 1.15 0.0000 Meckel syndrome, type 1 
MLF1 1.48 0.0000 myeloid leukemia factor 1 
MLL3 -1.14 0.0000 myeloid/lymphoid or mixed-lineage leukemia 3 
MLL4 1.46 0.0000 myeloid/lymphoid or mixed-lineage leukemia 4 
MLLT10 -1.07 0.0000 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); 
translocated to, 10 
MLPH 4.41 0.0000 melanophilin 
MLXIP -0.96 0.0000 MLX interacting protein 
MLYCD -1.14 0.0000 malonyl-CoA decarboxylase 
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MMAA -1.40 0.0000 methylmalonic aciduria (cobalamin deficiency) cblA type 
MMGT1 -1.19 0.0000 membrane magnesium transporter 1 
MMP1 6.74 0.0000 matrix metallopeptidase 1 (interstitial collagenase) 
MMP14 -2.60 0.0000 matrix metallopeptidase 14 (membrane-inserted) 
MMP15 -2.85 0.0000 matrix metallopeptidase 15 (membrane-inserted) 
MMP17 -2.35 0.0000 matrix metallopeptidase 17 (membrane-inserted) 
MMP19 -4.71 0.0000 matrix metallopeptidase 19 
MMP28 -1.80 0.0000 matrix metallopeptidase 28 
MMS19 -0.62 0.0000 MMS19 nucleotide excision repair homolog (S. cerevisiae) 
MNAT1 0.93 0.0000 menage a trois homolog 1, cyclin H assembly factor (Xenopus laevis) 
MNX1 3.35 0.0000 motor neuron and pancreas homeobox 1 
MON1A -1.21 0.0000 MON1 homolog A (yeast) 
MON1B -0.98 0.0000 MON1 homolog B (yeast) 
MORF4L1 -1.21 0.0000 mortality factor 4; mortality factor 4 like 1 
MOSPD2 -1.87 0.0000 motile sperm domain containing 2 
MPP3 2.61 0.0000 membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) 
MPP4 2.85 0.0000 membrane protein, palmitoylated 4 (MAGUK p55 subfamily member 4) 
MPP6 1.12 0.0000 membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) 
MPZL1 0.99 0.0000 myelin protein zero-like 1 
MRAS -1.78 0.0000 muscle RAS oncogene homolog 
MRPL21 1.15 0.0000 mitochondrial ribosomal protein L21 
MRPL3 0.97 0.0000 mitochondrial ribosomal protein L3 
MRPL32 0.98 0.0000 mitochondrial ribosomal protein L32 
MRPL36 0.85 0.0000 mitochondrial ribosomal protein L36 
MRPL39 1.11 0.0000 mitochondrial ribosomal protein L39 
MRPL42P5 -1.50 0.0000 mitochondrial ribosomal protein L42 pseudogene 5 
MRPL43 -0.88 0.0000 mitochondrial ribosomal protein L43 
MRPL54 -1.32 0.0000 mitochondrial ribosomal protein L54 
MRPS27 0.75 0.0000 mitochondrial ribosomal protein S27 
MRRF 0.77 0.0000 mitochondrial ribosome recycling factor 
MSH2 1.10 0.0000 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 
MSH3 0.97 0.0000 mutS homolog 3 (E. coli) 
MSH6 1.08 0.0000 mutS homolog 6 (E. coli) 
MSL1 -0.99 0.0000 male-specific lethal 1 homolog (Drosophila) 
MSL3L2 1.48 0.0000 male-specific lethal 3-like 2 (Drosophila) 
MSN -1.22 0.0000 moesin 
MSRA -2.22 0.0000 methionine sulfoxide reductase A 
142 
 
Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
MSX2 2.99 0.0000 msh homeobox 2 
MSX2P1 1.96 0.0000 msh homeobox 2 pseudogene 1 
MT1A -1.76 0.0000 metallothionein 1A 
MT1E -2.40 0.0000 metallothionein 1L (gene/pseudogene); metallothionein 1E; metallothionein 1 
pseudogene 3; metallothionein 1J (pseudogene) 
MT1F -4.95 0.0000 metallothionein 1F 
MT1G -1.75 0.0000 metallothionein 1G 
MT1H -1.57 0.0000 metallothionein 1H 
MT1L -1.45 0.0000 metallothionein 1L (gene/pseudogene); metallothionein 1E; metallothionein 1 
pseudogene 3; metallothionein 1J (pseudogene) 
MT1X -1.80 0.0000 metallothionein 1X 
MTBP 1.55 0.0000 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse) 
binding protein, 104kDa 
MTCH2 -1.61 0.0000 mitochondrial carrier homolog 2 (C. elegans) 
MTERFD1 1.30 0.0000 MTERF domain containing 1 
MTF1 -1.27 0.0000 metal-regulatory transcription factor 1 
MTHFD1L 1.40 0.0000 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 
MTIF3 -1.40 0.0000 mitochondrial translational initiation factor 3 
MTMR1 1.65 0.0000 myotubularin related protein 1 
MTMR14 -1.28 0.0000 myotubularin related protein 14 
MTMR4 1.14 0.0000 myotubularin related protein 4 
MTSS1 3.42 0.0000 metastasis suppressor 1 
MUM1 1.40 0.0000 melanoma associated antigen (mutated) 1 
MUT -1.55 0.0000 methylmalonyl Coenzyme A mutase 
MVP -1.65 0.0000 major vault protein 
MXI1 -1.48 0.0000 MAX interactor 1 
MYB 2.12 0.0000 v-myb myeloblastosis viral oncogene homolog (avian) 
MYBBP1A 0.96 0.0000 MYB binding protein (P160) 1a 
MYBL2 1.91 0.0000 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 
MYCBP 1.58 0.0000 c-myc binding protein 
MYD88 -1.60 0.0000 myeloid differentiation primary response gene (88) 
MYL12A -1.21 0.0000 myosin, light chain 12A, regulatory, non-sarcomeric 
MYL12B -0.86 0.0000 myosin, light chain 12B, regulatory 
MYL6 -1.65 0.0000 myosin, light chain 6, alkali, smooth muscle and non-muscle 
MYL9 -4.56 0.0000 myosin, light chain 9, regulatory 
MYO1B 1.77 0.0000 myosin IB 
MYO1E -2.44 0.0000 myosin IE 
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MYO5A -1.83 0.0000 myosin VA (heavy chain 12, myoxin) 
MYO5B 4.07 0.0000 similar to acetyl-Coenzyme A acyltransferase 2 (mitochondrial 
3-oxoacyl-Coenzyme A thiolase); similar to KIAA1119 protein; myosin VB 
MYO5C 2.39 0.0000 myosin VC 
MYO6 1.48 0.0000 myosin VI 
MYO9A -1.14 0.0000 myosin IXA 
MYRIP 2.75 0.0000 myosin VIIA and Rab interacting protein 
MYST1 1.45 0.0000 MYST histone acetyltransferase 1 
N4BP2L2 -2.21 0.0000 NEDD4 binding protein 2-like 2 
NAAA -1.86 0.0000 N-acylethanolamine acid amidase 
NAB1 2.09 0.0000 NGFI-A binding protein 1 (EGR1 binding protein 1) 
NACC2 -2.28 0.0000 NACC family member 2, BEN and BTB (POZ) domain containing 
NASP 1.41 0.0000 nuclear autoantigenic sperm protein (histone-binding) 
NAT8L 2.33 0.0000 N-acetyltransferase 8-like (GCN5-related, putative) 
NAT9 1.33 0.0000 N-acetyltransferase 9 (GCN5-related, putative) 
NAV1 -1.83 0.0000 neuron navigator 1 
NAV3 -3.05 0.0000 neuron navigator 3; similar to neuron navigator 3 
NCBP1 0.82 0.0000 nuclear cap binding protein subunit 1, 80kDa 
NCL 0.79 0.0000 nucleolin 
NCRNA00189 1.81 0.0000 chromosome 21 open reading frame 109 
NCSTN -1.36 0.0000 nicastrin 
NDNL2 1.01 0.0000 necdin-like 2 
NDP -2.51 0.0000 Norrie disease (pseudoglioma) 
NDUFA1 -1.10 0.0000 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa 
NDUFA7 -1.21 0.0000 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5kDa 
NDUFAF3 -1.21 0.0000 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 3 
NDUFB9 1.12 0.0000 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22kDa 
NDUFC1 -0.85 0.0000 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 
NDUFV2 -0.90 0.0000 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 
NEFH 5.45 0.0000 neurofilament, heavy polypeptide 
NEK1 -2.11 0.0000 NIMA (never in mitosis gene a)-related kinase 1 
NEK11 0.67 0.0000 NIMA (never in mitosis gene a)- related kinase 11 
NELL2 2.95 0.0000 NEL-like 2 (chicken) 
NET1 1.25 0.0000 neuroepithelial cell transforming 1 
NEU1 -1.96 0.0000 sialidase 1 (lysosomal sialidase) 
NEXN 2.15 0.0000 nexilin (F actin binding protein) 
NF1 -2.25 0.0000 neurofibromin 1 
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NFATC1 3.72 0.0000 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 
NFE2L2 -1.55 0.0000 nuclear factor (erythroid-derived 2)-like 2 
NFIB 3.85 0.0000 nuclear factor I/B 
NFIC -1.84 0.0000 nuclear factor I/C (CCAAT-binding transcription factor) 
NFIL3 -2.64 0.0000 nuclear factor, interleukin 3 regulated 
NFKBIA -2.07 0.0000 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha 
NFKBIL2 1.16 0.0000 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor-like 2 
NFS1 1.57 0.0000 NFS1 nitrogen fixation 1 homolog (S. cerevisiae) 
NFYB 1.17 0.0000 nuclear transcription factor Y, beta 
NGFR -3.64 0.0000 nerve growth factor receptor (TNFR superfamily, member 16) 
NGFRAP1 -1.79 0.0000 nerve growth factor receptor (TNFRSF16) associated protein 1 
NHLRC2 -1.08 0.0000 NHL repeat containing 2 
NICN1 -1.76 0.0000 nicolin 1 
NIN 1.57 0.0000 ninein (GSK3B interacting protein) 
NKAIN1 2.44 0.0000 Na+/K+ transporting ATPase interacting 1 
NKD2 2.22 0.0000 naked cuticle homolog 2 (Drosophila) 
NKX2-1 1.67 0.0000 NK2 homeobox 1 
NKX2-5 2.40 0.0000 NK2 transcription factor related, locus 5 (Drosophila) 
NKX3-2 2.04 0.0000 NK3 homeobox 2 
NLRP3 1.96 0.0000 NLR family, pyrin domain containing 3 
NLRX1 -3.06 0.0000 NLR family member X1 
NME1 1.00 0.0000 non-metastatic cells 1, protein (NM23A) expressed in; NME1-NME2 
readthrough transcript; non-metastatic cells 2, protein (NM23B) expressed in
NME2 0.90 0.0000 non-metastatic cells 1, protein (NM23A) expressed in; NME1-NME2 
readthrough transcript; non-metastatic cells 2, protein (NM23B) expressed in
NME2P1 1.14 0.0000 non-metastatic cells 2, protein (NM23B) expressed in, pseudogene 1 
NME3 -1.97 0.0000 non-metastatic cells 3, protein expressed in 
NMT2 1.65 0.0000 N-myristoyltransferase 2 
NMU 2.64 0.0000 neuromedin U 
NOC2L 1.30 0.0000 nucleolar complex associated 2 homolog (S. cerevisiae) 
NOC3L 0.98 0.0000 nucleolar complex associated 3 homolog (S. cerevisiae) 
NOL10 1.02 0.0000 nucleolar protein 10 
NOL11 1.50 0.0000 nucleolar protein 11 
NOL9 1.50 0.0000 nucleolar protein 9 
NOM1 0.96 0.0000 nucleolar protein with MIF4G domain 1 
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NONO -0.79 0.0000 non-POU domain containing, octamer-binding 
NOP2 1.03 0.0000 NOP2 nucleolar protein homolog (yeast) 
NOTCH1 -0.96 0.0000 Notch homolog 1, translocation-associated (Drosophila) 
NOV -1.53 0.0000 nephroblastoma overexpressed gene 
NPAS3 1.88 0.0000 neuronal PAS domain protein 3 
NPC1 -1.28 0.0000 Niemann-Pick disease, type C1 
NPC2 -1.44 0.0000 Niemann-Pick disease, type C2 
NPL -3.15 0.0000 N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 
NPM1 1.23 0.0000 nucleophosmin 1 (nucleolar phosphoprotein B23, numatrin) pseudogene 21; 
hypothetical LOC100131044; similar to nucleophosmin 1; nucleophosmin 
(nucleolar phosphoprotein B23, numatrin) 
NPPB 4.02 0.0000 natriuretic peptide precursor B 
NPR3 1.48 0.0000 natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide 
receptor C) 
NPTX1 4.14 0.0000 neuronal pentraxin I 
NQO2 -1.31 0.0000 NAD(P)H dehydrogenase, quinone 2 
NR0B1 3.23 0.0000 nuclear receptor subfamily 0, group B, member 1 
NR4A1 -3.89 0.0000 nuclear receptor subfamily 4, group A, member 1 
NR4A2 -2.74 0.0000 nuclear receptor subfamily 4, group A, member 2 
NRBF2 -1.36 0.0000 nuclear receptor binding factor 2 
NRBP2 -1.24 0.0000 nuclear receptor binding protein 2 
NRCAM -3.02 0.0000 neuronal cell adhesion molecule 
NRG1 2.69 0.0000 neuregulin 1 
NRN1 -3.44 0.0000 neuritin 1 
NRP1 1.71 0.0000 neuropilin 1 
NSF 1.46 0.0000 N-ethylmaleimide-sensitive factor 
NSUN2 0.97 0.0000 NOL1/NOP2/Sun domain family, member 2 
NTN4 3.07 0.0000 netrin 4 
NTNG1 -3.38 0.0000 netrin G1 
NUAK2 1.93 0.0000 NUAK family, SNF1-like kinase, 2 
NUCB2 -2.34 0.0000 nucleobindin 2 
NUDT10 2.28 0.0000 nudix (nucleoside diphosphate linked moiety X)-type motif 10 
NUDT21 2.14 0.0000 nudix (nucleoside diphosphate linked moiety X)-type motif 21 
NUDT3 -1.84 0.0000 nudix (nucleoside diphosphate linked moiety X)-type motif 3 
NUDT4 -1.91 0.0000 nudix (nucleoside diphosphate linked moiety X)-type motif 4; nudix 
(nucleoside diphosphate linked moiety X)-type motif 4 pseudogene 1 
NUDT9 -1.30 0.0000 nudix (nucleoside diphosphate linked moiety X)-type motif 9 
146 
 
Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
NUP107 1.43 0.0000 nucleoporin 107kDa 
NUP155 1.28 0.0000 nucleoporin 155kDa 
NUP205 1.26 0.0000 nucleoporin 205kDa 
NUP85 1.22 0.0000 nucleoporin 85kDa 
NXT1 1.54 0.0000 NTF2-like export factor 1 
OAF -3.04 0.0000 OAF homolog (Drosophila) 
OAT -2.17 0.0000 ornithine aminotransferase (gyrate atrophy) 
OAZ1 -1.74 0.0000 ornithine decarboxylase antizyme 1 
OBFC2A 1.65 0.0000 oligonucleotide/oligosaccharide-binding fold containing 2A 
OCA2 4.12 0.0000 oculocutaneous albinism II 
OCIAD2 -6.62 0.0000 OCIA domain containing 2 
ODC1 1.75 0.0000 ornithine decarboxylase 1 
ODZ4 2.00 0.0000 odz, odd Oz/ten-m homolog 4 (Drosophila) 
OGDHL 2.71 0.0000 oxoglutarate dehydrogenase-like 
OGFOD1 0.83 0.0000 2-oxoglutarate and iron-dependent oxygenase domain containing 1 
OLA1 1.79 0.0000 Obg-like ATPase 1 
OLFML2A -3.60 0.0000 olfactomedin-like 2A 
OLFML2B -2.40 0.0000 olfactomedin-like 2B 
OLFML3 -2.58 0.0000 olfactomedin-like 3 
OLIG1 3.87 0.0000 oligodendrocyte transcription factor 1 
OPA1 0.85 0.0000 optic atrophy 1 (autosomal dominant) 
OPHN1 -2.19 0.0000 oligophrenin 1 
OPLAH -2.44 0.0000 5-oxoprolinase (ATP-hydrolysing) 
OPN3 -1.85 0.0000 opsin 3 
OR7E5P -0.71 0.0000 olfactory receptor, family 7, subfamily E, member 5 pseudogene 
ORC5L 0.88 0.0000 origin recognition complex, subunit 5-like (yeast) 
ORMDL2 -1.07 0.0000 ORM1-like 2 (S. cerevisiae) 
OSBPL8 -2.21 0.0000 oxysterol binding protein-like 8 
OSGIN2 -0.75 0.0000 oxidative stress induced growth inhibitor family member 2 
OSR2 2.69 0.0000 odd-skipped related 2 (Drosophila) 
OSTF1 -1.31 0.0000 osteoclast stimulating factor 1 
OSTM1 -3.31 0.0000 osteopetrosis associated transmembrane protein 1 
OTUD1 -1.05 0.0000 OTU domain containing 1 
OTUD7B -1.18 0.0000 OTU domain containing 7B 
OVOS2 -5.37 0.0000 ovostatin; ovostatin 2 
OXSR1 -1.17 0.0000 oxidative-stress responsive 1 
P2RX7 -2.68 0.0000 purinergic receptor P2X, ligand-gated ion channel, 7 
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P4HA2 -2.02 0.0000 prolyl 4-hydroxylase, alpha polypeptide II 
PAAF1 1.05 0.0000 proteasomal ATPase-associated factor 1 
PABPC1 1.06 0.0000 poly(A) binding protein, cytoplasmic pseudogene 5; poly(A) binding protein, 
cytoplasmic 1 
PABPC3 0.96 0.0000 poly(A) binding protein, cytoplasmic 3 
PABPC4L 3.37 0.0000 poly(A) binding protein, cytoplasmic 4-like 
PAFAH1B3 0.91 0.0000 platelet-activating factor acetylhydrolase, isoform Ib, subunit 3 (29kDa) 
PAIP1 4.05 0.0000 poly(A) binding protein interacting protein 1; similar to poly(A) binding protein 
interacting protein 1 
PALM 1.57 0.0000 paralemmin 
PANK2 0.61 0.0000 pantothenate kinase 2 
PAPOLG 1.12 0.0000 poly(A) polymerase gamma 
PAQR6 -1.84 0.0000 progestin and adipoQ receptor family member VI 
PAQR8 -2.48 0.0000 progestin and adipoQ receptor family member VIII 
PAQR9 3.26 0.0000 progestin and adipoQ receptor family member IX 
PARD6B 1.35 0.0000 par-6 partitioning defective 6 homolog beta (C. elegans) 
PARP2 1.13 0.0000 poly (ADP-ribose) polymerase 2 
PARP4 -1.03 0.0000 poly (ADP-ribose) polymerase family, member 4 
PARVA -0.77 0.0000 parvin, alpha 
PASK 1.18 0.0000 PAS domain containing serine/threonine kinase 
PAX3 -1.32 0.0000 paired box 3 
PAX8 -2.03 0.0000 paired box 8 
PBRM1 -1.20 0.0000 polybromo 1 
PC -2.05 0.0000 pyruvate carboxylase 
PCBD2 0.95 0.0000 pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha (TCF1) 2 
PCBP1 -0.95 0.0000 poly(rC) binding protein 1 
PCBP4 -2.20 0.0000 poly(rC) binding protein 4 
PCCA -0.94 0.0000 propionyl Coenzyme A carboxylase, alpha polypeptide 
PCDH9 -2.42 0.0000 protocadherin 9 
PCDHB12 2.01 0.0000 protocadherin beta 12 
PCDHB5 3.26 0.0000 protocadherin beta 5 
PCDHB7 2.65 0.0000 protocadherin beta 7 
PCDHB9 2.16 0.0000 protocadherin beta 10; protocadherin beta 9 
PCDHGA2 -1.14 0.0000 protocadherin gamma subfamily A, 2 
PCMT1 -2.32 0.0000 protein-L-isoaspartate (D-aspartate) O-methyltransferase 
PCMTD1 -1.14 0.0000 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 
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PCNA 1.48 0.0000 proliferating cell nuclear antigen 
PCOLCE 2.48 0.0000 procollagen C-endopeptidase enhancer 
PCOLCE2 2.96 0.0000 procollagen C-endopeptidase enhancer 2 
PCSK1 7.06 0.0000 proprotein convertase subtilisin/kexin type 1 
PCSK1N 1.20 0.0000 proprotein convertase subtilisin/kexin type 1 inhibitor 
PCSK6 1.46 0.0000 proprotein convertase subtilisin/kexin type 6 
PCYT1A -0.89 0.0000 phosphate cytidylyltransferase 1, choline, alpha 
PDCD2L 2.33 0.0000 programmed cell death 2-like 
PDCD6IP -1.07 0.0000 programmed cell death 6 interacting protein 
PDE4DIP -1.89 0.0000 hypothetical protein LOC100134230; similar to KIAA0454 protein; similar to 
phosphodiesterase 4D interacting protein isoform 2; phosphodiesterase 4D 
interacting protein 
PDE7A 1.57 0.0000 phosphodiesterase 7A 
PDE8B 3.08 0.0000 phosphodiesterase 8B 
PDE9A 3.35 0.0000 phosphodiesterase 9A 
PDGFD 2.69 0.0000 platelet derived growth factor D 
PDGFRA 3.55 0.0000 platelet-derived growth factor receptor, alpha polypeptide 
PDGFRL 3.07 0.0000 platelet-derived growth factor receptor-like 
PDHB -1.48 0.0000 pyruvate dehydrogenase (lipoamide) beta 
PDK3 -0.84 0.0000 pyruvate dehydrogenase kinase, isozyme 3 
PDLIM4 -1.51 0.0000 PDZ and LIM domain 4 
PDPN -4.51 0.0000 podoplanin 
PDZRN3 -2.03 0.0000 PDZ domain containing ring finger 3 
PEA15 -1.18 0.0000 phosphoprotein enriched in astrocytes 15 
PEBP1 -2.57 0.0000 phosphatidylethanolamine binding protein 1 
PEG10 2.33 0.0000 paternally expressed 10 
PEPD -1.94 0.0000 peptidase D 
PER2 2.54 0.0000 period homolog 2 (Drosophila) 
PEX13 1.46 0.0000 peroxisomal biogenesis factor 13 
PEX14 -1.13 0.0000 peroxisomal biogenesis factor 14 
PFDN4 1.24 0.0000 prefoldin subunit 4 
PFKFB4 -3.35 0.0000 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 
PGBD1 -1.06 0.0000 piggyBac transposable element derived 1 
PGM3 -2.47 0.0000 phosphoglucomutase 3 
PGPEP1 -0.84 0.0000 pyroglutamyl-peptidase I 
PHB 0.72 0.0000 prohibitin 
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PHF11 -4.82 0.0000 PHD finger protein 11 
PHF14 1.01 0.0000 PHD finger protein 14 
PHF15 -1.21 0.0000 PHD finger protein 15 
PHF16 0.99 0.0000 PHD finger protein 16 
PHF17 -1.34 0.0000 PHD finger protein 17 
PHF20L1 1.70 0.0000 PHD finger protein 20-like 1 
PHF21B 2.07 0.0000 PHD finger protein 21B 
PHKA1 1.51 0.0000 phosphorylase kinase, alpha 1 pseudogene 1; phosphorylase kinase, alpha 1 
(muscle) 
PHTF1 -0.80 0.0000 putative homeodomain transcription factor 1 
PHTF2 0.77 0.0000 putative homeodomain transcription factor 2 
PHYHIPL 2.11 0.0000 phytanoyl-CoA 2-hydroxylase interacting protein-like 
PI4K2A -0.89 0.0000 phosphatidylinositol 4-kinase type 2 alpha 
PID1 3.38 0.0000 phosphotyrosine interaction domain containing 1 
PIGB -1.46 0.0000 phosphatidylinositol glycan anchor biosynthesis, class B 
PIGK -1.12 0.0000 phosphatidylinositol glycan anchor biosynthesis, class K 
PIGN -1.32 0.0000 phosphatidylinositol glycan anchor biosynthesis, class N 
PIK3C3 -1.09 0.0000 phosphoinositide-3-kinase, class 3 
PIK3R1 -2.12 0.0000 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 
PIM1 2.57 0.0000 pim-1 oncogene 
PIP4K2A -0.71 0.0000 phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
PITPNA -1.93 0.0000 phosphatidylinositol transfer protein, alpha 
PITPNC1 -2.00 0.0000 phosphatidylinositol transfer protein, cytoplasmic 1 
PITX2 4.75 0.0000 paired-like homeodomain 2 
PJA1 -1.25 0.0000 praja ring finger 1 
PKIG 1.00 0.0000 protein kinase (cAMP-dependent, catalytic) inhibitor gamma 
PKNOX2 -4.62 0.0000 PBX/knotted 1 homeobox 2 
PLA2G16 -2.92 0.0000 phospholipase A2, group XVI 
PLA2G4C -2.10 0.0000 phospholipase A2, group IVC (cytosolic, calcium-independent) 
PLA2G7 3.00 0.0000 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, 
plasma) 
PLAGL1 -2.59 0.0000 pleiomorphic adenoma gene-like 1 
PLAGL2 2.10 0.0000 pleiomorphic adenoma gene-like 2; similar to pleiomorphic adenoma 
gene-like 2 
PLAU 4.02 0.0000 plasminogen activator, urokinase 
PLBD2 -1.37 0.0000 phospholipase B domain containing 2 
PLCB4 3.32 0.0000 phospholipase C, beta 4 
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PLCE1 -1.52 0.0000 phospholipase C, epsilon 1 
PLCG1 1.75 0.0000 phospholipase C, gamma 1 
PLCH2 1.61 0.0000 phospholipase C, eta 2 
PLCL2 1.29 0.0000 phospholipase C-like 2 
PLD6 1.85 0.0000 phospholipase D family, member 6 
PLEK2 -2.44 0.0000 pleckstrin 2 
PLEKHA1 -2.05 0.0000 pleckstrin homology domain containing, family A (phosphoinositide binding 
specific) member 1 
PLEKHA4 -4.16 0.0000 pleckstrin homology domain containing, family A (phosphoinositide binding 
specific) member 4 
PLEKHA5 -1.27 0.0000 pleckstrin homology domain containing, family A member 5 
PLEKHB2 -1.72 0.0000 pleckstrin homology domain containing, family B (evectins) member 2 
PLEKHF1 -1.60 0.0000 pleckstrin homology domain containing, family F (with FYVE domain) 
member 1 
PLEKHG3 1.25 0.0000 pleckstrin homology domain containing, family G (with RhoGef domain) 
member 3 
PLEKHH2 3.51 0.0000 pleckstrin homology domain containing, family H (with MyTH4 domain) 
member 2 
PLEKHM1 -1.13 0.0000 pleckstrin homology domain containing, family M (with RUN domain) member 
1 
PLEKHM3 -1.13 0.0000 pleckstrin homology domain containing, family M, member 3 
PLEKHO1 -1.46 0.0000 pleckstrin homology domain containing, family O member 1 
PLIN3 -1.23 0.0000 mannose-6-phosphate receptor binding protein 1 
PLOD1 -1.82 0.0000 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 
PLOD3 -1.63 0.0000 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 
PLP1 -6.68 0.0000 proteolipid protein 1 
PLP2 -2.02 0.0000 proteolipid protein 2 (colonic epithelium-enriched) 
PLSCR3 -1.26 0.0000 phospholipid scramblase 3 
PLXNA2 2.29 0.0000 plexin A2 
PLXNA4 -1.42 0.0000 plexin A4 
PLXNB3 -2.08 0.0000 plexin B3 
PLXND1 -2.22 0.0000 plexin D1 
PM20D2 2.18 0.0000 peptidase M20 domain containing 2 
PMAIP1 4.29 0.0000 phorbol-12-myristate-13-acetate-induced protein 1 
PMEPA1 -2.20 0.0000 prostate transmembrane protein, androgen induced 1 
PMP22 -5.20 0.0000 peripheral myelin protein 22 
PMS2L2 1.22 0.0000 postmeiotic segregation increased 2-like 5; postmeiotic segregation 
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increased 2-like 5-like; similar to postmeiotic segregation increased 2-like 2; 
postmeiotic segregation increased 2-like 2 pseudogene 
PMS2L3 1.03 0.0000 postmeiotic segregation increased 2-like 3; zinc finger protein 12 
PMS2L5 0.91 0.0000 postmeiotic segregation increased 2-like 5; postmeiotic segregation 
increased 2-like 5-like; similar to postmeiotic segregation increased 2-like 2; 
postmeiotic segregation increased 2-like 2 pseudogene 
PNMA1 -1.01 0.0000 paraneoplastic antigen MA1 
PNMA2 4.01 0.0000 paraneoplastic antigen MA2 
PNMA3 2.35 0.0000 paraneoplastic antigen MA3 
PNMA5 1.62 0.0000 paraneoplastic antigen like 5 
PNPLA3 -2.25 0.0000 patatin-like phospholipase domain containing 3 
PNPLA4 -2.19 0.0000 patatin-like phospholipase domain containing 4 
PNPLA6 -1.94 0.0000 patatin-like phospholipase domain containing 6 
PNPO 1.13 0.0000 pyridoxamine 5'-phosphate oxidase 
PNPT1 1.01 0.0000 polyribonucleotide nucleotidyltransferase 1 
PODXL 1.92 0.0000 podocalyxin-like 
POLD3 1.05 0.0000 polymerase (DNA-directed), delta 3, accessory subunit 
POLD4 -1.36 0.0000 polymerase (DNA-directed), delta 4 
POLG2 1.67 0.0000 polymerase (DNA directed), gamma 2, accessory subunit 
POLK -1.77 0.0000 polymerase (DNA directed) kappa 
POLR2C 0.91 0.0000 polymerase (RNA) II (DNA directed) polypeptide C, 33kDa 
POLR2I 1.38 0.0000 polymerase (RNA) II (DNA directed) polypeptide I, 14.5kDa 
POMZP3 -0.77 0.0000 POM (POM121 homolog, rat) and ZP3 fusion 
PON2 -1.54 0.0000 paraoxonase 2 
PON3 -2.09 0.0000 paraoxonase 3 
POPDC3 -2.40 0.0000 popeye domain containing 3 
POU4F1 4.62 0.0000 POU class 4 homeobox 1 
PPAPDC3 -2.59 0.0000 phosphatidic acid phosphatase type 2 domain containing 3 
PPARA -2.62 0.0000 peroxisome proliferator-activated receptor alpha 
PPARG 3.18 0.0000 peroxisome proliferator-activated receptor gamma 
PPARGC1A 2.96 0.0000 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
PPFIA1 -1.25 0.0000 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 1 
PPIB -2.42 0.0000 peptidylprolyl isomerase B (cyclophilin B) 
PPIL1 1.00 0.0000 peptidylprolyl isomerase (cyclophilin)-like 1 
PPM1E 3.18 0.0000 protein phosphatase 1E (PP2C domain containing) 
PPP1R12A -1.70 0.0000 protein phosphatase 1, regulatory (inhibitor) subunit 12A 
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PPP1R12B -1.53 0.0000 protein phosphatase 1, regulatory (inhibitor) subunit 12B 
PPP1R13B 2.12 0.0000 protein phosphatase 1, regulatory (inhibitor) subunit 13B 
PPP1R14C 1.78 0.0000 protein phosphatase 1, regulatory (inhibitor) subunit 14C 
PPP1R1C -2.17 0.0000 protein phosphatase 1, regulatory (inhibitor) subunit 1C 
PPP1R3D -1.06 0.0000 protein phosphatase 1, regulatory (inhibitor) subunit 3D 
PPP2CB -1.49 0.0000 protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform 
PPP2R2A -1.29 0.0000 protein phosphatase 2 (formerly 2A), regulatory subunit B, alpha isoform 
PPP2R2D -0.95 0.0000 protein phosphatase 2, regulatory subunit B, delta isoform 
PPP2R3A -1.77 0.0000 protein phosphatase 2 (formerly 2A), regulatory subunit B'', alpha 
PPP2R5A -1.51 0.0000 protein phosphatase 2, regulatory subunit B', alpha isoform 
PPP3CB -1.71 0.0000 protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform 
PPP4R2 -1.31 0.0000 protein phosphatase 4, regulatory subunit 2 
PPRC1 0.93 0.0000 peroxisome proliferator-activated receptor gamma, coactivator-related 1 
PPT2 -2.88 0.0000 palmitoyl-protein thioesterase 2 
PRAME 3.29 0.0000 preferentially expressed antigen in melanoma 
PRDM11 1.52 0.0000 PR domain containing 11 
PRDX2 -1.87 0.0000 peroxiredoxin 2 
PREP -1.77 0.0000 prolyl endopeptidase 
PRIM1 2.07 0.0000 primase, DNA, polypeptide 1 (49kDa) 
PRIM2 0.83 0.0000 primase, DNA, polypeptide 2 (58kDa) 
PRKCD -1.49 0.0000 protein kinase C, delta 
PRKCDBP -3.28 0.0000 protein kinase C, delta binding protein 
PRKCH 3.85 0.0000 protein kinase C, eta 
PRKCZ 1.62 0.0000 protein kinase C, zeta 
PRKRA -1.19 0.0000 protein kinase, interferon-inducible double stranded RNA dependent activator
PRKRIP1 0.90 0.0000 PRKR interacting protein 1 (IL11 inducible) 
PRMT2 -1.37 0.0000 protein arginine methyltransferase 2 
PRMT5 1.02 0.0000 protein arginine methyltransferase 5 
PRMT6 -1.24 0.0000 protein arginine methyltransferase 6 
PROCR 1.94 0.0000 protein C receptor, endothelial (ERT-PCR) 
PROS1 -3.58 0.0000 protein S (alpha) 
PRPF3 0.92 0.0000 PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae) 
PRR3 1.35 0.0000 proline rich 3 
PRR5 1.37 0.0000 Rho GTPase activating protein 8; proline rich 5 (renal); PRR5-ARHGAP8 
fusion 
PRR5L 2.15 0.0000 proline rich 5 like 
PRR7 -1.01 0.0000 proline rich 7 (synaptic) 
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PRRG4 -1.67 0.0000 proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 
PRRT1 -1.61 0.0000 proline-rich transmembrane protein 1 
PRRX1 1.79 0.0000 paired related homeobox 1 
PRRX2 4.07 0.0000 paired related homeobox 2 
PRSS12 -2.39 0.0000 protease, serine, 12 (neurotrypsin, motopsin) 
PRUNE2 -3.93 0.0000 prune homolog 2 (Drosophila) 
PSAP -2.22 0.0000 prosaposin 
PSCA 1.54 0.0000 prostate stem cell antigen 
PSD3 -2.85 0.0000 pleckstrin and Sec7 domain containing 3 
PSIP1 1.74 0.0000 PC4 and SFRS1 interacting protein 1 
PSMD12 0.88 0.0000 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 
PSMD9 -0.80 0.0000 proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 
PSME1 -0.98 0.0000 proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) 
PSME3 1.04 0.0000 proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) 
PSMF1 1.19 0.0000 proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 
PSMG2 -0.99 0.0000 proteasome (prosome, macropain) assembly chaperone 2 
PSTPIP2 1.93 0.0000 proline-serine-threonine phosphatase interacting protein 2 
PTCD1 1.11 0.0000 pentatricopeptide repeat domain 1 
PTEN -2.15 0.0000 phosphatase and tensin homolog; phosphatase and tensin homolog 
pseudogene 1 
PTGR1 -1.60 0.0000 prostaglandin reductase 1 
PTGS2 3.24 0.0000 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and 
cyclooxygenase) 
PTK2 1.34 0.0000 PTK2 protein tyrosine kinase 2 
PTP4A1 -0.92 0.0000 protein tyrosine phosphatase type IVA, member 1 
PTP4A3 1.37 0.0000 protein tyrosine phosphatase type IVA, member 3 
PTPLB -2.75 0.0000 protein tyrosine phosphatase-like (proline instead of catalytic arginine), 
member b 
PTPMT1 -1.08 0.0000 protein tyrosine phosphatase, mitochondrial 1 
PTPRE -4.25 0.0000 protein tyrosine phosphatase, receptor type, E 
PTPRG 1.62 0.0000 protein tyrosine phosphatase, receptor type, G 
PTPRS -1.79 0.0000 protein tyrosine phosphatase, receptor type, S 
PURB -0.97 0.0000 purine-rich element binding protein B 
PUS1 0.98 0.0000 pseudouridylate synthase 1 
PUS7 1.34 0.0000 pseudouridylate synthase 7 homolog (S. cerevisiae) 
PXMP2 2.14 0.0000 hypothetical LOC100129532; peroxisomal membrane protein 2, 22kDa 
PYCR1 2.26 0.0000 pyrroline-5-carboxylate reductase 1 
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PYCRL 1.66 0.0000 pyrroline-5-carboxylate reductase-like 
PYGL -1.11 0.0000 phosphorylase, glycogen, liver 
PYROXD1 -1.66 0.0000 pyridine nucleotide-disulphide oxidoreductase domain 1 
PZP -3.05 0.0000 pregnancy-zone protein 
QDPR -1.41 0.0000 quinoid dihydropteridine reductase 
QPCT -2.91 0.0000 glutaminyl-peptide cyclotransferase 
QRSL1 -1.53 0.0000 glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 
QSER1 -0.79 0.0000 glutamine and serine rich 1 
RAB11FIP4 2.54 0.0000 RAB11 family interacting protein 4 (class II) 
RAB14 -1.05 0.0000 RAB14, member RAS oncogene family 
RAB18 -1.67 0.0000 RAB18, member RAS oncogene family 
RAB2A -1.29 0.0000 RAB2A, member RAS oncogene family 
RAB31 -2.37 0.0000 RAB31, member RAS oncogene family 
RAB33A -3.44 0.0000 RAB33A, member RAS oncogene family 
RAB36 -1.45 0.0000 RAB36, member RAS oncogene family 
RAB39B 2.56 0.0000 RAB39B, member RAS oncogene family 
RAB3D 2.14 0.0000 RAB3D, member RAS oncogene family 
RAB5A -2.49 0.0000 RAB5A, member RAS oncogene family 
RAB6A -1.21 0.0000 RAB6C, member RAS oncogene family; RAB6A, member RAS oncogene 
family; hypothetical LOC100130819; RAB6C-like 
RAB6B 1.93 0.0000 RAB6B, member RAS oncogene family 
RAB6C -1.27 0.0000 RAB6C, member RAS oncogene family; RAB6A, member RAS oncogene 
family; hypothetical LOC100130819; RAB6C-like 
RAB7B -4.02 0.0000 RAB7B, member RAS oncogene family 
RAB9A -2.35 0.0000 RAB9A, member RAS oncogene family 
RAB9B -1.07 0.0000 RAB9B, member RAS oncogene family 
RAB9P1 -2.30 0.0000 RAB9, member RAS oncogene family, pseudogene 1 
RABEP1 -1.93 0.0000 rabaptin, RAB GTPase binding effector protein 1 
RABEPK 0.87 0.0000 Rab9 effector protein with kelch motifs 
RAD50 1.17 0.0000 RAD50 homolog (S. cerevisiae) 
RAD51C 1.68 0.0000 RAD51 homolog C (S. cerevisiae) 
RAD51L3 -0.88 0.0000 RAD51-like 3 (S. cerevisiae) 
RAE1 1.44 0.0000 RAE1 RNA export 1 homolog (S. pombe) 
RAI14 1.80 0.0000 retinoic acid induced 14 
RANBP1 0.77 0.0000 similar to RAN binding protein 1; RAN binding protein 1 
RANBP17 2.11 0.0000 RAN binding protein 17 
RANBP9 -1.34 0.0000 RAN binding protein 9 
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RAP1A -2.32 0.0000 RAP1A, member of RAS oncogene family 
RAP1GDS1 -2.33 0.0000 RAP1, GTP-GDP dissociation stimulator 1 
RAPH1 -1.34 0.0000 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 
RASA4 1.85 0.0000 RAS p21 protein activator 4; RAS p21 protein activator 4 pseudogene 
RASD1 -3.53 0.0000 RAS, dexamethasone-induced 1 
RASD2 -1.03 0.0000 RASD family, member 2 
RASL10A 2.48 0.0000 RAS-like, family 10, member A 
RASL10B 1.37 0.0000 RAS-like, family 10, member B 
RASSF2 3.78 0.0000 Ras association (RalGDS/AF-6) domain family member 2 
RASSF4 -2.92 0.0000 Ras association (RalGDS/AF-6) domain family member 4 
RASSF5 2.34 0.0000 Ras association (RalGDS/AF-6) domain family member 5 
RAVER2 1.71 0.0000 ribonucleoprotein, PTB-binding 2 
RB1 -1.73 0.0000 retinoblastoma 1 
RBBP7 -1.04 0.0000 retinoblastoma binding protein 7 
RBBP9 1.09 0.0000 retinoblastoma binding protein 9 
RBM12 1.46 0.0000 RNA binding motif protein 12; copine I 
RBM47 -1.79 0.0000 RNA binding motif protein 47 
RBMS1 -0.94 0.0000 RNA binding motif, single stranded interacting protein 1 
RBPMS2 4.89 0.0000 RNA binding protein with multiple splicing 2 
RBX1 -0.60 0.0000 ring-box 1 
RCAN1 -3.18 0.0000 regulator of calcineurin 1 
RCAN2 3.41 0.0000 regulator of calcineurin 2 
RCC2 1.13 0.0000 regulator of chromosome condensation 2 
RCL1 2.04 0.0000 RNA terminal phosphate cyclase-like 1 
RDH11 -1.14 0.0000 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 
RDX -2.29 0.0000 radixin 
REC8 -2.64 0.0000 REC8 homolog (yeast) 
REEP1 2.74 0.0000 receptor accessory protein 1 
REEP3 -1.33 0.0000 receptor accessory protein 3 
REEP5 -1.02 0.0000 receptor accessory protein 5 
RELL1 1.56 0.0000 RELT-like 1 
RELN 2.56 0.0000 reelin 
RFC2 1.11 0.0000 replication factor C (activator 1) 2, 40kDa 
RFC4 1.42 0.0000 replication factor C (activator 1) 4, 37kDa 
RFESD 1.55 0.0000 Rieske (Fe-S) domain containing 
RFX5 -0.98 0.0000 regulatory factor X, 5 (influences HLA class II expression) 
RGS2 3.89 0.0000 regulator of G-protein signaling 2, 24kDa 
156 
 
Gene 
In DS-9 
ST88 vs HSC 
.logFC 
adjPVal Description 
RGS9BP 1.26 0.0000 regulator of G protein signaling 9 binding protein 
RHOA -2.23 0.0000 ras homolog gene family, member A 
RHOB -1.71 0.0000 ras homolog gene family, member B 
RHOJ -1.92 0.0000 ras homolog gene family, member J 
RHOQ -2.74 0.0000 ras homolog gene family, member Q; similar to small GTP binding protein 
TC10 
RILP -1.24 0.0000 Rab interacting lysosomal protein 
RILPL1 -1.09 0.0000 Rab interacting lysosomal protein-like 1 
RIMBP3 1.25 0.0000 RIMS binding protein 3B; RIMS binding protein 3C; RIMS binding protein 3 
RIMKLA 3.61 0.0000 ribosomal modification protein rimK-like family member A 
RIMS3 2.03 0.0000 regulating synaptic membrane exocytosis 3 
RINT1 1.03 0.0000 RAD50 interactor 1 
RIOK2 1.09 0.0000 RIO kinase 2 (yeast) 
RIPK1 -0.90 0.0000 receptor (TNFRSF)-interacting serine-threonine kinase 1 
RIT1 -1.22 0.0000 Ras-like without CAAX 1 
RLN2 2.63 0.0000 relaxin 2 
RMI1 1.50 0.0000 RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae) 
RNASE1 -4.16 0.0000 ribonuclease, RNase A family, 1 (pancreatic) 
RNASEK -2.16 0.0000 ribonuclease, RNase K 
RNASEN 1.18 0.0000 ribonuclease type III, nuclear 
RNF114 1.62 0.0000 ring finger protein 114 
RNF128 -5.93 0.0000 ring finger protein 128 
RNF13 -1.78 0.0000 ring finger protein 13 
RNF141 -0.89 0.0000 ring finger protein 141 
RNF149 0.82 0.0000 ring finger protein 149 
RNF175 2.91 0.0000 ring finger protein 175 
RNF2 1.06 0.0000 ring finger protein 2 
RNF217 -1.49 0.0000 ring finger protein 217 
RNF44 1.32 0.0000 ring finger protein 44 
RNF5 -1.45 0.0000 ring finger protein 5; ring finger protein 5 pseudogene 1 
ROPN1 -4.34 0.0000 ropporin, rhophilin associated protein 1 
ROPN1B -4.86 0.0000 ropporin, rhophilin associated protein 1B 
ROPN1L 1.51 0.0000 ropporin 1-like 
RPA2 1.23 0.0000 replication protein A2, 32kDa 
RPA3 1.33 0.0000 replication protein A3, 14kDa 
RPAP3 1.19 0.0000 RNA polymerase II associated protein 3 
RPIA 1.43 0.0000 ribose 5-phosphate isomerase A 
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RPL10 0.70 0.0000 ribosomal protein L10; ribosomal protein L10 pseudogene 15; ribosomal 
protein L10 pseudogene 6; ribosomal protein L10 pseudogene 16; ribosomal 
protein L10 pseudogene 9 
RPL13 -1.02 0.0000 ribosomal protein L13 pseudogene 12; ribosomal protein L13 
RPL13P5 -1.28 0.0000 ribosomal protein L13 pseudogene 5 
RPL23 -0.80 0.0000 ribosomal protein L23 pseudogene 6; ribosomal protein L23 
RPL23AP82 -1.58 0.0000 ribosomal protein L23a pseudogene 25; ribosomal protein L23a pseudogene 
82 
RPL28 -1.01 0.0000 ribosomal protein L28 
RPL37 1.09 0.0000 ribosomal protein L37 
RPL8 0.94 0.0000 ribosomal protein L8; ribosomal protein L8 pseudogene 2 
RPN1 -0.92 0.0000 ribophorin I 
RPP38 -0.68 0.0000 ribonuclease P/MRP 38kDa subunit 
RPRD1A -1.11 0.0000 regulation of nuclear pre-mRNA domain containing 1A 
RPRD1B 1.76 0.0000 regulation of nuclear pre-mRNA domain containing 1B 
RPS21 1.47 0.0000 ribosomal protein S21 
RPS28 -1.41 0.0000 ribosomal protein S28 pseudogene 6; ribosomal protein S28 pseudogene 9; 
ribosomal protein S28 
RPS2P32 1.04 0.0000 ribosomal protein S2 pseudogene 32 
RPS6KA1 -1.48 0.0000 ribosomal protein S6 kinase, 90kDa, polypeptide 1 
RPS6KA3 -2.11 0.0000 ribosomal protein S6 kinase, 90kDa, polypeptide 3 
RPS6KB1 1.40 0.0000 ribosomal protein S6 kinase, 70kDa, polypeptide 1 
RPS6KC1 -1.27 0.0000 ribosomal protein S6 kinase, 52kDa, polypeptide 1 
RRAGA -0.90 0.0000 Ras-related GTP binding A 
RRAGB -1.37 0.0000 Ras-related GTP binding B 
RRAGC -2.20 0.0000 Ras-related GTP binding C 
RRAS -1.06 0.0000 related RAS viral (r-ras) oncogene homolog 
RRP15 0.82 0.0000 ribosomal RNA processing 15 homolog (S. cerevisiae) 
RRP1B 1.47 0.0000 ribosomal RNA processing 1 homolog B (S. cerevisiae) 
RSBN1L 0.98 0.0000 round spermatid basic protein 1-like 
RSL1D1 1.61 0.0000 ribosomal L1 domain containing 1 
RSPH9 -1.37 0.0000 radial spoke head 9 homolog (Chlamydomonas) 
RSRC1 1.05 0.0000 arginine/serine-rich coiled-coil 1 
RSU1 -1.76 0.0000 Ras suppressor protein 1 
RTKN -1.74 0.0000 rhotekin 
RTN4R 2.77 0.0000 reticulon 4 receptor 
RUNX1 -2.49 0.0000 runt-related transcription factor 1 
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RUNX3 4.03 0.0000 runt-related transcription factor 3 
RYBP -1.24 0.0000 RING1 and YY1 binding protein 
S100A11 -1.75 0.0000 S100 calcium binding protein A11; S100 calcium binding protein A11 
pseudogene 
S100A16 -1.23 0.0000 S100 calcium binding protein A16 
S100A2 1.65 0.0000 S100 calcium binding protein A2 
S100A6 -2.02 0.0000 S100 calcium binding protein A6 
S100B -8.24 0.0000 S100 calcium binding protein B 
S100PBP 0.92 0.0000 S100P binding protein 
SAE1 0.85 0.0000 SUMO1 activating enzyme subunit 1 
SALL1 3.65 0.0000 sal-like 1 (Drosophila) 
SAMD13 2.10 0.0000 sterile alpha motif domain containing 13 
SAMD8 -1.01 0.0000 sterile alpha motif domain containing 8 
SAMD9 -1.56 0.0000 sterile alpha motif domain containing 9 
SAMHD1 -1.33 0.0000 SAM domain and HD domain 1 
SAP30 -0.94 0.0000 Sin3A-associated protein, 30kDa 
SASH1 -3.74 0.0000 SAM and SH3 domain containing 1 
SATB1 -2.57 0.0000 SATB homeobox 1 
SCAND3 2.42 0.0000 SCAN domain containing 3 
SCARA3 2.40 0.0000 scavenger receptor class A, member 3 
SCARB2 -3.92 0.0000 scavenger receptor class B, member 2 
SCCPDH -1.72 0.0000 saccharopine dehydrogenase (putative) 
SCD5 2.13 0.0000 stearoyl-CoA desaturase 5 
SCG2 1.82 0.0000 secretogranin II (chromogranin C) 
SCG5 -3.21 0.0000 secretogranin V (7B2 protein) 
SCHIP1 -0.83 0.0000 schwannomin interacting protein 1 
SCN4B 2.88 0.0000 sodium channel, voltage-gated, type IV, beta 
SCPEP1 -0.65 0.0000 serine carboxypeptidase 1 
SDC1 1.43 0.0000 syndecan 1 
SDC3 -1.46 0.0000 syndecan 3 
SDCCAG3 0.91 0.0000 serologically defined colon cancer antigen 3; similar to Serologically defined 
colon cancer antigen 3 
SDF2 -1.23 0.0000 stromal cell-derived factor 2 
SDF2L1 -1.33 0.0000 stromal cell-derived factor 2-like 1 
SDF4 -0.94 0.0000 stromal cell derived factor 4 
SDHAF1 1.32 0.0000 succinate dehydrogenase complex assembly factor 1 
SDSL 1.42 0.0000 serine dehydratase-like 
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SEC14L1 0.78 0.0000 SEC14-like 1 (S. cerevisiae); SEC14-like 1 pseudogene 
SEC14L2 -1.37 0.0000 SEC14-like 2 (S. cerevisiae) 
SEC31A 2.07 0.0000 SEC31 homolog A (S. cerevisiae) 
SECISBP2L -3.00 0.0000 SECIS binding protein 2-like 
SEL1L -2.18 0.0000 sel-1 suppressor of lin-12-like (C. elegans) 
SELENBP1 -2.60 0.0000 selenium binding protein 1 
SELK -1.42 0.0000 selenoprotein K; similar to HSPC297 
SELM -1.88 0.0000 selenoprotein M 
SELPLG -1.22 0.0000 selectin P ligand 
SELS -1.81 0.0000 selenoprotein S 
SEMA3A 3.46 0.0000 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3A 
SEMA3B -4.88 0.0000 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3B 
SEMA3D 4.95 0.0000 sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3D 
SEMA4F -0.90 0.0000 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 4F 
SEMA6A -2.80 0.0000 sema domain, transmembrane domain (TM), and cytoplasmic domain, 
(semaphorin) 6A 
SENP1 1.27 0.0000 SUMO1/sentrin specific peptidase 1 
SEP15 -0.97 0.0000 15 kDa selenoprotein 
SEPHS2 1.30 0.0000 selenophosphate synthetase 2 
SEPP1 -4.55 0.0000 selenoprotein P, plasma, 1 
SEPT11 1.02 0.0000 septin 11 
SEPT5 1.56 0.0000 septin 5 
SEPW1 -1.68 0.0000 selenoprotein W, 1 
SERF1B 1.09 0.0000 small EDRK-rich factor 1A (telomeric); small EDRK-rich factor 1B 
(centromeric) 
SERINC1 -1.85 0.0000 serine incorporator 1 
SERPINE2 -2.10 0.0000 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 
1), member 2 
SERTAD4 3.93 0.0000 SERTA domain containing 4 
SESN1 1.10 0.0000 sestrin 1 
SETD7 -1.09 0.0000 SET domain containing (lysine methyltransferase) 7 
SETDB2 -1.21 0.0000 SET domain, bifurcated 2 
SF3A3 0.73 0.0000 splicing factor 3a, subunit 3, 60kDa 
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SFRP1 -1.59 0.0000 secreted frizzled-related protein 1 
SFRS1 1.40 0.0000 splicing factor, arginine/serine-rich 1 
SFRS2B -1.33 0.0000 splicing factor, arginine/serine-rich 2B 
SFT2D1 -1.34 0.0000 SFT2 domain containing 1 
SFT2D2 -1.60 0.0000 SFT2 domain containing 2 
SFXN1 0.81 0.0000 sideroflexin 1 
SFXN2 1.60 0.0000 sideroflexin 2 
SFXN4 1.53 0.0000 sideroflexin 4 
SGCB -2.65 0.0000 sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) 
SGCE -1.31 0.0000 sarcoglycan, epsilon 
SGSM3 -1.62 0.0000 small G protein signaling modulator 3 
SH2D5 3.01 0.0000 SH2 domain containing 5 
SH3BGRL2 2.20 0.0000 SH3 domain binding glutamic acid-rich protein like 2 
SH3BGRL3 -1.13 0.0000 SH3 domain binding glutamic acid-rich protein like 3 
SH3GL1 -2.46 0.0000 SH3-domain GRB2-like 1 
SH3GL3 2.15 0.0000 SH3-domain GRB2-like 3 
SH3GLB1 -1.83 0.0000 SH3-domain GRB2-like endophilin B1 
SH3KBP1 -1.95 0.0000 SH3-domain kinase binding protein 1 
SH3PXD2A -4.90 0.0000 SH3 and PX domains 2A 
SHC1 1.50 0.0000 SHC (Src homology 2 domain containing) transforming protein 1 
SHC4 -3.12 0.0000 SHC (Src homology 2 domain containing) family, member 4 
SHISA2 2.53 0.0000 shisa homolog 2 (Xenopus laevis) 
SHISA4 -1.74 0.0000 shisa homolog 4 (Xenopus laevis) 
SHROOM1 1.48 0.0000 shroom family member 1 
SHROOM3 3.79 0.0000 shroom family member 3 
SIDT2 -1.99 0.0000 SID1 transmembrane family, member 2 
SIGIRR -1.69 0.0000 single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 
SIGMAR1 0.85 0.0000 sigma non-opioid intracellular receptor 1 
SIP1 1.22 0.0000 survival of motor neuron protein interacting protein 1 
SIRPA 3.27 0.0000 signal-regulatory protein alpha 
SIRT2 -1.79 0.0000 sirtuin (silent mating type information regulation 2 homolog) 2 (S. cerevisiae)
SIX1 2.09 0.0000 SIX homeobox 1 
SIX4 4.16 0.0000 SIX homeobox 4 
SKIV2L2 0.78 0.0000 superkiller viralicidic activity 2-like 2 (S. cerevisiae) 
SKP2 1.77 0.0000 S-phase kinase-associated protein 2 (p45) 
SLC12A4 -1.46 0.0000 solute carrier family 12 (potassium/chloride transporters), member 4 
SLC12A7 4.24 0.0000 solute carrier family 12 (potassium/chloride transporters), member 7 
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SLC15A3 -3.99 0.0000 solute carrier family 15, member 3 
SLC15A4 -1.93 0.0000 solute carrier family 15, member 4 
SLC16A9 4.12 0.0000 solute carrier family 16, member 9 (monocarboxylic acid transporter 9) 
SLC19A2 -2.08 0.0000 solute carrier family 19 (thiamine transporter), member 2 
SLC1A1 3.76 0.0000 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, 
system Xag), member 1 
SLC1A4 -1.75 0.0000 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 
SLC1A5 1.15 0.0000 solute carrier family 1 (neutral amino acid transporter), member 5 
SLC20A2 -1.54 0.0000 solute carrier family 20 (phosphate transporter), member 2 
SLC22A17 -0.79 0.0000 solute carrier family 22, member 17 
SLC22A18 -1.98 0.0000 solute carrier family 22, member 18 
SLC23A2 -1.12 0.0000 solute carrier family 23 (nucleobase transporters), member 2 
SLC25A12 1.27 0.0000 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 
SLC25A20 -3.61 0.0000 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
SLC25A36 0.81 0.0000 solute carrier family 25, member 36 
SLC26A10 1.75 0.0000 RhoA/RAC/CDC42 exchange factor; solute carrier family 26, member 10 
SLC26A11 1.14 0.0000 solute carrier family 26, member 11 
SLC27A2 2.20 0.0000 solute carrier family 27 (fatty acid transporter), member 2 
SLC27A4 -1.89 0.0000 solute carrier family 27 (fatty acid transporter), member 4 
SLC29A1 1.26 0.0000 solute carrier family 29 (nucleoside transporters), member 1 
SLC2A4RG 1.95 0.0000 SLC2A4 regulator 
SLC30A4 -0.91 0.0000 solute carrier family 30 (zinc transporter), member 4 
SLC35A1 -1.27 0.0000 solute carrier family 35 (CMP-sialic acid transporter), member A1 
SLC35A2 -1.56 0.0000 solute carrier family 35 (UDP-galactose transporter), member A2 
SLC35B2 -1.67 0.0000 solute carrier family 35, member B2 
SLC35F2 3.34 0.0000 solute carrier family 35, member F2 
SLC35F3 2.43 0.0000 solute carrier family 35, member F3 
SLC37A2 -2.28 0.0000 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 
SLC38A1 5.52 0.0000 solute carrier family 38, member 1 
SLC39A4 -2.42 0.0000 solute carrier family 39 (zinc transporter), member 4 
SLC39A7 -0.91 0.0000 solute carrier family 39 (zinc transporter), member 7 
SLC39A8 1.83 0.0000 solute carrier family 39 (zinc transporter), member 8 
SLC41A2 -1.40 0.0000 solute carrier family 41, member 2 
SLC45A4 1.71 0.0000 solute carrier family 45, member 4 
SLC48A1 1.52 0.0000 solute carrier family 48 (heme transporter), member 1 
SLC4A4 3.20 0.0000 solute carrier family 4, sodium bicarbonate cotransporter, member 4 
SLC5A6 1.27 0.0000 solute carrier family 5 (sodium-dependent vitamin transporter), member 6 
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SLC6A19 -1.20 0.0000 solute carrier family 6 (neutral amino acid transporter), member 19 
SLC7A8 -2.09 0.0000 solute carrier family 7 (cationic amino acid transporter, y+ system), member 8
SLC8A1 3.09 0.0000 solute carrier family 8 (sodium/calcium exchanger), member 1 
SLC9A7 -1.52 0.0000 solute carrier family 9 (sodium/hydrogen exchanger), member 7 
SLITRK4 5.03 0.0000 SLIT and NTRK-like family, member 4 
SLK -0.92 0.0000 STE20-like kinase (yeast) 
SMAD2 -1.15 0.0000 SMAD family member 2 
SMARCA5 -0.95 0.0000 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 5 
SMN1 0.88 0.0000 survival of motor neuron 1, telomeric; survival of motor neuron 2, centromeric
SMO 2.03 0.0000 smoothened homolog (Drosophila) 
SMPD1 -2.20 0.0000 sphingomyelin phosphodiesterase 1, acid lysosomal 
SMPD4 0.77 0.0000 sphingomyelin phosphodiesterase 4, neutral membrane (neutral 
sphingomyelinase-3) 
SMYD3 -1.53 0.0000 SET and MYND domain containing 3 
SNAPC1 1.50 0.0000 small nuclear RNA activating complex, polypeptide 1, 43kDa 
SNHG1 1.88 0.0000 small nucleolar RNA host gene 1 (non-protein coding) 
SNHG10 1.25 0.0000 small Cajal body-specific RNA 13; small nucleolar RNA host gene 10 
(non-protein coding) 
SNHG11 1.51 0.0000 small nucleolar RNA host gene 11 (non-protein coding) 
SNHG12 1.40 0.0000 small nucleolar RNA host gene 12 (non-protein coding) 
SNHG3-RCC1 1.47 0.0000 regulator of chromosome condensation 1; SNHG3-RCC1 readthrough 
transcript 
SNORD22 1.99 0.0000 small nucleolar RNA, C/D box 22 
SNRNP25 1.63 0.0000 small nuclear ribonucleoprotein 25kDa (U11/U12) 
SNRNP35 -0.96 0.0000 ATP-binding cassette, sub-family B (MDR/TAP), member 5; small nuclear 
ribonucleoprotein 35kDa (U11/U12) 
SNRPE 0.92 0.0000 small nuclear ribonucleoprotein polypeptide E-like 1; small nuclear 
ribonucleoprotein polypeptide E; similar to hCG23490 
SNRPF 1.22 0.0000 small nuclear ribonucleoprotein polypeptide F 
SNTB2 -1.57 0.0000 syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic 
component 2) 
SNX10 3.22 0.0000 sorting nexin 10 
SNX12 -1.21 0.0000 sorting nexin 12 
SNX14 -1.45 0.0000 sorting nexin 14 
SNX18 -2.12 0.0000 sorting nexin 18 
SNX25 -0.75 0.0000 sorting nexin 25 
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SNX27 -1.61 0.0000 sorting nexin family member 27 
SNX3 -1.56 0.0000 sorting nexin 3 
SNX5 1.32 0.0000 sorting nexin 5 
SOCS3 2.04 0.0000 suppressor of cytokine signaling 3 
SOCS6 -1.32 0.0000 suppressor of cytokine signaling 6 
SON 0.85 0.0000 SON DNA binding protein 
SORL1 4.13 0.0000 sortilin-related receptor, L(DLR class) A repeats-containing 
SORT1 -2.31 0.0000 sortilin 1 
SOX10 -3.28 0.0000 SRY (sex determining region Y)-box 10 
SOX2OT -4.10 0.0000 SOX2 overlapping transcript (non-protein coding) 
SOX3 3.62 0.0000 SRY (sex determining region Y)-box 3 
SOX4 -3.14 0.0000 SRY (sex determining region Y)-box 4 
SOX8 -2.68 0.0000 SRY (sex determining region Y)-box 8 
SPATA13 -1.70 0.0000 spermatogenesis associated 13 
SPATA6 -1.72 0.0000 spermatogenesis associated 6 
SPATS2 1.37 0.0000 spermatogenesis associated, serine-rich 2 
SPCS3 -1.32 0.0000 signal peptidase complex subunit 3 homolog (S. cerevisiae) 
SPEG 2.70 0.0000 SPEG complex locus 
SPHK1 -2.52 0.0000 sphingosine kinase 1 
SPOCK1 2.63 0.0000 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 
SPON1 4.86 0.0000 spondin 1, extracellular matrix protein 
SPON2 -2.61 0.0000 spondin 2, extracellular matrix protein 
SPP1 -4.13 0.0000 secreted phosphoprotein 1 
SPPL2A -2.36 0.0000 signal peptide peptidase-like 2A 
SPRY1 2.25 0.0000 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 
SPTBN1 -3.36 0.0000 spectrin, beta, non-erythrocytic 1 
SQRDL -3.30 0.0000 sulfide quinone reductase-like (yeast) 
SR140 1.44 0.0000 U2-associated SR140 protein 
SRBD1 -1.07 0.0000 S1 RNA binding domain 1 
SRF -0.72 0.0000 serum response factor (c-fos serum response element-binding transcription 
factor) 
SRGAP1 2.02 0.0000 SLIT-ROBO Rho GTPase activating protein 1 
SRGAP2P1 -3.16 0.0000 SLIT-ROBO Rho GTPase activating protein 2 pseudogene 1 
SRI -1.82 0.0000 sorcin 
SRPK1 0.94 0.0000 SFRS protein kinase 1 
SRPX -2.59 0.0000 sushi-repeat-containing protein, X-linked 
SRPX2 -1.92 0.0000 sushi-repeat-containing protein, X-linked 2 
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SRR -1.43 0.0000 serine racemase 
SS18L1 1.01 0.0000 synovial sarcoma translocation gene on chromosome 18-like 1 
SSBP4 1.53 0.0000 single stranded DNA binding protein 4 
SSH3 -2.36 0.0000 slingshot homolog 3 (Drosophila) 
SSR1 -1.19 0.0000 signal sequence receptor, alpha 
SSR2 -1.23 0.0000 signal sequence receptor, beta (translocon-associated protein beta) 
SSR3 1.30 0.0000 signal sequence receptor, gamma (translocon-associated protein gamma) 
SSTR1 5.24 0.0000 somatostatin receptor 1 
SSTR2 2.02 0.0000 somatostatin receptor 2 
ST3GAL2 -1.19 0.0000 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 
ST3GAL3 -1.05 0.0000 ST3 beta-galactoside alpha-2,3-sialyltransferase 3 
ST3GAL4 -2.25 0.0000 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 
ST3GAL5 2.28 0.0000 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
ST5 -1.51 0.0000 suppression of tumorigenicity 5 
ST6GAL1 -2.74 0.0000 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 
ST6GALNAC2 -4.10 0.0000 ST6 
(alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 2 
ST8SIA5 -1.80 0.0000 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 
STAC 3.37 0.0000 SH3 and cysteine rich domain 
STAG3L4 1.39 0.0000 stromal antigen 3-like 4 
STAM -1.08 0.0000 signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 
STAMBP -1.51 0.0000 STAM binding protein 
STARD13 -1.57 0.0000 StAR-related lipid transfer (START) domain containing 13 
STARD3 -1.49 0.0000 StAR-related lipid transfer (START) domain containing 3 
STARD8 -1.81 0.0000 StAR-related lipid transfer (START) domain containing 8 
STAT5B 1.52 0.0000 signal transducer and activator of transcription 5B 
STAU1 1.17 0.0000 staufen, RNA binding protein, homolog 1 (Drosophila) 
STBD1 -2.50 0.0000 starch binding domain 1 
STEAP2 1.82 0.0000 six transmembrane epithelial antigen of the prostate 2 
STK10 -1.24 0.0000 serine/threonine kinase 10 
STK11IP -1.39 0.0000 serine/threonine kinase 11 interacting protein 
STK17B 1.52 0.0000 serine/threonine kinase 17b 
STK39 1.32 0.0000 serine threonine kinase 39 (STE20/SPS1 homolog, yeast) 
STK40 -1.20 0.0000 serine/threonine kinase 40 
STMN2 2.45 0.0000 stathmin-like 2 
STMN3 2.57 0.0000 stathmin-like 3 
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STOM 1.26 0.0000 stomatin 
STOX2 -2.50 0.0000 storkhead box 2 
STRA13 1.65 0.0000 stimulated by retinoic acid 13 homolog (mouse) 
STRAP -1.58 0.0000 serine/threonine kinase receptor associated protein 
STRBP 2.00 0.0000 spermatid perinuclear RNA binding protein 
STX12 -1.13 0.0000 syntaxin 12 
STX2 -1.91 0.0000 syntaxin 2 
STX7 -1.62 0.0000 syntaxin 7 
STXBP3 -1.50 0.0000 syntaxin binding protein 3 
STXBP5 -1.91 0.0000 syntaxin binding protein 5 (tomosyn) 
STXBP6 1.82 0.0000 syntaxin binding protein 6 (amisyn) 
STYK1 1.60 0.0000 serine/threonine/tyrosine kinase 1 
SUB1 0.71 0.0000 SUB1 homolog (S. cerevisiae) 
SULF2 4.83 0.0000 sulfatase 2 
SUSD1 -1.53 0.0000 sushi domain containing 1 
SUZ12 -4.20 0.0000 suppressor of zeste 12 homolog (Drosophila) 
SVIL -2.73 0.0000 supervillin 
SYCP1 1.58 0.0000 synaptonemal complex protein 1 
SYCP2 2.88 0.0000 synaptonemal complex protein 2 
SYNJ2 2.75 0.0000 synaptojanin 2 
SYNM -1.34 0.0000 synemin, intermediate filament protein 
SYNRG -0.83 0.0000 AP1 gamma subunit binding protein 1 
SYT11 -1.21 0.0000 synaptotagmin XI 
SYT12 1.10 0.0000 synaptotagmin XII 
SYT13 4.33 0.0000 synaptotagmin XIII 
SYTL5 2.13 0.0000 synaptotagmin-like 5 
TACC1 -2.20 0.0000 transforming, acidic coiled-coil containing protein 1 
TAF12 0.72 0.0000 TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 20kDa 
TAF1A 1.68 0.0000 TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 
48kDa 
TAF4 1.88 0.0000 TAF4 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
135kDa 
TAF7 1.01 0.0000 TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
55kDa 
TAF7L 2.83 0.0000 TAF7-like RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 50kDa 
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TAF8 -1.20 0.0000 TAF8 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
43kDa 
TAGLN3 2.68 0.0000 transgelin 3 
TAL1 3.33 0.0000 T-cell acute lymphocytic leukemia 1 
TALDO1 -2.15 0.0000 transaldolase 1 
TAOK2 1.10 0.0000 TAO kinase 2 
TAOK3 -1.95 0.0000 TAO kinase 3 
TAP1 -2.29 0.0000 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 
TAPBP -1.67 0.0000 TAP binding protein (tapasin) 
TARBP1 1.06 0.0000 TAR (HIV-1) RNA binding protein 1 
TARDBP 1.60 0.0000 TAR DNA binding protein 
TARSL2 -3.24 0.0000 threonyl-tRNA synthetase-like 2 
TATDN1 1.36 0.0000 TatD DNase domain containing 1 
TBC1D10A -1.87 0.0000 TBC1 domain family, member 10A 
TBC1D23 -0.88 0.0000 TBC1 domain family, member 23 
TBC1D24 1.41 0.0000 TBC1 domain family, member 24 
TBC1D4 1.49 0.0000 TBC1 domain family, member 4 
TBC1D7 -1.43 0.0000 TBC1 domain family, member 7 
TBC1D9B -1.17 0.0000 TBC1 domain family, member 9B (with GRAM domain) 
TBL1Y -1.06 0.0000 transducin (beta)-like 1Y-linked 
TBL2 1.00 0.0000 transducin (beta)-like 2 
TBRG4 1.29 0.0000 transforming growth factor beta regulator 4 
TBX1 6.46 0.0000 T-box 1 
TBX2 -2.80 0.0000 T-box 2 
TBX3 2.47 0.0000 T-box 3 
TBXA2R -3.09 0.0000 thromboxane A2 receptor 
TBXAS1 2.31 0.0000 thromboxane A synthase 1 (platelet) 
TCEA3 3.22 0.0000 transcription elongation factor A (SII), 3 
TCEAL3 -1.59 0.0000 transcription elongation factor A (SII)-like 3 
TCEAL4 -1.62 0.0000 transcription elongation factor A (SII)-like 4 
TCEAL5 -1.07 0.0000 transcription elongation factor A (SII)-like 5 
TCEAL6 -1.47 0.0000 transcription elongation factor A (SII)-like 6 
TCEAL8 -1.07 0.0000 transcription elongation factor A (SII)-like 8 
TCF15 4.86 0.0000 transcription factor 15 (basic helix-loop-helix) 
TCF25 -1.81 0.0000 transcription factor 25 (basic helix-loop-helix) 
TCF3 0.93 0.0000 transcription factor 3 (E2A immunoglobulin enhancer binding factors 
E12/E47) 
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TCFL5 1.39 0.0000 transcription factor-like 5 (basic helix-loop-helix) 
TCIRG1 -3.37 0.0000 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit 
A3 
TCOF1 1.27 0.0000 Treacher Collins-Franceschetti syndrome 1 
TCTA -1.19 0.0000 T-cell leukemia translocation altered gene 
TCTN3 -0.93 0.0000 tectonic family member 3 
TDRD3 -0.81 0.0000 tudor domain containing 3 
TET3 -1.05 0.0000 tet oncogene family member 3 
TEX10 0.92 0.0000 testis expressed 10 
TEX15 1.61 0.0000 testis expressed 15 
TEX2 -1.70 0.0000 testis expressed 2 
TFAP2A -2.48 0.0000 transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) 
TFAP2B -3.25 0.0000 transcription factor AP-2 beta (activating enhancer binding protein 2 beta) 
TFPI 2.71 0.0000 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
TGFA -4.50 0.0000 transforming growth factor, alpha 
TGFB1 1.69 0.0000 transforming growth factor, beta 1 
TGFBR2 -2.27 0.0000 transforming growth factor, beta receptor II (70/80kDa) 
TGIF1 -1.29 0.0000 TGFB-induced factor homeobox 1 
TGIF2 1.23 0.0000 TGFB-induced factor homeobox 2 
TGOLN2 -1.56 0.0000 trans-golgi network protein 2 
THAP10 1.11 0.0000 THAP domain containing 10 
THBS2 -3.69 0.0000 thrombospondin 2 
THBS4 4.42 0.0000 thrombospondin 4 
THOC3 1.24 0.0000 similar to THO complex 3; THO complex 3 
THOC4 1.91 0.0000 THO complex 4 
THSD1 1.46 0.0000 thrombospondin, type I, domain containing 1 
THSD4 2.69 0.0000 thrombospondin, type I, domain containing 4 
THUMPD2 0.94 0.0000 THUMP domain containing 2 
THUMPD3 -4.50 0.0000 THUMP domain containing 3 
THY1 2.31 0.0000 Thy-1 cell surface antigen 
TIGD1 1.50 0.0000 tigger transposable element derived 1 
TIGD3 1.44 0.0000 tigger transposable element derived 3 
TIGD7 1.68 0.0000 tigger transposable element derived 7 
TIMELESS 1.56 0.0000 timeless homolog (Drosophila) 
TIMM10 1.22 0.0000 translocase of inner mitochondrial membrane 10 homolog (yeast) 
TIMM50 1.30 0.0000 translocase of inner mitochondrial membrane 50 homolog (S. cerevisiae) 
TIMP1 -2.06 0.0000 TIMP metallopeptidase inhibitor 1 
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TIMP3 -6.00 0.0000 TIMP metallopeptidase inhibitor 3 
TINF2 -0.98 0.0000 TERF1 (TRF1)-interacting nuclear factor 2 
TIPRL -0.98 0.0000 TIP41, TOR signaling pathway regulator-like (S. cerevisiae) 
TJP2 1.67 0.0000 tight junction protein 2 (zona occludens 2) 
TK1 1.91 0.0000 thymidine kinase 1, soluble 
TKTL1 -3.10 0.0000 transketolase-like 1 
TLE4 2.73 0.0000 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 
TLR1 -4.61 0.0000 toll-like receptor 1 
TLR6 -2.67 0.0000 toll-like receptor 6 
TM4SF1 2.04 0.0000 transmembrane 4 L six family member 1 
TM9SF2 -1.00 0.0000 transmembrane 9 superfamily member 2 
TM9SF3 -0.92 0.0000 transmembrane 9 superfamily member 3 
TMBIM1 -2.18 0.0000 transmembrane BAX inhibitor motif containing 1 
TMBIM6 -1.63 0.0000 transmembrane BAX inhibitor motif containing 6 
TMC7 -3.31 0.0000 transmembrane channel-like 7 
TMCO6 1.09 0.0000 transmembrane and coiled-coil domains 6 
TMED10 -1.94 0.0000 transmembrane emp24-like trafficking protein 10 (yeast) 
TMED10P -1.90 0.0000 transmembrane emp24-like trafficking protein 10 (yeast) pseudogene 
TMED5 -1.96 0.0000 transmembrane emp24 protein transport domain containing 5 
TMEFF2 3.88 0.0000 transmembrane protein with EGF-like and two follistatin-like domains 2 
TMEM100 -1.80 0.0000 transmembrane protein 100 
TMEM102 -1.90 0.0000 transmembrane protein 102 
TMEM107 -1.56 0.0000 transmembrane protein 107 
TMEM108 2.67 0.0000 transmembrane protein 108 
TMEM111 -0.99 0.0000 transmembrane protein 111 
TMEM116 0.96 0.0000 transmembrane protein 116 
TMEM127 -1.11 0.0000 transmembrane protein 127 
TMEM140 -1.86 0.0000 transmembrane protein 140 
TMEM154 2.58 0.0000 transmembrane protein 154 
TMEM158 2.02 0.0000 transmembrane protein 158 
TMEM169 -2.86 0.0000 transmembrane protein 169 
TMEM173 1.51 0.0000 transmembrane protein 173 
TMEM178 2.18 0.0000 transmembrane protein 178 
TMEM184B -1.65 0.0000 transmembrane protein 184B 
TMEM184C -1.84 0.0000 transmembrane protein 184C 
TMEM186 1.61 0.0000 transmembrane protein 186 
TMEM2 -1.84 0.0000 transmembrane protein 2 
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TMEM200A 4.53 0.0000 transmembrane protein 200A 
TMEM208 -1.46 0.0000 transmembrane protein 208 
TMEM209 1.46 0.0000 transmembrane protein 209 
TMEM216 1.30 0.0000 transmembrane protein 216 
TMEM220 -2.14 0.0000 transmembrane protein 220 
TMEM35 2.08 0.0000 transmembrane protein 35 
TMEM47 -2.71 0.0000 transmembrane protein 47 
TMEM50A -1.08 0.0000 transmembrane protein 50A 
TMEM51 3.49 0.0000 transmembrane protein 51 
TMEM62 -1.18 0.0000 transmembrane protein 62 
TMEM71 -3.43 0.0000 transmembrane protein 71 
TMEM87A -2.15 0.0000 transmembrane protein 87A 
TMEM87B -1.12 0.0000 transmembrane protein 87B 
TMEM8B -1.10 0.0000 transmembrane protein 8B 
TMEM97 1.10 0.0000 transmembrane protein 97 
TMEM9B -1.92 0.0000 TMEM9 domain family, member B 
TMOD1 4.18 0.0000 tropomodulin 1 
TMOD2 -3.58 0.0000 tropomodulin 2 (neuronal) 
TMPRSS5 -3.57 0.0000 transmembrane protease, serine 5 
TMTC1 5.43 0.0000 transmembrane and tetratricopeptide repeat containing 1 
TMTC2 -5.28 0.0000 transmembrane and tetratricopeptide repeat containing 2 
TMX3 -1.21 0.0000 thioredoxin-related transmembrane protein 3 
TNC -2.50 0.0000 tenascin C 
TNFAIP1 -1.46 0.0000 tumor necrosis factor, alpha-induced protein 1 (endothelial) 
TNFAIP2 2.32 0.0000 tumor necrosis factor, alpha-induced protein 2 
TNFAIP6 -4.40 0.0000 tumor necrosis factor, alpha-induced protein 6 
TNFRSF11B 4.49 0.0000 tumor necrosis factor receptor superfamily, member 11b 
TNFRSF14 -3.05 0.0000 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry 
mediator) 
TNFRSF25 2.79 0.0000 tumor necrosis factor receptor superfamily, member 25 
TNFSF12 -3.04 0.0000 TNFSF12-TNFSF13 readthrough transcript; tumor necrosis factor (ligand) 
superfamily, member 12; tumor necrosis factor (ligand) superfamily, member 
13 
TNRC6B -1.50 0.0000 trinucleotide repeat containing 6B 
TNS3 -1.80 0.0000 tensin 3 
TOLLIP -1.93 0.0000 toll interacting protein 
TOMM5 1.04 0.0000 translocase of outer mitochondrial membrane 5 homolog (yeast) 
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TOP1P2 1.51 0.0000 topoisomerase (DNA) I pseudogene 2 
TOX2 1.78 0.0000 TOX high mobility group box family member 2 
TP53RK 0.78 0.0000 TP53 regulating kinase 
TPBG 2.37 0.0000 trophoblast glycoprotein 
TPD52L2 1.26 0.0000 tumor protein D52-like 2 
TPM4 -1.72 0.0000 tropomyosin 4 
TPMT -1.37 0.0000 thiopurine S-methyltransferase 
TPT1 -1.48 0.0000 similar to tumor protein, translationally-controlled 1; tumor protein, 
translationally-controlled 1 
TRADD -1.44 0.0000 TNFRSF1A-associated via death domain 
TRAF1 -3.33 0.0000 TNF receptor-associated factor 1 
TRAF3IP3 1.02 0.0000 TRAF3 interacting protein 3 
TRAK1 -1.03 0.0000 trafficking protein, kinesin binding 1 
TRAM1 -1.10 0.0000 translocation associated membrane protein 1 
TRAM2 -0.93 0.0000 translocation associated membrane protein 2 
TRAP1 1.84 0.0000 TNF receptor-associated protein 1 
TRAPPC2P1 -0.90 0.0000 trafficking protein particle complex 2; trafficking protein particle complex 2 
pseudogene 1 
TRIB1 2.72 0.0000 tribbles homolog 1 (Drosophila) 
TRIM2 -3.64 0.0000 tripartite motif-containing 2 
TRIM6 1.58 0.0000 TRIM6-TRIM34 readthrough transcript; tripartite motif-containing 6; tripartite 
motif-containing 34 
TRIM63 -1.73 0.0000 tripartite motif-containing 63 
TRIO -1.15 0.0000 triple functional domain (PTPRF interacting) 
TRIT1 0.95 0.0000 tRNA isopentenyltransferase 1 
TRMT12 0.97 0.0000 tRNA methyltransferase 12 homolog (S. cerevisiae) 
TRPC3 2.17 0.0000 transient receptor potential cation channel, subfamily C, member 3 
TRPM7 -1.85 0.0000 transient receptor potential cation channel, subfamily M, member 7 
TRPV2 -1.37 0.0000 transient receptor potential cation channel, subfamily V, member 2 
TRUB2 -1.74 0.0000 TruB pseudouridine (psi) synthase homolog 2 (E. coli) 
TSEN54 1.48 0.0000 tRNA splicing endonuclease 54 homolog (S. cerevisiae) 
TSGA14 3.41 0.0000 testis specific, 14 
TSHZ3 1.74 0.0000 teashirt zinc finger homeobox 3 
TSKU 1.67 0.0000 tsukushin 
TSPAN8 3.61 0.0000 tetraspanin 8 
TSPYL1 -1.41 0.0000 TSPY-like 1 
TTC19 -1.51 0.0000 tetratricopeptide repeat domain 19 
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TTC39C -1.17 0.0000 tetratricopeptide repeat domain 39C 
TTC9C 0.89 0.0000 tetratricopeptide repeat domain 9C 
TTLL7 -2.16 0.0000 tubulin tyrosine ligase-like family, member 7 
TTPAL 1.52 0.0000 tocopherol (alpha) transfer protein-like 
TUBD1 1.49 0.0000 tubulin, delta 1 
TUBGCP4 0.86 0.0000 tubulin, gamma complex associated protein 4 
TULP3 -1.24 0.0000 tubby like protein 3 
TWIST2 2.45 0.0000 twist homolog 2 (Drosophila) 
TWSG1 -1.79 0.0000 twisted gastrulation homolog 1 (Drosophila) 
TXNDC15 -1.16 0.0000 thioredoxin domain containing 15 
TXNDC16 -0.99 0.0000 thioredoxin domain containing 16 
TXNL1 -0.64 0.0000 thioredoxin-like 1 
TXNL4B -1.11 0.0000 thioredoxin-like 4B 
TYMS 1.56 0.0000 thymidylate synthetase 
UAP1L1 -1.66 0.0000 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 
UBA1 -1.13 0.0000 ubiquitin-like modifier activating enzyme 1 
UBA2 2.01 0.0000 ubiquitin-like modifier activating enzyme 2 
UBA5 0.74 0.0000 ubiquitin-like modifier activating enzyme 5 
UBA7 -1.21 0.0000 ubiquitin-like modifier activating enzyme 7 
UBC -1.49 0.0000 ubiquitin C 
UBE2A -1.44 0.0000 ubiquitin-conjugating enzyme E2A (RAD6 homolog) 
UBE2J1 -1.14 0.0000 ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) 
UBL3 -2.82 0.0000 ubiquitin-like 3 
UBL5 -0.82 0.0000 ubiquitin-like 5 
UBXN8 -1.33 0.0000 UBX domain protein 8 
UFC1 -0.93 0.0000 ubiquitin-fold modifier conjugating enzyme 1 
UGGT2 -1.33 0.0000 UDP-glucose ceramide glucosyltransferase-like 2 
UGT8 -1.85 0.0000 UDP glycosyltransferase 8 
UHRF1BP1L -1.41 0.0000 UHRF1 binding protein 1-like 
UMPS 1.07 0.0000 uridine monophosphate synthetase 
UNC13B -0.79 0.0000 unc-13 homolog B (C. elegans) 
UPF1 1.14 0.0000 UPF1 regulator of nonsense transcripts homolog (yeast) 
UPF3B 0.89 0.0000 UPF3 regulator of nonsense transcripts homolog B (yeast) 
UPRT -1.25 0.0000 uracil phosphoribosyltransferase (FUR1) homolog (S. cerevisiae) 
URB2 1.69 0.0000 URB2 ribosome biogenesis 2 homolog (S. cerevisiae) 
USO1 -1.07 0.0000 USO1 homolog, vesicle docking protein (yeast) 
USP10 -1.78 0.0000 ubiquitin specific peptidase 10 
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USP3 1.41 0.0000 ubiquitin specific peptidase 3 
USP53 -2.01 0.0000 ubiquitin specific peptidase 53 
USP54 -1.53 0.0000 ubiquitin specific peptidase 54 
USP7 1.37 0.0000 ubiquitin specific peptidase 7 (herpes virus-associated) 
USP9X -1.89 0.0000 ubiquitin specific peptidase 9, X-linked 
UTP15 1.22 0.0000 UTP15, U3 small nucleolar ribonucleoprotein, homolog (S. cerevisiae) 
UTP3 -0.92 0.0000 UTP3, small subunit (SSU) processome component, homolog (S. cerevisiae)
UTRN -2.67 0.0000 utrophin 
UXS1 -1.16 0.0000 UDP-glucuronate decarboxylase 1 
UXT -1.23 0.0000 ubiquitously-expressed transcript 
VAMP5 -2.58 0.0000 vesicle-associated membrane protein 5 (myobrevin) 
VAT1 -1.33 0.0000 vesicle amine transport protein 1 homolog (T. californica) 
VAT1L 3.44 0.0000 vesicle amine transport protein 1 homolog (T. californica)-like 
VGLL4 -1.74 0.0000 vestigial like 4 (Drosophila) 
VHL -1.27 0.0000 von Hippel-Lindau tumor suppressor 
VIM -1.85 0.0000 vimentin 
VKORC1 -1.05 0.0000 vitamin K epoxide reductase complex, subunit 1 
VMA21 -1.21 0.0000 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) 
VMAC -1.27 0.0000 vimentin-type intermediate filament associated coiled-coil protein 
VOPP1 1.89 0.0000 similar to EGFR-coamplified and overexpressed protein; EGFR-coamplified 
and overexpressed protein 
VPS13C -1.35 0.0000 vacuolar protein sorting 13 homolog C (S. cerevisiae) 
VPS24 -1.07 0.0000 vacuolar protein sorting 24 homolog (S. cerevisiae); ring finger protein 103 
VPS26A -1.18 0.0000 vacuolar protein sorting 26 homolog A (S. pombe) 
VPS35 -1.11 0.0000 hypothetical protein LOC100133770; vacuolar protein sorting 35 homolog (S. 
cerevisiae) 
VPS36 -1.13 0.0000 vacuolar protein sorting 36 homolog (S. cerevisiae) 
VPS37B -0.99 0.0000 vacuolar protein sorting 37 homolog B (S. cerevisiae) 
VSNL1 3.11 0.0000 visinin-like 1 
VWA1 -3.59 0.0000 von Willebrand factor A domain containing 1 
VWF -1.06 0.0000 von Willebrand factor 
WARS -1.30 0.0000 tryptophanyl-tRNA synthetase 
WASF1 1.17 0.0000 WAS protein family, member 1 
WASF3 0.97 0.0000 WAS protein family, member 3 
WBP5 -2.66 0.0000 WW domain binding protein 5 
WDFY3 -1.48 0.0000 WD repeat and FYVE domain containing 3 
WDR1 -0.88 0.0000 WD repeat domain 1 
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WDR19 -1.96 0.0000 WD repeat domain 19 
WDR4 2.05 0.0000 WD repeat domain 4 
WDR43 1.59 0.0000 WD repeat domain 43 
WDR44 -1.18 0.0000 WD repeat domain 44 
WDR45 -1.58 0.0000 WD repeat domain 45 
WDR67 1.23 0.0000 WD repeat domain 67 
WDR7 -1.65 0.0000 WD repeat domain 7 
WDR72 -2.33 0.0000 WD repeat domain 72 
WDR74 1.16 0.0000 WD repeat domain 74 
WDR75 1.25 0.0000 WD repeat domain 75 
WDR81 -1.43 0.0000 WD repeat domain 81 
WDR90 1.75 0.0000 WD repeat domain 90 
WDYHV1 1.37 0.0000 WDYHV motif containing 1 
WIPF1 -1.78 0.0000 WAS/WASL interacting protein family, member 1 
WIPF2 -1.45 0.0000 WAS/WASL interacting protein family, member 2 
WNK4 2.31 0.0000 WNK lysine deficient protein kinase 4 
WNT10B 1.21 0.0000 wingless-type MMTV integration site family, member 10B 
WNT3 2.37 0.0000 wingless-type MMTV integration site family, member 3 
WNT5A 3.62 0.0000 wingless-type MMTV integration site family, member 5A 
WSB2 -1.92 0.0000 WD repeat and SOCS box-containing 2 
WT1 1.43 0.0000 Wilms tumor 1 
WWC1 2.52 0.0000 WW and C2 domain containing 1 
WWC3 -1.63 0.0000 WWC family member 3 
WWOX -1.50 0.0000 WW domain containing oxidoreductase 
YBX2 3.61 0.0000 Y box binding protein 2 
YEATS2 1.02 0.0000 YEATS domain containing 2 
YIPF6 -1.39 0.0000 Yip1 domain family, member 6 
YTHDF1 1.26 0.0000 YTH domain family, member 1 
YTHDF2 -0.86 0.0000 YTH domain family, member 2 
ZADH2 -1.08 0.0000 zinc binding alcohol dehydrogenase domain containing 2 
ZAK 1.97 0.0000 sterile alpha motif and leucine zipper containing kinase AZK 
ZBTB20 -1.86 0.0000 zinc finger and BTB domain containing 20 
ZBTB24 -1.13 0.0000 zinc finger and BTB domain containing 24 
ZBTB38 -2.32 0.0000 zinc finger and BTB domain containing 38 
ZBTB4 -1.58 0.0000 zinc finger and BTB domain containing 4 
ZBTB44 -2.00 0.0000 zinc finger and BTB domain containing 44 
ZBTB46 1.67 0.0000 zinc finger and BTB domain containing 46 
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ZBTB7A -2.04 0.0000 zinc finger and BTB domain containing 7A 
ZC3H8 1.56 0.0000 zinc finger CCCH-type containing 8 
ZC3HAV1L 2.35 0.0000 zinc finger CCCH-type, antiviral 1-like 
ZCCHC17 -1.16 0.0000 zinc finger, CCHC domain containing 17 
ZCCHC3 1.98 0.0000 zinc finger, CCHC domain containing 3 
ZDHHC17 -1.51 0.0000 zinc finger, DHHC-type containing 17 
ZDHHC20 -0.90 0.0000 zinc finger, DHHC-type containing 20 
ZDHHC23 2.08 0.0000 zinc finger, DHHC-type containing 23 
ZDHHC7 -1.77 0.0000 zinc finger, DHHC-type containing 7 
ZEB2 -2.89 0.0000 zinc finger E-box binding homeobox 2 
ZFP2 -1.42 0.0000 zinc finger protein 2 homolog (mouse) 
ZFP41 1.18 0.0000 zinc finger protein 41 homolog (mouse) 
ZFP62 0.93 0.0000 zinc finger protein 62 homolog (mouse) 
ZFP64 3.17 0.0000 zinc finger protein 64 homolog (mouse) 
ZFYVE16 -1.26 0.0000 zinc finger, FYVE domain containing 16 
ZFYVE27 -1.54 0.0000 zinc finger, FYVE domain containing 27 
ZIC5 4.15 0.0000 Zic family member 5 (odd-paired homolog, Drosophila) 
ZMAT2 0.97 0.0000 zinc finger, matrin type 2 
ZMAT4 2.01 0.0000 zinc finger, matrin type 4 
ZMIZ1 -2.46 0.0000 zinc finger, MIZ-type containing 1 
ZNF101 0.99 0.0000 zinc finger protein 101 
ZNF107 2.08 0.0000 zinc finger protein 107 
ZNF121 -1.49 0.0000 zinc finger protein 121 
ZNF138 2.71 0.0000 zinc finger protein 138 
ZNF146 1.99 0.0000 zinc finger protein 146 
ZNF181 1.18 0.0000 zinc finger protein 181 
ZNF185 2.51 0.0000 zinc finger protein 185 (LIM domain) 
ZNF195 1.42 0.0000 zinc finger protein 195 
ZNF202 1.52 0.0000 zinc finger protein 202 
ZNF211 -0.74 0.0000 zinc finger protein 211 
ZNF217 1.97 0.0000 zinc finger protein 217 
ZNF226 -1.92 0.0000 zinc finger protein 226 
ZNF236 -1.48 0.0000 zinc finger protein 236 
ZNF24 -2.32 0.0000 zinc finger protein 24 
ZNF25 -0.91 0.0000 zinc finger protein 25 
ZNF250 1.61 0.0000 zinc finger protein 250 
ZNF251 1.23 0.0000 zinc finger protein 251 
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ZNF26 1.24 0.0000 zinc finger protein 26 
ZNF266 -1.00 0.0000 zinc finger protein 266 
ZNF273 1.96 0.0000 zinc finger protein 273 
ZNF280C 1.36 0.0000 zinc finger protein 280C 
ZNF280D -1.78 0.0000 zinc finger protein 280D 
ZNF30 1.68 0.0000 zinc finger protein 30 
ZNF302 1.58 0.0000 zinc finger protein 302 
ZNF334 2.16 0.0000 zinc finger protein 334 
ZNF337 1.37 0.0000 zinc finger protein 337 
ZNF34 0.64 0.0000 zinc finger protein 34 
ZNF343 0.85 0.0000 zinc finger protein 343 
ZNF382 1.56 0.0000 zinc finger protein 382 
ZNF433 -1.25 0.0000 zinc finger protein 433 
ZNF436 0.96 0.0000 zinc finger protein 436 
ZNF44 -1.31 0.0000 zinc finger protein 44 
ZNF440 -1.60 0.0000 zinc finger protein 440 
ZNF461 1.61 0.0000 zinc finger protein 461 
ZNF462 -1.04 0.0000 zinc finger protein 462 
ZNF48 1.91 0.0000 zinc finger protein 48 
ZNF490 -0.91 0.0000 zinc finger protein 490 
ZNF507 1.05 0.0000 zinc finger protein 507 
ZNF512B 1.36 0.0000 zinc finger protein 512B 
ZNF513 -1.43 0.0000 zinc finger protein 513 
ZNF521 4.27 0.0000 zinc finger protein 521 
ZNF524 -1.59 0.0000 zinc finger protein 524 
ZNF529 2.66 0.0000 zinc finger protein 529 
ZNF561 -0.92 0.0000 zinc finger protein 561; zinc finger protein 812 
ZNF562 -1.07 0.0000 zinc finger protein 562 
ZNF563 -1.39 0.0000 zinc finger protein 563 
ZNF565 1.16 0.0000 zinc finger protein 565 
ZNF567 2.14 0.0000 zinc finger protein 567 
ZNF598 0.96 0.0000 zinc finger protein 598 
ZNF599 1.26 0.0000 zinc finger protein 599 
ZNF618 4.20 0.0000 zinc finger protein 618 
ZNF623 0.82 0.0000 zinc finger protein 623 
ZNF643 1.55 0.0000 zinc finger protein 643 
ZNF644 -1.61 0.0000 zinc finger protein 644 
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ZNF646 1.20 0.0000 zinc finger protein 646 
ZNF658B 1.26 0.0000 zinc finger protein 658 pseudogene; zinc finger protein 658B 
ZNF670 1.38 0.0000 zinc finger protein 670 
ZNF671 -2.53 0.0000 zinc finger protein 671 
ZNF678 1.32 0.0000 zinc finger protein 678 
ZNF681 2.57 0.0000 zinc finger protein 681 
ZNF689 1.59 0.0000 zinc finger protein 689 
ZNF69 -1.43 0.0000 zinc finger protein 69 
ZNF696 1.27 0.0000 zinc finger protein 696 
ZNF7 1.18 0.0000 zinc finger protein 7 
ZNF706 -1.36 0.0000 zinc finger protein 706 
ZNF764 0.99 0.0000 zinc finger protein 764 
ZNF783 1.53 0.0000 zinc finger family member 783 
ZNF791 -1.20 0.0000 zinc finger protein 791 
ZNF850P 1.27 0.0000 zinc finger protein 850 pseudogene 
ZNF853 2.51 0.0000 zinc finger protein 853 
ZNF92 1.30 0.0000 zinc finger protein 92 
ZNRD1 0.92 0.0000 zinc ribbon domain containing 1 
ZRANB3 0.78 0.0000 zinc finger, RAN-binding domain containing 3 
ZSCAN18 -4.17 0.0000 zinc finger and SCAN domain containing 18 
ZSCAN21 0.71 0.0000 zinc finger and SCAN domain containing 21 
ZSWIM5 2.78 0.0000 zinc finger, SWIM-type containing 5 
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ABCC4 0.74 0.0091 0.90 0.0000 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4 
ACP1 0.67 0.0001 0.69 0.0000 acid phosphatase 1, soluble 
ACTG2 -1.79 0.0008 -3.96 0.0000 actin, gamma 2, smooth muscle, enteric 
ADAL 0.69 0.0029 0.99 0.0000 adenosine deaminase-like 
ADAM10 -0.73 0.0046 -2.86 0.0000 ADAM metallopeptidase domain 10 
ADAM17 -0.99 0.0000 -1.66 0.0000 ADAM metallopeptidase domain 17 
ADRB2 0.63 0.0051 2.01 0.0000 adrenergic, beta-2-, receptor, surface 
AIP -0.71 0.0079 -0.74 0.0005 aryl hydrocarbon receptor interacting protein 
AKR1B10 -0.81 0.0057 -2.78 0.0000 aldo-keto reductase family 1, member B10 (aldose 
reductase); aldo-keto reductase family 1, member 
B10-like 
ALS2 0.60 0.0087 0.76 0.0000 amyotrophic lateral sclerosis 2 (juvenile) 
ANKHD1 0.65 0.0096 1.01 0.0000 ankyrin repeat and KH domain containing 1; 
ANKHD1-EIF4EBP3 readthrough transcript; eukaryotic 
translation initiation factor 4E binding protein 3 
ASB1 0.59 0.0028 1.20 0.0000 ankyrin repeat and SOCS box-containing 1 
ATAD2 0.99 0.0057 2.24 0.0000 ATPase family, AAA domain containing 2 
B3GALT4 -0.96 0.0042 -4.85 0.0000 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 4 
BACE1 -0.99 0.0009 -2.15 0.0000 beta-site APP-cleaving enzyme 1 
BAT5 -0.74 0.0018 -0.93 0.0000 HLA-B associated transcript 5 
BBS7 -0.64 0.0001 -1.13 0.0000 Bardet-Biedl syndrome 7 
BDH2 -1.30 0.0000 -0.82 0.0001 3-hydroxybutyrate dehydrogenase, type 2 
BMP2 1.25 0.0006 1.77 0.0000 bone morphogenetic protein 2 
C10orf114 -1.83 0.0000 -2.44 0.0000 chromosome 10 open reading frame 114 
C15orf38 -0.72 0.0007 -0.71 0.0000 chromosome 15 open reading frame 38 
C17orf58 0.59 0.0075 1.91 0.0000 chromosome 17 open reading frame 58 
C1orf103 1.01 0.0025 1.97 0.0000 chromosome 1 open reading frame 103 
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C1orf27 0.68 0.0067 0.93 0.0000 chromosome 1 open reading frame 27 
C22orf9 -0.82 0.0054 -1.64 0.0000 chromosome 22 open reading frame 9 
C6orf105 1.79 0.0042 2.02 0.0001 chromosome 6 open reading frame 105 
C6orf125 -0.60 0.0047 -0.85 0.0000 chromosome 6 open reading frame 125 
C8orf46 -0.98 0.0002 -1.50 0.0000 chromosome 8 open reading frame 46 
CALHM2 -1.31 0.0033 -3.99 0.0000 calcium homeostasis modulator 2 
CAMK2N1 1.08 0.0025 1.07 0.0003 calcium/calmodulin-dependent protein kinase II inhibitor 
1 
CARD6 -0.79 0.0007 -1.92 0.0000 caspase recruitment domain family, member 6 
CCDC80 -0.70 0.0031 -1.47 0.0000 coiled-coil domain containing 80 
CCL2 -2.48 0.0007 -2.09 0.0004 chemokine (C-C motif) ligand 2 
CCNL1 0.71 0.0075 0.93 0.0000 cyclin L1 
CD151 -1.00 0.0022 -0.93 0.0005 CD151 molecule (Raph blood group) 
CDK2AP1 -0.84 0.0001 -1.46 0.0000 cyclin-dependent kinase 2 associated protein 1 
CDK2AP2 -0.85 0.0011 -0.94 0.0000 cyclin-dependent kinase 2 associated protein 2 
CDKN2A -0.66 0.0031 -3.86 0.0000 cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4) 
CFI -3.13 0.0000 -1.82 0.0000 complement factor I 
CNOT6 0.59 0.0049 0.63 0.0003 CCR4-NOT transcription complex, subunit 6 
CNP -0.65 0.0024 -2.68 0.0000 2',3'-cyclic nucleotide 3' phosphodiesterase 
COL4A2 -0.67 0.0084 -0.73 0.0005 collagen, type IV, alpha 2 
CREBZF 0.70 0.0037 2.16 0.0000 CREB/ATF bZIP transcription factor 
CRNDE 0.79 0.0019 3.53 0.0000 hCG1815491 
CXXC5 -1.59 0.0060 -1.12 0.0004 CXXC finger 5 
CYBRD1 -1.73 0.0007 -1.17 0.0000 cytochrome b reductase 1 
DCP2 1.55 0.0000 1.09 0.0000 DCP2 decapping enzyme homolog (S. cerevisiae) 
DCPS -0.67 0.0038 -1.22 0.0000 decapping enzyme, scavenger 
DDR1 -1.12 0.0000 -2.96 0.0000 discoidin domain receptor tyrosine kinase 1 
DIDO1 0.59 0.0060 1.97 0.0000 death inducer-obliterator 1 
DNAJB12 -0.75 0.0058 -1.23 0.0000 DnaJ (Hsp40) homolog, subfamily B, member 12 
DOCK4 1.49 0.0000 1.55 0.0000 dedicator of cytokinesis 4 
DOK1 -0.66 0.0061 -1.15 0.0000 docking protein 1-like protein; docking protein 1, 62kDa 
(downstream of tyrosine kinase 1) 
DUT 0.60 0.0044 0.80 0.0000 deoxyuridine triphosphatase 
EHD2 -1.04 0.0057 -1.63 0.0000 EH-domain containing 2 
ELMOD2 -1.09 0.0000 -1.27 0.0000 ELMO/CED-12 domain containing 2 
EXT2 -0.85 0.0030 -1.38 0.0000 exostoses (multiple) 2 
FADS2 -1.95 0.0000 -2.65 0.0000 fatty acid desaturase 2 
179 
 
Gene 
In DS-10 
siNf1 vs Ctrl 
(DS-1) 
Adj 
PVal 
ST88 vs HSC
(DS-4) 
Adj 
PVal 
Descriptions 
FAM116A -1.13 0.0001 -1.35 0.0000 family with sequence similarity 116, member A 
FAM20C -0.78 0.0019 -2.47 0.0000 family with sequence similarity 20, member C 
FAM45A -0.70 0.0055 -0.72 0.0001 family with sequence similarity 45, member A 
FEM1B -0.63 0.0075 -0.89 0.0000 fem-1 homolog b (C. elegans) 
FGD6 1.14 0.0000 2.07 0.0000 FYVE, RhoGEF and PH domain containing 6 
FKBP1B -1.14 0.0000 -0.87 0.0000 FK506 binding protein 1B, 12.6 kDa 
FLJ10357 -1.17 0.0000 -0.81 0.0001 hypothetical protein FLJ10357 
FLJ39632 1.24 0.0046 3.54 0.0000 hypothetical LOC642477; hypothetical LOC400879 
FLJ40330 0.78 0.0009 0.85 0.0000 hypothetical LOC645784 
FNTB -0.73 0.0062 -2.63 0.0000 farnesyltransferase, CAAX box, beta 
FZD4 -0.86 0.0006 -1.88 0.0000 frizzled homolog 4 (Drosophila) 
GALC -0.98 0.0001 -1.02 0.0000 galactosylceramidase 
GALNT10 0.95 0.0029 1.32 0.0000 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 10 (GalNAc-T10) 
GAS5 0.86 0.0002 1.64 0.0000 growth arrest-specific 5 (non-protein coding) 
GBP2 -1.35 0.0001 -2.05 0.0000 guanylate binding protein 2, interferon-inducible 
GCA 1.14 0.0084 1.37 0.0002 grancalcin, EF-hand calcium binding protein 
GCH1 1.02 0.0028 1.41 0.0000 GTP cyclohydrolase 1 
GFRA1 -1.57 0.0010 -3.74 0.0000 GDNF family receptor alpha 1 
GOSR2 0.73 0.0047 1.06 0.0000 golgi SNAP receptor complex member 2 
GSTT2 -0.82 0.0082 -5.59 0.0000 glutathione S-transferase theta 2B (gene/pseudogene); 
glutathione S-transferase theta 2 
H3F3A -1.41 0.0000 -1.14 0.0000 H3 histone, family 3B (H3.3B); H3 histone, family 3A 
pseudogene; H3 histone, family 3A; similar to H3 
histone, family 3B; similar to histone H3.3B 
HEXIM1 -0.60 0.0065 -0.86 0.0000 hexamethylene bis-acetamide inducible 1 
HIPK2 1.46 0.0001 1.79 0.0000 homeodomain interacting protein kinase 2; similar to 
homeodomain interacting protein kinase 2 
HLA-DMA -0.73 0.0023 -5.07 0.0000 major histocompatibility complex, class II, DM alpha 
HSPA5 -0.77 0.0023 -1.57 0.0000 hypothetical gene supported by AF216292; 
NM_005347; heat shock 70kDa protein 5 
(glucose-regulated protein, 78kDa) 
IFI16 -0.67 0.0042 -0.94 0.0000 interferon, gamma-inducible protein 16 
IFRD1 0.80 0.0029 1.49 0.0000 interferon-related developmental regulator 1 
IRF9 -0.95 0.0016 -1.35 0.0000 interferon regulatory factor 9 
ITFG3 -0.74 0.0069 -0.95 0.0000 integrin alpha FG-GAP repeat containing 3 
KCNN4 -1.08 0.0046 -3.91 0.0000 potassium intermediate/small conductance 
calcium-activated channel, subfamily N, member 4 
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KIAA1609 0.65 0.0071 0.78 0.0001 KIAA1609 
KNTC1 0.69 0.0012 1.38 0.0000 kinetochore associated 1 
KRCC1 -1.09 0.0000 -1.22 0.0000 lysine-rich coiled-coil 1 
LAT2 1.92 0.0000 0.98 0.0001 linker for activation of T cells family, member 2 
LDB2 0.87 0.0000 0.63 0.0000 LIM domain binding 2 
LOC100132
790 
1.50 0.0003 1.15 0.0004 hypothetical protein LOC100132790; hypothetical 
LOC100132670; hypothetical LOC100132263 
LOC399959 1.04 0.0053 2.96 0.0000 hypothetical LOC399959 
LOC442421 -0.61 0.0016 -0.91 0.0000 hypothetical LOC442421 
LOC550643 -0.84 0.0000 -1.01 0.0000 hypothetical LOC550643 
LOC554202 0.59 0.0046 1.58 0.0000 hypothetical LOC554202 
LRRC41 -0.72 0.0043 -0.75 0.0003 leucine rich repeat containing 41 
LRRC8D -0.59 0.0010 -0.75 0.0000 leucine rich repeat containing 8 family, member D 
MAGED2 -0.68 0.0058 -1.27 0.0000 melanoma antigen family D, 2 
MANF -0.64 0.0012 -1.05 0.0000 mesencephalic astrocyte-derived neurotrophic factor 
MAP4 -1.01 0.0009 -2.44 0.0000 microtubule-associated protein 4 
MAPK14 -0.61 0.0021 -1.07 0.0000 mitogen-activated protein kinase 14 
MARCKS -1.15 0.0017 -1.13 0.0002 myristoylated alanine-rich protein kinase C substrate 
MCAM -0.69 0.0084 -2.10 0.0000 melanoma cell adhesion molecule 
MCTP1 1.13 0.0002 1.06 0.0001 multiple C2 domains, transmembrane 1 
MMP17 -0.89 0.0035 -2.35 0.0000 matrix metallopeptidase 17 (membrane-inserted) 
MOCS1 -0.77 0.0012 -0.90 0.0000 molybdenum cofactor synthesis 1 
MPP4 1.80 0.0002 2.85 0.0000 membrane protein, palmitoylated 4 (MAGUK p55 
subfamily member 4) 
MTHFD1L 0.61 0.0075 1.40 0.0000 methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
MXI1 -0.67 0.0024 -1.48 0.0000 MAX interactor 1 
MYL9 -1.40 0.0002 -4.56 0.0000 myosin, light chain 9, regulatory 
MYO5B 1.12 0.0000 4.07 0.0000 similar to acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase); similar 
to KIAA1119 protein; myosin VB 
NAB1 0.86 0.0000 2.09 0.0000 NGFI-A binding protein 1 (EGR1 binding protein 1) 
NACC2 -0.98 0.0039 -2.28 0.0000 NACC family member 2, BEN and BTB (POZ) domain 
containing 
NCSTN -0.75 0.0014 -1.36 0.0000 nicastrin 
NF1 -1.15 0.0006 -2.25 0.0000 neurofibromin 1 
NGFRAP1 -0.77 0.0024 -1.79 0.0000 nerve growth factor receptor (TNFRSF16) associated 
protein 1 
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NIPSNAP3
A 
-0.84 0.0007 -0.83 0.0000 nipsnap homolog 3A (C. elegans) 
NME3 -1.08 0.0028 -1.97 0.0000 non-metastatic cells 3, protein expressed in 
NRIP3 1.29 0.0008 1.26 0.0001 nuclear receptor interacting protein 3 
OLFML2A -2.60 0.0010 -3.60 0.0000 olfactomedin-like 2A 
OLFML2B -1.37 0.0014 -2.40 0.0000 olfactomedin-like 2B 
OPA1 0.61 0.0082 0.85 0.0000 optic atrophy 1 (autosomal dominant) 
P4HB -0.71 0.0091 -0.85 0.0002 prolyl 4-hydroxylase, beta polypeptide 
PABPC1 0.61 0.0006 1.06 0.0000 poly(A) binding protein, cytoplasmic pseudogene 5; 
poly(A) binding protein, cytoplasmic 1 
PABPC3 0.71 0.0007 0.96 0.0000 poly(A) binding protein, cytoplasmic 3 
PARVA -0.61 0.0092 -0.77 0.0000 parvin, alpha 
PCDH7 -1.35 0.0018 -1.76 0.0000 protocadherin 7 
PCMTD2 0.96 0.0001 1.60 0.0000 protein-L-isoaspartate (D-aspartate) O-methyltransferase 
domain containing 2 
PDZRN3 -1.88 0.0000 -2.03 0.0000 PDZ domain containing ring finger 3 
PGM1 -0.88 0.0000 -0.83 0.0000 phosphoglucomutase 1 
PHTF2 0.67 0.0001 0.77 0.0000 putative homeodomain transcription factor 2 
PLEKHB2 -0.68 0.0000 -1.72 0.0000 pleckstrin homology domain containing, family B 
(evectins) member 2 
PLEKHO1 -0.89 0.0049 -1.46 0.0000 pleckstrin homology domain containing, family O 
member 1 
PLSCR3 -0.62 0.0040 -1.26 0.0000 phospholipid scramblase 3 
PLXND1 -1.44 0.0012 -2.22 0.0000 plexin D1 
PMP22 -0.86 0.0077 -5.20 0.0000 peripheral myelin protein 22 
PODXL 1.15 0.0006 1.92 0.0000 podocalyxin-like 
POU4F1 0.93 0.0087 4.62 0.0000 POU class 4 homeobox 1 
PPAPDC1A -1.13 0.0028 -1.47 0.0000 phosphatidic acid phosphatase type 2 domain containing 
1A 
PPAPDC3 -1.86 0.0000 -2.59 0.0000 phosphatidic acid phosphatase type 2 domain containing 
3 
PPT1 -0.85 0.0016 -0.96 0.0000 palmitoyl-protein thioesterase 1 
PPT2 -0.68 0.0085 -2.88 0.0000 palmitoyl-protein thioesterase 2 
PRKCDBP -1.27 0.0000 -3.28 0.0000 protein kinase C, delta binding protein 
PRR7 -0.61 0.0059 -1.01 0.0000 proline rich 7 (synaptic) 
PSAT1 0.84 0.0063 1.07 0.0001 chromosome 8 open reading frame 62; phosphoserine 
aminotransferase 1 
PTPLA -0.74 0.0011 -0.93 0.0000 protein tyrosine phosphatase-like (proline instead of 
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catalytic arginine), member A 
PXN 0.70 0.0011 0.65 0.0000 paxillin 
RABAC1 -0.65 0.0096 -1.01 0.0000 Rab acceptor 1 (prenylated) 
RBBP4 0.66 0.0060 1.70 0.0000 hypothetical LOC642954; retinoblastoma binding 
protein 4 
RDH11 -0.61 0.0004 -1.14 0.0000 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 
RELL1 0.61 0.0046 1.56 0.0000 RELT-like 1 
RHOJ -1.09 0.0014 -1.92 0.0000 ras homolog gene family, member J 
RNF32 0.63 0.0074 0.71 0.0003 ring finger protein 32 
RUNX2 -2.45 0.0000 -1.99 0.0000 runt-related transcription factor 2 
SCD -1.81 0.0035 -2.33 0.0000 stearoyl-CoA desaturase (delta-9-desaturase) 
SELM -1.67 0.0000 -1.88 0.0000 selenoprotein M 
SEP15 -0.61 0.0012 -0.97 0.0000 15 kDa selenoprotein 
SERPINA5 -0.91 0.0018 -1.25 0.0000 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 5 
SFRS1 0.64 0.0036 1.40 0.0000 splicing factor, arginine/serine-rich 1 
SFRS12IP1 0.75 0.0094 1.02 0.0000 SFRS12-interacting protein 1; family with sequence 
similarity 159, member B 
SHISA4 -0.70 0.0065 -1.74 0.0000 shisa homolog 4 (Xenopus laevis) 
SIAE -0.72 0.0025 -0.76 0.0000 sialic acid acetylesterase 
SIDT2 -0.81 0.0069 -1.99 0.0000 SID1 transmembrane family, member 2 
SLBP 0.63 0.0039 0.93 0.0000 stem-loop binding protein 
SLC27A1 -0.93 0.0060 -0.99 0.0004 solute carrier family 27 (fatty acid transporter), member 
1 
SLC35B2 -0.69 0.0036 -1.67 0.0000 solute carrier family 35, member B2 
SLC38A1 1.02 0.0013 5.52 0.0000 solute carrier family 38, member 1 
SLC38A10 -0.60 0.0080 -0.66 0.0004 solute carrier family 38, member 10 
SOCS2 -1.00 0.0024 -1.25 0.0000 suppressor of cytokine signaling 2 
SPATA2 0.65 0.0089 1.11 0.0000 spermatogenesis associated 2 
SPG20 -1.43 0.0000 -0.87 0.0000 spastic paraplegia 20 (Troyer syndrome) 
SREBF1 -1.46 0.0000 -1.48 0.0000 sterol regulatory element binding transcription factor 1 
SRGAP1 0.96 0.0009 2.02 0.0000 SLIT-ROBO Rho GTPase activating protein 1 
SRPX2 -1.00 0.0005 -1.92 0.0000 sushi-repeat-containing protein, X-linked 2 
SSH3 -1.11 0.0007 -2.36 0.0000 slingshot homolog 3 (Drosophila) 
SSR3 0.97 0.0000 1.30 0.0000 signal sequence receptor, gamma (translocon-associated 
protein gamma) 
ST5 -0.95 0.0006 -1.51 0.0000 suppression of tumorigenicity 5 
STRBP 0.74 0.0000 2.00 0.0000 spermatid perinuclear RNA binding protein 
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SUSD1 -0.88 0.0036 -1.53 0.0000 sushi domain containing 1 
SYNM -0.70 0.0093 -1.34 0.0000 synemin, intermediate filament protein 
SYT11 -1.08 0.0000 -1.21 0.0000 synaptotagmin XI 
TCEAL3 -0.66 0.0002 -1.59 0.0000 transcription elongation factor A (SII)-like 3 
TCEAL5 -0.76 0.0002 -1.07 0.0000 transcription elongation factor A (SII)-like 5 
TCEAL6 -0.69 0.0001 -1.47 0.0000 transcription elongation factor A (SII)-like 6 
TCEAL8 -0.59 0.0025 -1.07 0.0000 transcription elongation factor A (SII)-like 8 
TEX15 0.83 0.0035 1.61 0.0000 testis expressed 15 
TK2 -0.90 0.0004 -0.98 0.0000 thymidine kinase 2, mitochondrial 
TLR1 -0.75 0.0055 -4.61 0.0000 toll-like receptor 1 
TMEM117 1.14 0.0004 1.12 0.0000 transmembrane protein 117 
TMEM150A -0.93 0.0019 -0.85 0.0005 transmembrane protein 150A 
TMEM209 0.78 0.0042 1.46 0.0000 transmembrane protein 209 
TMEM50A -0.76 0.0007 -1.08 0.0000 transmembrane protein 50A 
TNFAIP1 -0.69 0.0000 -1.46 0.0000 tumor necrosis factor, alpha-induced protein 1 
(endothelial) 
TNFAIP6 -1.92 0.0016 -4.40 0.0000 tumor necrosis factor, alpha-induced protein 6 
TNFSF12 -1.09 0.0017 -3.04 0.0000 TNFSF12-TNFSF13 readthrough transcript; tumor 
necrosis factor (ligand) superfamily, member 12; tumor 
necrosis factor (ligand) superfamily, member 13 
TNS3 -0.75 0.0076 -1.80 0.0000 tensin 3 
TOLLIP -0.64 0.0024 -1.93 0.0000 toll interacting protein 
TOM1L2 -0.96 0.0018 -1.05 0.0000 target of myb1-like 2 (chicken) 
TP53I3 -0.87 0.0014 -0.85 0.0001 tumor protein p53 inducible protein 3 
TWSG1 -1.12 0.0008 -1.79 0.0000 twisted gastrulation homolog 1 (Drosophila) 
UBE2B -0.91 0.0036 -0.65 0.0003 ubiquitin-conjugating enzyme E2B (RAD6 homolog) 
UROS -0.69 0.0029 -0.75 0.0001 uroporphyrinogen III synthase 
USP3 0.62 0.0089 1.41 0.0000 ubiquitin specific peptidase 3 
VWA1 -1.57 0.0076 -3.59 0.0000 von Willebrand factor A domain containing 1 
WWC3 -0.74 0.0014 -1.63 0.0000 WWC family member 3 
ZBTB4 -0.73 0.0014 -1.58 0.0000 zinc finger and BTB domain containing 4 
ZDHHC20 -0.60 0.0024 -0.90 0.0000 zinc finger, DHHC-type containing 20 
ZEB2 -0.78 0.0079 -2.89 0.0000 zinc finger E-box binding homeobox 2 
ZNF185 1.51 0.0001 2.51 0.0000 zinc finger protein 185 (LIM domain) 
ZNF26 0.77 0.0001 1.24 0.0000 zinc finger protein 26 
ZNF30 0.63 0.0036 1.68 0.0000 zinc finger protein 30 
ZNF643 0.72 0.0001 1.55 0.0000 zinc finger protein 643 
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ABSTRACT 
IDENTIFICATION OF TRANSCRIPTIONAL MECHANISMS 
DOWNSTREAM OF NF1 GENE DEFICIENCY IN MALIGANT 
PERIPHERAL NERVE SHEATH TUMORS 
by 
DAOCHUN SUN 
December 2012 
Advisor: Michael A. Tainsky, Ph.D. 
Major: Molecular Biology and Genetics 
Degree: Doctor of Philosophy 
Malignant peripheral nerve sheath tumor (MPNST) is a type of soft tissue sarcoma 
that occurs in carriers of mutations in the neurofibromatosis type I gene (Nf1) as well as 
sporadically. Plexiform neurofibromas in NF1 patients have a significant risk of 
developing into MPNSTs leading to increased morbidity and mortality from this 
syndrome. Surgery is the primary intervention but it is not always effective due to the 
tendency of MPNSTs to infiltrate the surrounding tissue or grow in an inoperable location.  
Neurofibromin, the protein coded by the Nf1 gene, functions as a GTPase activating 
protein (GAP) whose mutation leads to constitutive activation of RAS and 
mitogen-activated protein kinase (MAPK) signaling in NF1 patients’ tumors.  However, 
therapeutic targeting of RAS and MAPK have had limited success.   
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 In this study, we modulated NRAS, MEK1/2 and neurofibromin levels in MPNST 
cell lines and determined the global gene expression changes that were associated with 
each experimental condition.  Gene expression changes due to neurofibromin deficiency 
but independent of NRAS and MEK1/2 regulation were characterized for the first time in 
MPNST cell lines and led me to focus on bone morphogenetic protein 2 (Bmp2) and its 
signaling pathway.  The BMP2-SMAD1/5 pathway was activated in NF1-associated 
MPNST cells and inhibition of BMP2 signaling by LDN-193189 or shRNA to BMP2 
decreased the motility and invasion of NF1-associated MPNST cells in vitro thus 
providing evidence of a critical function for BMP2 signaling in MPNST malignancy. 
The stratification of gene changes according to pathway responses has provided a 
clarification of one mechanism within the complex effects of neurofibromin in MPNST 
pathology and some novel targets for future therapeutic intervention.
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